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ABSTRACT 
Nancy K. Gillis: Exploring Clinical and Genetic Factors to Optimize the Use of Tyrosine Kinase 
Inhibitors in Clinical Practice 
(Under the direction of Howard L. McLeod and Tim Wiltshire) 
Multi-targeted tyrosine kinase inhibitors (TKIs) are widely prescribed anticancer agents 
that provide significant benefit in survival across a range of cancers; however, 20-30% of 
individuals do not respond, demonstrating intrinsic resistance. The goal of this dissertation was 
to identify demographic, clinical, and genetic factors predictive of inefficacy to the multi-
targeted TKIs.   
A retrospective analysis of 108,825 cancer patients revealed a heightened incidence of a 
Stevens-Johnson syndrome (SJS), a life-threatening adverse event, in cancer patients and 
suggested that TKIs may trigger the reaction, necessitating drug discontinuation. In a 
retrospective study of outcomes in routine clinical practice, chart reviews of 266 patients treated 
with multi-targeted TKIs identified a resistance rate of 21%. Duration of TKI treatment was 
significantly longer in non-resistant patients; however, there were no significant differences in 
demographics, tumor type treated, or TKI received. Similar rates of resistance in the subgroups 
suggest that there may be unidentified shared markers of resistance to these agents.    
A methodology study to determine the utility of archived formalin-fixed paraffin-
embedded (FFPE) samples for genetic analyses was conducted. FFPE tumor samples 
representing a range of ages, tissue sources, and diagnoses were obtained for next-generation 
sequencing (NGS). We found no association between age of FFPE samples and sequencing 
failure; however, there was an association between DNA yield and ability to generate NGS. Both 
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failed samples were derived from bone, suggesting that bone is not an ideal source for FFPE-
derived DNA.  
To identify genetic predictors of intrinsic resistance, cancer patients treated with multi-
targeted TKIs were classified as resistant or non-resistant, and tumor FFPE samples were used to 
generate NGS and copy number variation (CNV). NTRK1, KDR, TGFBR2, and PTPN11 were 
more commonly mutated in resistant patients and CDK4, CDKN2B, and ERBB2 demonstrated 
differential patterns of CNVs between groups. In combined analysis using random forest and a 
decision tree, CNV in CDK4 and CDKN2B were the most important features, and alone could 
differentiate 55% of individuals as resistant or non-resistant, thus implicating the cyclin-
dependent pathway as an important factor in resistance to multi-targeted TKIs. This dissertation 
presents foundational evidence for the personalization of multi-targeted TKI prescribing and 
management.           
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CHAPTER 1: BACKGROUND: THE PHARMACOGENOMICS OF DRUG 
RESISTANCE TO PROTEIN KINASE INHIBITORS
1
  
Summary 
Dysregulation of growth factor cell signaling is a major driver of most human cancers.  
This has led to the development of numerous drugs targeting protein kinases, with demonstrated 
efficacy in the treatment of a wide spectrum of cancers. Despite their high initial response rates 
and survival benefits, the majority of patients eventually develop resistance to these targeted 
therapies. Discussed in this chapter are examples of established mechanisms of drug resistance to 
anticancer therapies, including drug target mutations or gene amplifications, emergence of 
alternate signaling pathways, and pharmacokinetic variation.  This reveals a role for 
pharmacogenomic analysis to identify and monitor for resistance, with possible therapeutic 
strategies to combat resistance. Gaps in the understanding of mechanisms of intrinsic resistance 
are also highlighted.  
 
Introduction  
Cancer is a genetic disease that arises primarily from the accumulation of genetic changes 
in genes regulating cellular growth, proliferation, and survival. Gain of function alterations 
inducing hyperactivity of oncogenes or loss of function alterations leading to inactivation of 
tumor suppressor genes cause deregulation of cellular signaling, a fundamental trait of cancer 
                                                 
1
 This article is updated from an article previously published.  The original citation is as follows: 
Gillis, NK & McLeod, HL. The pharmacogenomics of drug resistance to protein kinase 
inhibitors. Drug Resist Updat. 2016 Sep;28:28-42.  
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cells. In healthy cells, homeostasis is conveyed via growth factors binding to cell surface 
receptors, primarily protein kinases, which then activate intracellular signaling pathways and 
regulate cell cycle progression.
1
 Deregulation of these signals results in uncontrollable cellular 
proliferation, metabolism, survival and, ultimately, cancer. Somatic (acquired, or tumor) 
mutations lead to constitutive activation of these signaling pathways. For example, mutations in 
the B-raf proto-oncogene, BRAF, a serine/threonine kinase, cause constitutive signaling through 
the mitogen-activated protein kinase (MAPK) pathway and are commonly observed in 
melanoma, colorectal (CRC), and papillary thyroid cancers.
2
 Identification of the genes and 
pathways deregulated in cancer, such as BRAF, has led to a rapid increase in the design and 
approval of therapies targeting these genetic drivers of oncogenesis. Targeted anti-cancer 
therapies function by interfering with specific molecular alterations that regulate cellular 
signaling and drive tumor growth. By binding to or inhibiting a known molecular driver, targeted 
therapies interrupt the signaling pathways, causing cellular deregulation and leading to cancer 
cell apoptosis or cell death. For example, vemurafenib selectively inhibits BRAF V600-mutated 
cancer cells, abrogating MAPK-mediated signaling, preventing proliferation of BRAF-mutated 
cells, and ultimately resulting in apoptosis.
3
 
To optimize the use of targeted therapies, the genetic alterations causing pathway 
deregulation in each patient’s tumor must be identified. This is the modern concept of 
personalized cancer medicine (or precision medicine). Pharmacogenomics is the study of how 
genetic variations influence the response of an individual to drugs. In the context of cancer, there 
are two genomes relevant to predicting drug response or resistance: (1) germline, or inherited, 
genetics may affect drug exposure, potentially causing variability in efficacy and/or toxicity, and 
(2) somatic, or tumor, genetics are the acquired alterations that may initiate and perpetuate 
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cellular deregulation. Generally, it is the somatic germline that is interrogated to identify 
alterations driving oncogenesis and to select targeted therapies. Despite overall efficacy of 
targeted agents, drug resistance phenomena continue to be a primary hindrance to the curative 
treatment of solid tumors and hematologic malignancies.
4-6
  Hence, deciphering the molecular 
mechanisms underlying resistance should enhance targeted individualized cancer medicine.
7-9
 
 Due to their critical role in regulating cellular signaling, greater than twenty protein 
kinase inhibitors (PKIs) have been developed and approved across a wide range of tumor types. 
Despite their overall high response rates, many patients for whom the drugs are indicated will not 
have any evidence of disease control, while others will have transient benefit followed by tumor 
growth. This lack of complete and durable responses is indicative of drug resistance. If the 
correct alteration driving tumor growth is not identified from the outset, intrinsic resistance may 
be observed. On the other hand, when the tumor cells evolve mechanisms to overcome targeted 
inhibition, the patient develops acquired resistance and stops responding to therapies that were 
previously effective. Discussed in this chapter are the various classifications of cancer drug 
resistance, examples of how pharmacogenomics plays a role in resistance to PKIs, and possible 
therapeutic strategies to overcome cancer drug resistance.   
Classifications of drug resistance mechanisms important in cancer  
Drug resistance is the lack of therapeutic benefit or response to a medication. In cancer, 
drug resistance is apparent with an increase in tumor size or metastasis (i.e., disease progression). 
Various mechanisms of resistance can result in lack of complete or durable response to cancer 
therapies (Figure 1.1). An overview of the common classifications of resistance is provided 
below. It is important to note that a single pharmacogenomic biomarker may represent multiple 
mechanisms of drug resistance.  
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Pharmacological vs. biological resistance  
Pharmacological resistance reflects inadequate drug exposure at the drug target, and can 
be caused by environmental factors (e.g., drug-drug interactions, non-compliance), germline 
pharmacogenomics (i.e., inter-individual variability in drug metabolism or pharmacokinetics) 
(Figure 1.1A & 1.1C), or drug sequestration away from its target.
10,11
 For example, addition of an 
antacid to alleviate gastroesophageal reflux caused by some PKI therapies will affect gastric 
absorption and exposure to the PKI, thereby leading to pharmacological resistance.
12
 The 
observation that PKI-sensitive clones reemerge post-PKI discontinuation demonstrates the 
cytostatic, rather than cytotoxic, nature of some targeted therapies.
13,14
 Therefore, inconsistent 
suppression of the drug target due to missed doses may lead to upregulation of the cancer-driving 
pathways and, ultimately, cancer progression.  
Biological resistance results from cancer cell evolution in the presence of adequate drug 
exposure.
5,6,15
 In the context of cancer, biological resistance can arise from somatic alterations in 
drug targets or pathways (Figure 1.1B & 1.1C). Examples include genetic alterations in the drug 
target itself, activation of alternative signaling pathways (bypass tracks), alteration in signaling 
proteins downstream of the drug target, or phenotypic switch. Most known mechanisms of 
resistance to targeted cancer therapies are of the biological resistance subtype.  
Intrinsic vs. acquired resistance 
Cancer drug resistance can also be classified based on timing during the course of 
treatment. Intrinsic resistance (also referred to as innate, inherent, or primary resistance) is the 
absence of discernible, even transitory beneficial effect from a medication. From the outset, there 
is neither cessation in tumor growth nor increase in survival benefits (Figure 1.1D). Evidence of 
intrinsic resistance is apparent in waterfall plots, in which some patients fail to meet Response 
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Evaluation Criteria in Solid Tumors. For example, approximately 20% of BRAF V600-mutated 
melanoma patients do not respond to BRAF inhibitors, demonstrating intrinsic drug resistance.
16
 
Mechanisms of intrinsic resistance can include germline or somatic alterations. Intrinsic 
resistance is a major challenge in cancer therapy, and it is important to elucidate the mechanisms 
conferring lack of therapeutic benefit; however, these mechanisms remain less well understood 
at this time.  
Acquired or secondary resistance is the progression of disease after an initial benefit. In 
oncology, the tumor initially shrinks (responds) but eventually begins to increase in size (Figure 
1.1E). While intrinsic drug resistance can be due to germline or somatic mutations, acquired 
resistance is most commonly attributed to somatic mutations (an exception would be a new drug-
drug interaction due to changes in therapy). Mechanisms that result in acquired drug resistance 
include genetic alterations in the drug target, activation of bypass tracks, alteration in 
downstream signaling proteins, phenotypic switch, drug efflux, and drug 
compartmentalization.
15,17,18
 
Germline pharmacogenomics as a mechanism of pharmacological resistance 
Germline pharmacogenomics can affect one’s inherent response to a medication or 
therapy. In the context of cancer, germline pharmacogenomics has most widely been associated 
with risk of developing adverse effects, rather than drug resistance.
19
 Since adverse effects 
generally result from off-target (i.e., non-tumor) effects, it is logical that genetic variation in the 
germ cells throughout the body would confer risk to adverse events. However, due to the 
inherited nature of germline genetics, they may also play a role in one’s initial response to 
therapy. In fact, there are a few well-studied examples of how germline variation can confer 
intrinsic resistance to anticancer medications (Table 1.1).  
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Germline variation in TPMT as a pharmacogenomics predictor of response and adverse events  
Germline variation in TPMT, the gene that encodes the thiopurine S-methyltranserfase 
(TPMT) enzyme, affects response to thiopurine drugs. Chemotherapeutic thiopurines include 6-
mercaptopurine and 6-thioguanine, which are used in the treatment of pediatric and adult acute 
lymphocytic leukemia (ALL) (azathioprine is a prodrug of 6-mercaptopurine used in non-
malignant conditions). Thiopurine drugs are inactive prodrugs that are bioactivated and 
metabolized via competing routes: (1) xanthine oxidase converts 6-mercaptopurine to an inactive 
metabolite, 6-thiouric acid; (2) hypoxanthine phosphoribosyltransferase (HPRT) converts 
thiopurines to activated nucleotide analogues, which can be incorporated into DNA or RNA, 
hence interfering with replication and transcription, resulting in cytotoxicity; and (3) TPMT 
inactivates thiopurines through methylation. The nucleotide analogues formed by HPRT are 
responsible for the efficacy and toxicity of thiopurine drugs, and insufficient TPMT activity 
results in upregulation of HPRT-mediated metabolism, conferring response. Patients with low 
TPMT activity have greater exposure to activated thioguanine nucleotides, resulting in the 
potential for greater efficacy, but also increased risk of severe toxicity.
20
 This variation in 
activated nucleotide exposure is a well-established predictor of treatment outcomes. Patients with 
TPMT loss-of-function variants have significantly lower rates of minimal residual disease 
positivity after receiving 6-mercaptopurine therapy when compared to wild-type TPMT 
individuals.
21
 Increased risk of relapse has also been associated with wild-type TPMT in children 
receiving 6-mercaptopurine, likely due to insufficient thioguanine nucleotide exposure, thus 
conferring a type of pharmacological resistance.
22
 Due to increased toxicity risk, decreased 
dosing for patients with TPMT variants is recommended;
23
 however, it is unclear how this may 
affect relapse rates.
24,25
 A recent study reported that patients with 6-mercaptopurine non-
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adherence were at a 2.7-fold increased risk of relapse when compared to patients with a mean 
drug adherence rate of 95% or greater (p = 0.01), further emphasizing the importance of 
continuous drug exposure and adherence as a means to avoid development of drug resistance.
26
  
Germline alterations in BIM as a predictor of intrinsic pharmacological resistance 
A common variant in BCL2L11 (also known as BIM) has been associated with intrinsic 
resistance to PKIs. BIM is a member of the B-cell CLL/lymphoma 2 (Bcl-2) family of genes and 
encodes a Bcl-2 homology domain 3 (BH3). BH3 activates cell death by either opposing the pro-
survival members of the Bcl-2 family or by binding to the pro-apoptotic Bcl-2 family members 
and causing activation of their pro-apoptotic functions.
27
 PKIs induce upregulation and 
stabilization of BIM through inhibition of the MAPK pathway, therefore, the activity of BIM is 
required for PKIs to induce apoptosis in kinase-driven cancers.
28
 Recently, a 2,903 bp germline 
deletion polymorphism in intron 2 of BIM was identified, which was associated with inferior 
responses to PKIs (i.e., imatinib, gefitinib, erlotinib, and afatinib) in chronic myeloid leukemia 
(CML), non-small cell lung cancer (NSCLC), and pediatric ALL patients.
29-31
 Functionally, this 
mutation results in alternative RNA splicing, leading to decreased production of BIM isoforms 
containing the essential BH3 domain.  
Since its discovery, conflicting evidence of the ability of BIM variation to predict 
intrinsic resistance to PKIs has been reported.
32-34
 Two retrospective studies failed to observe an 
association between BIM genotype and response rates to PKIs in NSCLC patients.
35,36
 However, 
a systematic review and meta-analysis of 951 patients supported the BIM deletion polymorphism 
as a predictor of shorter progression free survival (PFS) in NSCLC patients who were treated 
with PKIs (adjusted HR = 2.38, p < 0.001).
37
 Another meta-analysis found that the BIM deletion 
polymorphism was associated with response rates (HR = 0.44, 95% CI = 0.27-0.7) and PFS (HR 
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= 2.19, 95% CI = 1.7-2.8) in NSCLC, but not in CML.
38
 Further evidence indicating a lack of 
benefit or increased risk of harm in individuals carrying BIM deletions is warranted before this 
biomarker of intrinsic resistance can be implemented in clinical practice.  
Methods to overcome BIM-related PKI resistance are already being explored. A 
preclinical study in NSCLC cell lines and xenograft models indicated that cells harboring the 
common BIM deletion had enhanced response to gefitinib when treated in combination with a 
histone deacetylase inhibitor, vorinostat.
39
 Vorinostat functioned by increasing expression of 
BH3 in a dose-dependent manner, thus restoring sensitivity to tyrosine kinase inhibition. These 
findings further support the importance of BIM expression in PKI response and provide evidence 
to suggest that combination therapeutics may be a potential strategy to overcome this form of 
resistance.  
Additional germline pharmacogenomic markers as predictors of drug resistance 
One potential mechanism that can confer pharmacological resistance is decreased drug 
exposure at the drug target, which can result from drug-drug interactions or inter-individual 
genetic variability (Figure 1.1A). There are a few well-established examples of germline genetics 
affecting exposure to anticancer therapies.
19
 While outside the scope of this review, the 
importance of an established link between active drug exposure levels and clinical outcomes or 
adverse events must be emphasized. Drug exposure is predicted to affect drug efficacy or 
toxicity; however, discrete evidence must exist before clinical implementation is warranted.
40
  
Somatic pharmacogenomics as a mechanism of drug resistance 
Somatic mutations result in upregulation of oncogenic pathways, and their effects can be 
inhibited with the use of targeted therapies. Since 2003, over twenty PKIs have been approved to 
target various somatic alterations across a broad range of cancer types (including hematologic 
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and solid malignancies), and more than twenty additional PKIs are currently in clinical trials.
41
 
Because these drugs target protein kinases, somatic alterations in the targets or pathways may 
confer resistance or response (Table 1.1). Some well-established examples of somatic genetic 
drivers of resistance to PKIs are discussed below.   
RAS status as a predictor of intrinsic resistance to EGFR inhibition in CRC 
The epidermal growth factor receptor (EGFR or ErbB-1) is a transmembrane protein 
kinase that binds epidermal growth factor, inducing dimerization and autophosporylation, which 
signals downstream pathways (i.e., MAPK and PI3K/Akt) that mediate cellular proliferation and 
survival (Figure 1.2). The EGFR signaling pathway plays a pivotal role in tumor growth and 
progression in many cancer types, including glioblastoma, NSCLC, head and neck cancers, and 
CRC. EGFR is overexpressed in approximately 50% of CRC patients, and is associated with 
disease progression and poor prognosis.
42
 Anti-EGFR monoclonal antibodies, such as cetuximab 
and panitumumab, were hypothesized to be effective in colorectal tumors over-expressing 
EGFR, and were initially U.S. Food and Drug Administration (FDA) approved for that 
indication; however, as monotherapy, the response rates to cetuximab and panitumumab were 
only 10% and 30%, respectively, indicating potential intrinsic resistance.
43,44
 Retrospective 
analysis of phase III clinical study data revealed differential response to anti-EGFR monoclonal 
antibodies dependent on Kirsten rat sarcoma viral oncogene (KRAS) homolog.
45
 When stratified 
by KRAS mutation status, response rate to panitumumab in wild-type individuals was 17%, 
whereas 0% of individuals with mutant KRAS responded. Similarly, KRAS mutations were 
associated with resistance and decreased overall survival (OS) in patients receiving cetuximab.
46
 
These observations provided evidence for KRAS as a biomarker of intrinsic resistance to EGFR-
targeted monoclonal antibodies.  
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KRAS is a member of the rat sarcoma virus (RAS) family of oncogenes, which also 
includes HRAS (Harvey rat sarcoma viral oncogene homolog) and NRAS (neuroblastoma RAS 
viral oncogene homolog). Mutations in RAS genes lead to the constitutive activation of the 
MAPK pathway independent of EGFR status. Interestingly, in CRC, mutations in KRAS are 
significant enough to negate EGFR inhibition. A prospective-retrospective analysis of 1,183 
patients who received either FOLFOX-panitumumab or FOLFOX alone revealed that mutation 
status in both KRAS and NRAS were predictive of response to panitumumab (HR for progression 
or death in RAS wild-type 0.72, 95% CI 0.58–0.99, p= 0.0004).47 Recently, the American Society 
of Clinical Oncology released a provisional clinical opinion update recommending NRAS and 
KRAS mutation testing in CRC patients who are candidates for anti-EGFR monoclonal 
antibodies, supporting the significance of this biomarker as a predictor of intrinsic drug 
resistance.
48
 Additional potential markers of intrinsic resistance have since been identified in 
models of KRAS wild-type patient xenografts, including ERBB2 (HER2), FGFR1, PDGFRA, and 
MAP2K1 (MEK); secondary mutations in EGFR at the site of cetuximab binding were identified 
in acquired resistance.
49
 Further studies demonstrating effects on patient outcomes are needed 
before clinical implementation of these novel biomarkers can be recommended.  
EGFR status as a mediator of resistance to EGFR PKIs in NSCLC 
Mutations in EGFR are one of the most common cancer drivers identified in NSCLC 
tumors. Approximately 15% of NSCLC patients in the U.S. have an EGFR mutation, and the 
incidence is approximately 35% in patients of Asian descent.
50
 In the U.S., EGFR mutations are 
most prevalent in females (17.9% vs. 8%, p= 0.002), non-smokers (42% vs. 6.6%, p < 0.001), 
and adenocarcinomas (15.6%).
51
 The mutations are typically located in exons 18 to 21 of EGFR, 
the region that encodes the catalytic tyrosine kinase domain. Approximately 90% of the 
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mutations are short exon 19 deletions or the L858R point mutation in exon 21, which result in 
enhanced EGFR signaling.
52
 Mutations in EGFR are predictive of response to EGFR inhibitors, 
such as erlotinib and gefitinib, in NSCLC. However, despite 70–80% response rates to EGFR 
PKIs, a majority of patients will acquire resistance after 10-12 months.
53,54
 Absence of initial 
EGFR mutations confers lower overall response rates in NSCLC patients, a relative intrinsic 
resistance.
55,56
 
 Acquired resistance to EGFR inhibitors in NSCLC is complex and heterogeneous, but 
ultimately all mechanisms drive sustained signaling through downstream cancer pathways (e.g., 
MAPK or PI3K/Akt pathways). Known mechanisms of drug resistance include secondary 
genetic alterations in EGFR, upregulation of parallel signaling pathways, or phenotypic 
transformation (Figure 1.2). The most common mechanism of acquired resistance in EGFR-
positive NSCLCs is the single-nucleotide mutation T790M, which occurs in approximately 50–
60% of acquired resistance cases.
52
 Also known as the gatekeeper residue, substitution of bulky 
methionine at this position causes steric hindrance and prevents EGFR inhibitors from binding 
and eliciting their pharmacologic effect. Other EGFR mutations have been identified in patients 
with acquired resistance, but their frequencies are much lower (Figure 1.3). Another common 
mechanism of acquired resistance to EGFR PKIs is amplification of the MET proto-oncogene 
(MET), a receptor tyrosine kinase, which has been reported in up to 22% of resistant samples.
57
 
MET amplification drives resistance by inducing EGFR-independent phosphorylation of ERBB3 
(HER3), which activates downstream PI3K/Akt signaling despite the presence of an EGFR 
inhibitor.
57
 Amplifications of ERBB2 (HER2) and PIK3CA have also been identified in patients 
with acquired resistance, similarly functioning to activate shared pathways independent of 
EGFR.
14,58
 Phenotypic transformation as a mechanism of acquired resistance occurs when the 
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histology of the tumor transitions to small cell lung cancer (SCLC) or from epithelial to 
mesenchymal subtype, and occurs in approximately 14% and 5%, respectively.
14,59
 Interestingly, 
transformed SCLCs retain the primary EGFR activating mutations, but do not carry T790M or 
MET amplification. Not much is known about the mechanism of histological transformation, but 
currently it is recommended that these patients receive standard SCLC treatments.
60
  
 Numerous strategies are being investigated to overcome first-generation EGFR inhibitor 
resistance due to secondary EGFR mutations or bypass track signaling. One strategy was to 
develop more potent inhibitors of EGFR, such as the FDA-approved second-generation EGFR 
inhibitor, afatinib, which irreversibly binds to and inhibits EGFR as well as HER2, HER3, and 
HER4. Despite its first-line indication and increased potency, afatinib has not demonstrated 
promise in the setting of acquired drug resistance. LUX-Lung 1, a phase 2b/3 trial of afatinib in 
patients who had progressed after treatment with an EGFR PKI, failed to meet its primary 
endpoint of OS (HR 1.08, 95% CI 0.86-1·35; p=0.74), and response rates were less than 10%.
61
 
Demonstrating more promise than the second generation EGFR PKIs in combating acquired 
resistance are the third generation EGFR inhibitors: the recently approved osimertinib and 
rociletinib, which is in clinical trials. Like the second-generation inhibitors, these are irreversible 
EGFR inhibitors; however, they have higher affinity for mutant EGFR, including T790M, than 
for wild-type EGFR. In the pivotal phase 2 study of osimertinib in NSCLC patients who had 
progressed after treatment with a first generation PKI, response rates in T790M-positive patients 
were 61%. In a similar phase 1/2 study of rociletinib, patients with the T790M mutation had an 
objective response rate of 59%.
62,63
  
Despite their therapeutic promise in acquired resistance to first generation EGFR PKIs, 
mechanisms of potential acquired resistance to third generation EGFR PKIs have already been 
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reported. A study in patients who progressed on rociletinib reported that half of T790M-positive 
NCSLCs treated with rociletinib became T790-wild-type at progression.
64
 Loss of T790M was 
also observed in 27% patients who progressed on osimertinib, and 40% acquired a novel EGFR 
mutation, C797S, which is also resistant to rociletinib.
65
 One possible strategy to overcome loss 
of T790M is combination therapy of an EGFR PKI with a monoclonal antibody that targets 
EGFR (e.g., NCT02496663). Recently, a preclinical study identified mutations and 
amplifications in NRAS and KRAS as mechanisms of acquired resistance to osimertinib.
66
 Due to 
their upstream signaling of MEK, alterations in NRAS and KRAS may confer response to MEK 
inhibitors. As such, clinical studies investigating combination therapy with third generation 
EGFR PKIs and MEK inhibitors are also underway (e.g., NCT02580708).  
 Therapeutic strategies targeting resistance mediated by upregulation of bypass signaling 
pathways are less established. Postulated strategies mainly consist of studies investigating dual 
inhibition of EGFR and known bypass tracks. In an ongoing phase 1b/2 clinical study of gefitinib 
plus a novel MET inhibitor (INC280) in patients who progressed on a first-line EGFR PKI, 
partial responses were only observed in 6/41 (15%) individuals.
67
 A phase 1b study investigated 
concurrent inhibition of HER2 and EGFR with the combination of afatinib (dual HER2/EGFR 
inhibitor) and cetuximab in NSCLC patients who had progressed on gefitinib or erlotinib, and 
overall response rate (ORR) was 29% and PFS was 4.7 months.
68
 A phase 2 clinical trial 
combining erlotinib with a PI3K inhibitor (BKM120) is currently ongoing in patients who 
acquired resistance to erlotinib (NCT01487265); the combination of afatinib and sirolimus is 
also being studied to overcome resistance due to mTOR (mechanistic target of rapamycin, a 
serine/threonine kinase) activation (NCT00993499), a downstream component of the PI3K/Akt 
pathway. These preliminary results suggest that dual inhibition of multiple signaling pathways 
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may confer response in some individuals; however, an understanding of which individuals will 
benefit and durability of response is crucial.  
Acquired resistance to ALK inhibitors 
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase normally expressed in 
the nervous system that plays an important role in brain development. ALK rearrangements, 
mutations, and amplifications have been identified in numerous tumor types including anaplastic 
large cell lymphoma, neuroblastoma, and NSCLC. Chromosomal rearrangements resulting in 
gene fusions are the most common type of ALK alterations. Clinically, ALK alterations are 
known to be most actionable in NSCLC, where the most common rearrangement observed is 
echinoderm microtubule associated protein like 4 (EML4)-ALK .
69
 Multiple variants of EML4-
ALK have been reported; however, they all encode the same cytoplasmic portion of ALK, but 
have different EML4 truncations.
70
 Fusions of ALK with other genes have also been described, 
but occur at much lower frequencies.
71
 These fusion proteins mediate ligand-independent 
dimerization of ALK, and like EGFR mutations, result in constitutive activation and downstream 
signaling through the MAPK and PI3K/Akt pathways.
69
 Interestingly, ALK gene arrangements 
are largely mutually exclusive with EGFR or KRAS mutations.
72
 Cancers harboring ALK 
rearrangements, classified as ALK positive, derive clinical benefit from ALK PKI therapies.  
 Crizotinib is a first generation ALK PKI, which also inhibits the MET and ROS proto-
oncogenes (MET and ROS1), which encode receptor tyrosine kinases. Crizotinib first received 
accelerated FDA approval for ALK-positive NSCLC in 2011 based on durable, objective 
response rates of 61% in a single-arm phase 1 study, and is now recommended first-line in ALK-
rearranged NSCLC.
73
 Crizotinib inhibits ALK phosphorylation and signal transduction through 
G1-S phase cell cycle arrest and induction of cellular apoptosis.
74
 Despite high response rates 
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(74% in the first-line phase 3 study), resistance to crizotinib develops 10-12 months after therapy 
initiation.
75
  
As observed with EGFR inhibitors, acquired resistance to crizotinib is heterogeneous and 
complex (Figure 1.3). Mechanisms of resistance that have been reported include somatic 
alterations (amplification and/or mutation) in ALK, activation of alternative signaling pathways, 
and genetic alterations in other important oncogenes. A case of phenotypic neuroendocrine 
transformation was recently reported in a patient who developed acquired resistance to 
crizotinib.
76
 Unlike that observed in EGFR inhibitor resistance, only approximately one-third of 
patients with crizotinib resistance harbor an ALK mutation. Two of the most commonly observed 
mutations are L1196M and G1269. Amino acid 1196 is the gatekeeper residue of ALK and, 
similar to EGFR, it controls access to the active site; therefore, the bulky substitution of 
methionine causes steric hindrance, impeding crizotinib binding.
77
 Individual mutations confer 
variable degrees of crizotinib resistance.
78,79
 Activation of alternative signaling pathways, or 
bypass tracks, can occur via genomic or non-genomic mechanisms. These alterations lead to 
constitutive activation of redundant downstream pathways, rendering crizotinib incapable of 
suppressing tumor growth. Non-genomic mechanisms of resistance include increased 
phosphorylation of other tyrosine kinases (e.g., EGFR, IGF-1R, and Src), and genomic 
alterations include mutations in EGFR, c-KIT, MAPK, and KRAS (Figure 1.3).
80
     
 Multiple potential strategies exist to combat crizotinib resistance. The most well 
established second-line therapeutic option in patients who progress after receiving crizotinib is 
second-generation ALK inhibitors. Ceritinib, an FDA-approved second-generation ALK 
inhibitor, is 20-fold more potent against ALK than crizotinib and also inhibits IGF-1R (insulin-
like growth factor 1 receptor). In a phase 1 clinical study, among the 80 patients who had 
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received crizotinib previously, there was a 56% response rate to ceritinib in patients with various 
ALK resistance mutations.
81
 However, a preclinical study suggested that some crizotinib-
resistance mutations (F1174C and G1202R) may not be sensitive to ceritinib and, in fact, may be 
mechanisms of acquired resistance to ceritinib as well.
82
  Alectinib, another second-generation 
ALK inhibitor with efficacy in patients who progressed on crizotinib received FDA-approval 
December 2015.
83
 Acquired mutations in ALK (I1171N and F1245C) confer resistance to 
alectinib, but are susceptible to ceritinib.
84,85
 Interestingly, acquired resistance to lorlatinib (via 
ALK L1198F), a third-generation ALK inihibitor in clinical trials, has been reported to enhance 
crizotinib binding and resensitize resistant tumors.
86
 Findings such as these may be important 
when considering sequencing of therapy in resistant patients.    
Strategies to overcome crizotinib resistance due to bypass track signaling are less 
understood; however, rational combination therapies have been postulated. For example, a 
preclinical study in ALK-positive NSCLC cell lines with acquired IGF-1R upregulation 
demonstrated improved efficacy of combined ALK (crizotinib) and IGF-1R inhibition (OSI-
906).
87
 In the case of EGFR-mediated mechanism of acquired resistance, combination therapy 
with an ALK and EGFR inhibitor has been suggested to be effective.
79,88
 Other possible 
combinations include ALK inhibition concurrently with MEK or Src inhibitors. Heat shock 
protein 90 (HSP90) inhibitors have also demonstrated efficacy against ALK-sensitive and ALK-
mutant NSCLCs.
79,89
 HSP90 is a molecular chaperone that aids in proper folding of specific 
target proteins; ALK fusion proteins are substrates of HSP90. The combination of crizotinib plus 
HSP90 inhibitors is currently in clinical trials (NCT01712217).    
Acquired resistance to BCR-ABL inhibitors in hematologic malignancies 
Imatinib is an inhibitor of the BCR-ABL fusion gene, also referred to as the Philadelphia 
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chromosome, that is characteristic of CML and presents at lower frequencies in ALL and acute 
myeloid leukemia (AML). BCR-ABL is a constitutively active tyrosine kinase that functions by 
binding ATP and transferring a phosphate group to tyrosine residues to activate downstream 
signaling molecules. Imatinib competitively binds to the kinase pocket of BCR-ABL, inhibiting 
phosphorylation and downstream signaling.
90-92
 The majority of CML patients will achieve 
clinically significant responses to imatinib. A complete and durable cytogenetic response is 
achieved in up to 80% of newly diagnosed patients and approximately 60% of patients with 
chronic-phase CML;
93,94
 however, up to 27% of patients will develop resistance and relapse.
95
  
 Acquired resistance to imatinib occurs as a consequence of reactivation of BCR-ABL 
signaling, which can be due to BCR-ABL amplification, elimination of imatinib from the cell by 
multidrug efflux transporters, or, most commonly, by the development of BCR-ABL mutations.
96
 
The acquired mutations in BCR-ABL that have been associated with resistance to imatinib and 
other BCR-ABL inhibitors, such as nilotinib and dasatinib, are located in twelve key positions of 
ABL1 (Abelson murine leukemia viral oncogene, homolog 1).  These result in amino acid 
substitutions that change the BCR-ABL binding site, altering the ability of the PKI to bind and 
inhibit downstream signaling.
97
 The most commonly observed BCR-ABL mutation conferring 
acquired resistance is T315I, followed by E255K/V. Interestingly, multiple acquired mutations in 
BCR-ABL have been identified, and the degree of imatinib (and other BCR-ABL PKI) resistance 
is dependent on the location of the point mutation within the BCR-ABL binding site.
98
 Strategies 
to overcome acquired resistance to BCR-ABL PKIs are currently being explored.  
 The second-generation PKIs, such as nilotinib and dasatinib, were designed with a higher 
affinity for BCR-ABL in attempts to combat imatinib resistance. While they are able to 
overcome some mutations observed in acquired imatinib resistance, they are ineffective against 
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the common T315I mutation.
97
 In 2012, a third generation BCR-ABL PKI, ponatinib, was 
approved. Ponatinib is unique in that it is a high affinity pan-BCR-ABL inhibitor with activity in 
T315I-positive CML. Despite its effectiveness against the acquired T315I mutation, emergence 
of compound mutations in BCR-ABL have been identified as conferring differential resistance to 
ponatinib.
97
 Complex screening of resistance mutations and sensitivity to BCR-ABL PKIs is 
necessary to optimize therapy selection at the time of disease progression. 
Acquired resistance to BCR-ABL inhibitors in solid tumors  
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of 
the gastrointestinal tract, characterized by positive staining for KIT (the v-kit Hardy-Zuckerman 
4 feline sarcoma viral oncogene). Approximately 95% of GISTs express KIT, 80% have 
mutations in KIT, and 10% have mutations in the platelet-derived growth factor receptor alpha 
(PDGFRA).
99
 Wild-type GISTs lack KIT expression as well as KIT and PDGFRA mutations; 
alterations identified in wild-type patients include mutations in BRAF, RAS, NF1, and succinate 
dehydrogenase deficiency. Imatinib is first-line treatment in GIST due to its inhibition of KIT 
and PDGFRA. Furthermore, KIT and PDGFRA mutations are associated with response to 
imatinib, with 84% of mutation-positive patients achieving a partial response compared to 0% of 
wild-type patients.
100
 Despite high initial response rates, approximately 80% of GIST patients 
develop imatinib resistance within 12–36 months.99  
 As observed in hematologic malignancies, acquired imatinib resistance in GIST is most 
commonly due to secondary alterations in the drug targets; however, because the oncogenic 
targets differ, so do the resistance alterations. A retrospective analysis of tumors from patients 
who progressed on the phase 2 imatinib trial indicated that 22 of 33 (67%) patients with acquired 
resistance had secondary mutations in KIT or PDGFRA.
101
 Interestingly, secondary KIT 
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mutations were only observed in patients with primary KIT mutations, and the secondary 
PDGFRA mutation was identified in a patient with a primary PDGFRA mutation. The acquired 
mutations were all located within the ATP-binding pocket of KIT (e.g., T670I, the gatekeeper 
mutation) or the activation loop, thus inhibiting imatinib binding and inactivation of KIT-
mediated signaling.  
Current treatment strategies for acquired resistance to imatinib in GIST provide more 
potent inhibition of KIT and PDGFRA. Sunitinib, a multi-targeted PKI with activity against KIT, 
PDGFRA, VEGF, and numerous other tyrosine kinases, is currently approved second-line in 
patients with imatinib-resistant disease. Sunitinib has activity against all resistant genotypes, but 
response rates are significantly higher in wild-type GIST (p= 0.04) and patients with mutations 
in the ATP-binding domain (p= 0.0005) when compared to patients with alterations in the 
activation loop.
102
 Efficacy of the third-line treatment, regorafenib, may be due to sufficient 
activity in patients with acquired alterations in the activation loop of KIT.
103
 Despite their 
increased specificity for resistant disease, phase 3 clinical trial response rates to sunitinib and 
regorafenib were only 7% and 4.5%, and time to progression was 27 and 17 weeks, 
respectively.
104,105
 These low response rates suggest that the majority of imatinib-resistant GISTs 
may be entirely resistant to KIT inhibition, require more potent inhibitors, or may require 
alternative inhibition strategies.    
 Mutations and amplifications of KIT are also observed in melanomas (~3%), with higher 
frequencies in mucosal (39%), acral (36%), and chronically sun-damaged (28%) subtypes, 
suggesting possible benefit from imatinib.
106
 A phase 2 trial of imatinib in patients with KIT-
positive metastatic melanoma demonstrated potential efficacy, with 53.5% of the patients 
achieving a response and a 6-month PFS rate of 36.6%.
107
 Another phase 2 trial identified 
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differential response rates between melanoma patients with KIT mutations versus KIT 
amplification (54% vs. 0%, respectively).
108
 Retrospective data from patients with KIT-mutated 
melanoma demonstrated potential efficacy of sunitinib; of 4 evaluable patients, 3 (75%) 
responded to sunitinib (1 complete remission and 2 partial responses).
109
 Additional studies 
support use of sunitinib in mucosal and acral subtypes of melanoma, but failed to show an 
association between KIT status and response.
110,111
 Despite clinical benefit and relatively high 
initial response rates, most patients eventually progress on these therapies.  
Similar to hematologic malignancies and GIST, the current strategy to overcome acquired 
resistance to KIT inhibition in melanoma is the use of more potent inhibitors. Nilotinib, the 
BCR-ABL PKI used in chemoresistant CML, also has activity against KIT, PDGFR, DDR, and 
several other protein kinases, with greater potency than imatinib. Recently, a phase 2 study of 
niltonib demonstrated potential efficacy in patients with acquired resistance to prior KIT 
inhibitors. The primary endpoint, 4-month disease control, was achieved in 27% of resistant 
patients (95% CI 8% - 56%), and two partial responses (18.2%, CI 3% - 47%) were observed.
112
 
A similar phase 2 study of nilotinib in KIT-positive melanomas in a Korean population failed to 
meet its primary endpoint of response rate (overall response rate was 16.7%); however, six of the 
seven responses observed occurred in patients with KIT mutations only (24% response rate in 
KIT-mutated melanoma), suggesting that nilotinib may provide benefit in this subgroup.
113
 As in 
GIST, KIT status seems to be a biomarker of response to imatinib in melanoma, but resistance 
inevitably develops. Current strategies to combat resistance are the same as GIST, with stronger 
inhibition of KIT, but response rates are low and not durable. Further understanding of the 
mechanisms of resistance and means to effectively suppress drivers of drug resistance are crucial 
to achieve durable responses in GIST and melanoma patients.     
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Acquired resistance to BRAF inhibition 
BRAF, a serine/threonine kinase, plays a key role in the MAPK signaling pathway, which 
affects cell division, differentiation, and growth. Mutations in BRAF have been associated with 
numerous cancers, including CRC, melanoma, thyroid carcinoma, NSCLC, and non-Hodgkin’s 
lymphoma. Most commonly observed are somatic mutations causing activation of BRAF, 
specifically a valine to glutamine or lysine substation at position 600 (V600E/K), and 
constitutive signaling through the MAPK pathway. The discovery of BRAF mutations in cancer 
led to development of drugs aimed at inhibiting this oncogenic driver. In 2011, the first selective 
BRAF inhibitor, vemurafenib, was FDA-approved for the first-line treatment of BRAF V600E-
positive melanoma after interim review of a phase 3 randomized controlled trial that 
demonstrated improved six-month OS (84% vs. 64%) and PFS (5.3 months vs. 1.6 months).
114
 
Dabrafenib, a second BRAF inhibitor, demonstrated similar efficacy (PFS 5.1 vs. 2.7 months, 
HR 0.30, p<0.0001) and, was approved for the treatment of BRAF-positive melanoma in 2013; 
however, efficacy of BRAF inhibitors alone is not durable and most patients develop resistance 
within 6–8 months.16,115  
 Most mechanisms of acquired resistance to BRAF inhibitors involve reactivation of the 
MAPK pathway; unlike EGFR and ALK, no secondary or gatekeeper-type mutations have been 
identified as resistance drivers.
116
 Secondary resistance may be driven upstream (e.g., 
upregulation and activation of the other receptor tyrosine kinases), downstream (e.g., activating 
MEK1/2 mutations), at the level of BRAF (e.g., alternative splicing, BRAF V600E amplification), 
or elevated CRAF levels. Observed genetic alterations in the setting of acquired resistance 
include mutations that activate NRAS, MEK1, and MEK2.
116-118
 Amplification of mitogen-
activated protein kinase kinase kinase 8 (MAP3K8 or COT) is another mechanism of resistance, 
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which results in RAF-independent activation of MEK and ERK signaling.
119
  
One potential strategy to circumvent or delay BRAF inhibitor resistance is dual inhibition 
of components of the MAPK-pathway. In a phase 3 clinical trial of BRAF and MEK inhibition 
vs. BRAF inhibition alone in melanoma, the combination of dabrafenib plus trametinib improved 
PFS when compared to dabrafenib alone (9.3 vs. 8.8 months, HR 0.75, p= 0.03); significant 
improvements in response rates and OS were also observed.
120
 Trametinib is now FDA approved 
as monotherapy or in combination with dabrafenib. Interestingly, the benefit of MEK inhibitors 
was not observed when administered as monotherapy in patients who had progressed after initial 
benefit from a BRAF inhibitor, suggesting that MEK inhibition alone is not sufficient to 
overcome BRAF resistance.
121
 Preclinical data suggests another potential strategy to delay or 
overcome resistance caused by increased MAPK signaling is concurrent or sequential inhibition 
of BRAF and ERK; however, acquired resistance still occurs within 12 months.
122-124
 Known 
mechanisms of acquired resistance to BRAF plus MEK inhibition are similar to those observed 
with BRAF inhibitor monotherapy, and include amplification of BRAF V600, which activates 
CRAF and subsequently MAPK signaling, and acquired MEK1/2 mutations.
125-127
 Preclinical 
studies investigating even broader combination therapy consisting of concurrent BRAF, MEK, 
and PI3K/mTOR inhibition have demonstrated potential efficacy in BRAF/MEK-induced 
resistance.
125,126,128
 In addition, like ALK, BRAF V600E is a client of HSP90, and preclinical 
studies suggest that treatment with an HSP inhibitor may be another successful strategy to 
overcome BRAF and MEK inhibitor resistance.
129
      
 MAPK-independent mechanisms of acquired resistance to BRAF inhibition have also 
been identified, and dual inhibition has been proposed as a strategy to overcome this resistance. 
The most well studied bypass track of BRAF inhibitor resistance is activation through the 
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PI3K/Akt signaling pathway. For example, increased expression of PDGFRB or IGF-1R has 
been observed in cell culture and patient xenograft models of secondary resistance. Over-
activation of these receptors results in activation of alternate signaling pathways (e.g., 
PI3K/Akt), which can reduce the cancer cells’ dependency on MAPK signaling, rendering the 
cells resistant to BRAF-mediated inhibition.
116,130
 Secondary mutations in PI3K pathway 
regulatory genes, such as AKT1/3, PIK3CA, PIK3CG, PIK3R2, and PTEN have also been 
observed, further supporting combination therapy with PI3K inhibitors.
131
 Preclinical data 
demonstrated efficacy of concurrent PI3K and MEK inhibition in BRAF resistant cell lines, and 
clinical trials of this combination are currently underway (NCT01363232, NCT01337765). 
Recently, expression of yes-associated protein 1 (YAP1), a member of the Hippo signaling 
pathway, was associated with resistance to BRAF and MEK inhibition, and preclinical studies 
demonstrated that triple therapy with a BRAF, MEK, and YAP inhibitor may be a promising 
strategy to increase response in the setting of resistance.
132
   
Mechanisms of resistance to multi-targeted PKIs 
The multi-targeted PKIs, axitinib, cabozantinib, pazopanib, regorafenib, sorafenib, 
sunitinib, and vandetanib, represent a unique class of PKIs due to their inhibition of multiple 
diverse protein kinase targets.
133
 This promiscuous inhibition results in broad efficacy across 
both solid and hematologic malignancies, but also contributes to numerous side effects that may 
be attributed inhibition of non-cancer driving pathways. While these agents demonstrated overall 
efficacy in clinical trials, approximately 20-30% of patients treated with multi-targeted PKIs 
experienced a best response of progressive disease, indicating no therapeutic benefit from the 
outset (intrinsic resistance).
104,134-140
 Similarly, in a systematic review of twelve medical centers, 
Heng and colleagues observed that 26% of 1,056 renal cell carcinoma patients treated with 
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multi-targeted PKIs demonstrated intrinsic resistance.
141
 Interestingly, evidence of cross-
resistance to these agents has been demonstrated.
142
 Despite their broad use in clinical practice, 
there is a paucity of data on mechanisms of resistance to the multi-targeted PKIs (Table 1.1). 
Using in vivo short hairpin RNA screening in mouse models of hepatocellular carcinoma (HCC), 
Rudalska and colleagues found that elevated Mapk14-Atf2 signaling predicted poor response to 
sorafenib.
143
 Individual pharmacogenomic studies have also reported associations between 
germline mutations in drug transporters (ABCG2/BCRP and ABCB1/P-gp), drug metabolizing 
genes (CYP3A5), and pharmacodynamic genes (VEGFR3) with resistance; however, lack of 
replication to date limits clinical translation of these findings.
144-147
 Lysosomal sequestration, 
resulting in insufficient active drug exposure, has been demonstrated as another potential 
mechanism of non-response to multi-targeted PKIs in multiple studies.
148,149
 One study detected 
an association between increased interleukin 8, a pro-angiogenic cytokine, expression with 
acquired resistance to these agents.
150
 Despite these individual findings, no biomarkers of 
intrinsic or acquired resistance to multi-targeted PKIs have demonstrated sufficient evidence to 
warrant implementation into practice. The overwhelming lack of studies using clinical data to 
explore somatic genetics as predictors of resistance to multi-targeted PKIs is also notable, 
especially considering that most of the biomarkers currently implemented within routine clinical 
practice for other agents fall within this category (Table 1.1).   
Conclusions 
Targeted therapies are increasingly common and recommended first-line in some cancer 
types due to their impressive increases in response rates and survival benefits when compared to 
standard cytotoxic chemotherapy. However, even in the presence of a genetic biomarker 
predictive of response, not all patients will benefit from such therapies (intrinsic resistance), and 
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for those who do, durable response rates are low (acquired resistance). Therefore, equally 
important as identifying targetable oncogenic alterations is the identification of biomarkers of 
intrinsic resistance and the ability to anticipate potential mechanisms of acquired resistance that 
may develop.  
As discussed, the most common mechanisms of acquired resistance to targeted therapies 
induce upregulation of the drug target or bypass signaling through the same or similar pathways, 
resulting in cancer progression. These patterns imply an evolutionary-like process in which the 
cells most fit to regulate cellular proliferation and survival are selected. The question of whether 
or not resistant cells are present at undetectable concentrations at diagnosis or whether they 
develop post-treatment remains unanswered. Specifically, does resistance arise from pre-existing 
clones or is there drug-induced selection pressure that drives acquisition of mutations? It is likely 
that both may be the case.  
An important concept in the context of resistance to anticancer therapies is that a 
biomarker conferring response or resistance in one tumor type may or may not be predictive in 
all tumor types. For example, approximately 10% of CRCs carry BRAF V600 mutations, but are 
resistant to BRAF inhibition.
151,152
 However, in a recent basket study of vemurafenib in BRAF 
V600-mutated non-melanoma cancers, which included seven tumor classifications, only patients 
with NSCLC and Erdheim-Chester disease or Langerhans’-cell histiocytosis met the 
predetermined overall response rate of >35%, suggesting that BRAF status may be important in 
those tumor types.
153
 Recently, vemurafenib also demonstrated efficacy in BRAF-positive hairy 
cell leukemia.
154
 Another example is RAS-status as a predictor of intrinsic resistance to EGFR 
monoclonal antibodies in CRC, but not predictive of response to EGFR inhibition in NSCLC. 
Interestingly, secondary mutations in EGFR have been reported as mechanisms of acquired 
26 
 
resistance in both tumor types. Lack of efficacy across tumor types may be reflective of 
differential oncogenic drivers or compensatory resistance mechanisms. In CRC, data suggests 
that BRAF inhibition is overcome through increased EGFR-mediated signaling; this bypass track 
is not clinically relevant in melanoma due to low basal levels of EGFR in this cancer type.
155
 
Therefore, dual BRAF and EGFR inhibition may be required to increase response rates in BRAF-
mutant CRC.
156,157
 The benefit of imatinib in hematologic malignancies with BCR-ABL 
translocations and solid tumors with KIT or PDGFRA mutations is a unique example of how 
different oncogenic drivers may respond to the same therapy, but result in different genetic 
mechanisms of acquired resistance.   
Future directions 
Treatment modalities to prevent and overcome drug resistance are critical to increase the 
rate of durable responses to cancer therapies (Figure 1.4). To date, most strategies used in 
clinical practice involve sequential dosing once resistance develops (Figure 1.4A). An alternative 
strategy is to predict and target known resistance pathways from the outset using combination 
therapy (Figure 1.4B). The strength of this approach is supported by the increased benefit of 
dabrafenib plus trametinib vs. dabrafenib alone in BRAF-mutated melanoma.
158
  However, while 
this prolongs duration of response, resistance inevitably develops. Studies indicate development 
of BRAF inhibitor dependence in melanoma cells, which may also be combatted with 
intermittent or continuous dosing (Figure 1.4C).
159,160
 Another possible strategy is pulse dosing, 
in which the targeted therapy is administered for a short time (maybe until progression), stopped 
temporarily, and then restarted (Figure 1.4D). This method is supported by serial biopsies of 
EGFR-positive NSCLC resistance which demonstrated that patients may re-develop the T790M 
mutation after withdrawal and, therefore, respond to re-initiation of an EGFR inhibitor.
14
 Finally, 
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some patients with advanced disease may benefit from immunotherapy, but identification of this 
subset is much less understood.   
Despite overall response rates of 50% to 80% in clinical trials of targeted anticancer 
therapies, there is a paucity of data on mechanisms of intrinsic resistance. Intrinsic resistance 
may be due to germline genetics (e.g., BIM or TPMT) or somatic alterations (e.g., KRAS in 
CRC). Drug metabolism and germline variants that may affect exposure to cancer therapies are 
also an important consideration in the context of intrinsic resistance.
19,161
 However, robust 
examples of intrinsic resistance to targeted anti-cancer therapies are lacking. Furthermore, 
mechanisms of resistance to PKIs that inhibit multiple targets, such as sorafenib and sunitinib, 
are even more challenging to elucidate due to the heterogeneity of their effects, and are even less 
studied (Table 1.1). Another interesting gap in the area of resistance to anticancer therapies 
involves potential racial disparities. Certain alterations are more common in some races (e.g., 
EFGR mutations in Asian populations), suggesting potential differences in racial trends of 
oncogenic drivers. Because clinical and genetic studies enroll a vast majority of Caucasian 
patients, these potential disparities in genetic oncogenesis between races, which can greatly 
affect response rates, have yet to be elucidated.     
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Tables and Figures 
Table 1.1: Summary of FDA-approved protein kinase inhibitors and known mechanisms of resistance  
Class Drug Generation Indication Indication subgroup Innate (primary) resistance 
Acquired (secondary) 
resistance 
EGFR 
inhibitors 
erlotinib 1st NSCLC 
EGFR exon 19 deletions 
or exon 21 (L858R) 
substitution mutations 
EGFR wildtype, BIM deletion 
secondary EGFR mutations 
(e.g., T790M), MET 
amplification, HER2 
amplification (see Fig. 3) 
gefetinib 1st NSCLC 
afatinib 2nd NSCLC 
osimertinib 3rd NSCLC EGFR T790M-positive EGFR wildtype 
loss of T790M, secondary 
EGFR mutations (e.g., 
C797S) 
cetuximab 
panitumumab 
monocolonal 
antibodies 
CRC 
head and neck 
KRAS wildtype RAS mutations 
secondary mutations in 
EGFR, RAS or BRAF; 
activation of HER2 or MET 
ALK 
inhibitors 
crizotinib 1st NSCLC 
ALK+, recommended for 
pts with ROS1 
translocation 
ALK wildtype 
secondary ALK mutations, 
ALK fusion amplification, 
bypass signaling (e.g., EGFR, 
KIT, IGF1R) (see Fig. 3) 
ceritinib 2nd NSCLC 
ALK+, resistant to 
crizotinib, ALK I1171N+  
ALK wildtype 
secondary ALK mutations 
(e.g., G1202R) 
alectinib 2nd NSCLC 
ALK+, resistant to 
crizotinib 
secondary ALK mutations 
(e.g., I1171N) 
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BCR-ABL 
inhibitors 
imatinib 1st 
CML, ALL, 
MDS, GIST 
Ph+ 
BIM deletion; KIT and 
PDGFRA wildtype (GIST) 
BCR-ABL1 T315I and others 
in heme; KIT and PDGFR 
secondary mutations in GIST 
bosutinib 2nd CML 
Ph+ 
 If used first-line, BCR-ABL1 
T315I and others 
dastinib 2nd CML, ALL BCR-ABL1 T315I 
nilotinib 2nd CML 
 
ponatinib 3rd CML, ALL 
Ph+ for whom no other 
PKI is indicated, or 
T315I positive 
 
BCR-ABL1 compound 
mutations 
BTK inhibitor ibrutinib 
 
CLL, MCL, 
WM  
C481S, point mutations in 
phospholipase Cy2 (PLCg2) 
Mutations in BTK and 
downstream 
HER2 
inhibitor 
lapatinib 
 
breast HER2+ 
 
deregulation of PIK3CA 
pathway, AXL over-
expression 
BRAF 
inhibitors 
dabrafenib 
 
melanoma BRAF V600E or V600K 
RAC1 mutations, loss of PTEN 
or NF1, CCND1 over-
expression, abundance of HGF 
re-activation of the MAPK 
pathway, activating mutations 
in NRAS, activating MEK 1/2 
mutations, elevated CRAF 
(see Fig. 3) 
vemurafenib 
 
melanoma BRAF V600E 
MEK 
inhibitor 
trametinib 
 
melanoma BRAF V600E or V600K 
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Multi-targeted 
VEGF 
inhibitors 
axitinib 
cabozantinib 
pazopanib 
regorafenib 
sorafenib 
sunitinib 
 
vandetanib 
 
RCC 
thyroid 
thyroid 
RCC, sarcoma 
CRC, GIST 
HCC, RCC, 
thyroid 
thyroid 
   
mTOR 
inhibitor 
everolimus 
 
breast, pNET, 
RCC, 
angiolyolipoma, 
SEGA 
breast HER2- 
TSC1/TSC2 mutations predict 
response  
ER inhibitors 
tamoxifen, 
fulvustrant     
ESR1 mutations 
HER2 
inhibitor 
trastuzumab 
 
breast, gastric HER2+ 
PIK3CA mutations possibly 
predictive of response in 
neoadjuvant setting (not 
predictive in adjuvant) 
 
SMO inhibitor vismodegib 
 
basal cell 
carcinoma   
SMO mutations 
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Figure 1.1: Mechanisms of oncology drug resistance. (A) Pharmacological resistance. Drug-
drug interactions and germline pharmacogenetic variants can affect drug exposure at the tumor 
site. Pharmacological properties can affect drug penetration into the central nervous system. (B) 
Biological resistance. Somatic (acquired) mutations in the drug target can affect the drug’s 
ability to effectively inhibit oncogenesis. Somatic alterations downstream of the drug target can 
result in constitutive upregulation of oncogenic pathways. Genetic alterations may also activate 
alternative oncogenic signaling pathways. Some tumor types may transform into other tumor 
types (e.g., non-small cell lung cancer to small cell lung cancer). (C) Pharmacological drug 
resistance results from inadequate drug levels at the site of action, whereas biological drug 
resistance results despite adequate drug levels at the site of action. (D) Intrinsic resistance is the 
lack of even transitory clinical benefit – the tumor continues to progress despite treatment. (E) 
Acquired resistance is the lack of tumor response to medication despite initial benefit.   
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Figure 1.2: Example mechanisms of resistance to EGFR inhibitors and potential treatment 
strategies: The MAPK and PI3K/AKT pathways. EGFR-mutated non-small cell lung cancers 
show initial response to EGFR inhibitors (e.g., erlotinib, gefetinib). Mechanisms of acquired 
resistance include secondary EGFR mutations, downstream mutations that result in EGFR-
independent activation of MAPK or PI3K/AKT signaling pathways, or mutations in alternative 
protein kinases that bypass EGFR-mediated signaling through MAPK and/or PI3K/AKT 
pathways. Potential treatment strategies to combat acquired resistance to EGFR inhibitors 
include stronger inhibiton of EGFR (e.g., afatinib), combination therapy with a MEK (e.g., 
trametinib) or mTOR (e.g., sirolimus) inhibitor, or inhibition of bypass tracks. 
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Figure 1.3: Mechanisms of acquired resistance to protein kinase inhibitors. (A) and (B) data 
from Camdige et al., 2014. (C) Data from Shi et al., 2013. The all-blue pie chart represents 
MAPK-mediated mechanisms of resistance. PI3K/AKT-mediated mechanisms include AKT1/3 
mutations (3%), mutations in positive-regulatory genes, PIK3CA and PIK3CG, and mutations in 
negative-regulatory genes PIK3R2, PTEN, and PHLPP1.  
Blue shades throughout correspond to alterations within the targeted oncogenic track; orange 
shades correspond to alterations regulating alternative or bypass tracks; yellow shades 
correspond to phenotypic transformations. NSCLC: non-small cell lung cancer, SCLC: small cell 
lung cancer, EMT: epithelial to mesenchymal subtype.  
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Figure 1.4: Potential treatment strategies to combat anticancer drug resistance. (A) 
Sequential dosing. Begin treatment with single targeted therapy, once resistance develops, switch 
to drug that targets resistant cells. (B) Combination therapy. Begin therapy with a medication 
that targets the identified oncogenic marker in combination with a drug targeting predicted 
resistance mechanisms. (C) Continuous therapy. Begin treatment with a single targeted therapy, 
once resistance develops, add medication that targets resistance mechanism. (D) Pulse dosing. 
Begin treatment with single targeted therapy and periodically administer medication that targets 
predicted resistance mechanism. (A) represents the most commonly used strategy to date. Some 
data suggest that (B), (C), and/or (D) may delay development of acquired resistance. 
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SPECIFIC AIMS 
AIM 1: Understand demographic and clinical factors that may influence activity of multi-
targeted tyrosine kinase inhibitor (TKI) therapy. 
1a: Perform a large-scale retrospective study to explore the proposed association between multi-
targeted TKI administration and the life-threatening adverse events, Stevens-Johnson syndrome 
and toxic epidermal necrolysis. This may elucidate potential risks of multi-targeted TKI 
treatment that contribute to lack of therapeutic benefit. Discussed in Chapter 2 
1b: Perform a retrospective cohort study to explore the potential association between 
demographic and clinical characteristics with intrinsic resistance to multi-targeted TKIs. This 
will provide information on whether certain subsets of patients are less likely to derive benefit 
from multi-targeted TKI therapy. Discussed in Chapter 3 
AIM 2: Understand the impact of somatic genetics on resistance to multi-targeted TKIs. 
2a: Conduct a methodology evaluation study to assess the utility of a diverse collection of 
formalin-fixed paraffin-embedded samples as a source for somatic genetic information. 
Execution of this aim will inform sample selection for genetic analysis sub-aims. Discussed in 
Chapter 4 
2b: Utilize next-generation sequencing to identify somatic point mutations that are associated 
with intrinsic resistance to multi-targeted TKIs. This will be the first analysis aimed at 
elucidating genetic mechanisms of intrinsic resistance to the widely prescribed multi-targeted 
TKIs.  Discussed in Chapter 5 
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2c: Detect somatic copy number variations that are associated with intrinsic resistance. This will 
provide insight into another potential genetic mechanism of intrinsic resistance in the context of 
multi-targeted TKIs. Discussed in Chapter 5 
AIM 3: Develop an initial genetic model to pre-emptively identify patients resistant to 
multi-targeted TKIs. Completion of this aim will provide a preliminary decision algorithm that, 
with validation, can be easily translated into clinical practice to pre-emptively distinguish 
patients unlikely to respond to multi-targeted TKIs, thus guiding clinical decision-making toward 
other therapeutic options.  Discussed in Chapter 5 
  
 37 
 
 
 
 
 
 
CHAPTER 2: EXPLORING THE PROPOSED LINK BETWEEN TYROSINE KINASE 
INHIBITORS AND THE INCIDENCE OF STEVENS-JOHNSON SYNDROME AND 
TOXIC EPIDERMAL NECROLYSIS IN A LARGE CANCER PATIENT COHORT
2
  
Summary 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare life-
threatening mucocutaneous reactions most commonly triggered by medications. Case reports and 
small case series have suggested that cancer patients may be at increased risk of experiencing 
SJS/TEN, but a comprehensive assessment had not been performed. Additionally, multiple 
published case reports linked tyrosine kinase inhibitors (TKIs) to SJS/TEN reactions, and multi-
targeted TKIs have been reported in over thirty individuals in the FDA Adverse Event Reporting 
System. We conducted a retrospective cohort study to determine whether cancer patients are at 
increased risk for SJS/TEN and to explore the potential association of TKI administration with 
SJS/TEN. Cancer patients (n = 108,825; 2002-2015) were screened for ICD-9 codes suggestive 
of SJS/TEN. Chart reviews were conducted to confirm diagnoses, and culprit drugs for cases 
were abstracted from medical records. A total of 121 patients were identified with potential 
SJS/TEN reactions. Diagnosis was confirmed in 20 individuals, possible diagnoses in 30 
individuals, and 12 individuals reported historical diagnoses, corresponding to an average annual 
incidence of 6-15 cases per 100,000 individuals. The most common trigger was antibiotics, 
followed by antineoplastics and anticonvulsants. Three patients were treated with TKIs closely 
                                                 
2
 This article is updated from an article submitted for publication.  The citation for the article 
under review is as follows: Gillis NK, Hicks JK, Bell GC, Kanetsky PA, McLeod HL. Incidence 
and triggers of Stevens-Johnson syndrome and toxic epidermal necrolysis in a large cancer 
patient cohort. 2017. In review. 
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preceding or at the time of SJS/TEN reaction; one possible SJS/TEN case was linked to 
administration of a multi-targeted TKI. This corresponds to a prevalence of 20-60 cases per 
100,000 individuals in patients treated with TKIs, which may indicate a heightened risk with 
TKIs; however, inherent challenges to confirm SJS/TEN diagnosis and culprits warrant 
additional investigation. Our data demonstrate that cancer patients may be at up to a 150-fold 
increased risk for SJS/TEN compared to the general population.  
 
Introduction  
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-
threatening mucocutaneous skin reactions most commonly attributed to medications.  They are 
variants of erythema multiforme, characterized by extensive necrosis and detachment of the 
epidermis, and are classified by percentage of body surface involved (SJS involves less than 
10%, SJS/TEN overlap involves 10-30%, and TEN involves greater than 30%). SJS and TEN are 
extremely rare, with incidence in the general population ranging from 1-2 cases per million per 
year, although increased risk is associated with certain genetic alterations, diseases, and 
medications.
162-164
 Due to the life-threatening nature of SJS/TEN, early identification and 
withdrawal of the causative agent(s) is crucial to maximize prognosis. Of the over two hundred 
culprit drugs identified, the medications most commonly known to trigger SJS and TEN include 
xanthine oxidase inhibitors, aromatic anticonvulsants, nonsteroidal anti-inflammatory drugs, and 
sulfonamide antibiotics.
165
 Non-pharmacological risk factors reported include inherited genetics 
(i.e., HLA status), vaccinations, infections, and HIV/AIDS.
165-167
   
Case reports and small case series have suggested that cancer patients may also be at 
increased risk of experiencing SJS/TEN, but a comprehensive assessment has not been 
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performed. A recent large observational study on the epidemiology of SJS/TEN in a medically 
diverse population suggested that active cancer may be one factor associated with increased 
risk.
168
 Another review of 32 TEN cases found that cancer was the most common comorbidity (9 
patients, 28%).
169
 A systematic literature review identified 83 published reports of anticancer 
drugs implicated as culprits for SJS/TEN reactions.
170
 While the study found only a statistically 
significant association of SJS with bendamustine, multiple other anticancer medications were 
linked to cases of SJS or TEN, including immunomodulators (e.g., thalidomide, lenolidamide, 
methotrexate), tyrosine kinase inhibitors (TKIs), and cytotoxic antineoplastics (e.g., docetaxel). 
Multiple case reports have also linked TKIs, including the multi-targeted TKIs, to SJS/TEN 
reactions.
171-180
 As of February 2017, the multi-targeted TKIs have been reported in thirty-seven 
cases in the FDA Adverse Event Reporting System, with sorafenib having the most associations 
(17 cases of SJS or TEN).     
We conducted a retrospective study to identify the incidence and triggers of SJS/TEN in a 
large cancer patient cohort. We compared the incidence of SJS/TEN in our cancer patient cohort 
to that reported in the general population. We conducted detailed medical chart reviews to 
explore cases for possible links with TKIs.   
Methods 
Patients were identified through a retrospective search of electronic health records at 
Moffitt Cancer Center. Moffitt Cancer Center’s Institutional Review Board approved this study 
and waived the requirement for informed consent. All cancer patients treated at Moffitt Cancer 
Center from June 15, 2002 through June 15, 2015 and who had International Classification of 
Disease (ICD-9) codes available in the electronic health records were eligible for study inclusion. 
The ICD-9 codes 695.1 (erythema multiforme, which encompassed SJS/TEN pre-2009), 695.12 
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(erythema multiforme major), 695.13 (SJS post-2009), 695.14 (SJS/TEN overlap post-2009), and 
695.15 (TEN post-2009) were utilized to identify patients who may have experienced SJS/TEN.  
Retrospective chart reviews of identified patients were completed independently by two 
clinicians to confirm SJS/TEN diagnosis. Patients’ allergies, oncologist clinical notes, 
medication lists, dermatology consult notes (when applicable), and pathology notes (when 
applicable) were reviewed to confirm SJS/TEN diagnoses and identify any culprit drug(s). 
Patients were classified independently according to chart reviews as (1) confirmed SJS and/or 
TEN diagnosed at Moffitt Cancer Center, (2) possible SJS and/or TEN [included cases diagnosed 
at an outside hospital while a patient at Moffitt and uncertain differential diagnoses (e.g., SJS vs. 
drug eruption)], (3) historical (occurring prior to coming to Moffitt) SJS and/or TEN, or (4) 
failure to confirm SJS and/or TEN diagnosis. When necessary, adjudication of conflicting 
conclusions was completed through collaborative chart reviews and discussion. Culprit drugs 
were abstracted from chart reviews and represent the hypothesized triggers according to the 
patients’ physicians. Concomitant TKIs at the time of SJS/TEN were also recorded.  
The primary outcome was average annual incidence of SJS/TEN over the 13-year period. 
Annual incidences were calculated as the number of unique patients with a SJS/TEN diagnosis 
divided by the total number of patients screened that year. Incidences were calculated for 
confirmed SJS/TEN cases (condition 1) and confirmed or possible SJS/TEN cases (conditions 1 
and 2). Timing of historical cases (condition 3) relative to cancer diagnoses was unknown, so 
these cases were excluded from calculations. Prevalence of SJS/TEN in patients receiving TKIs 
was calculated as number of patients on TKIs at time of SJS/TEN diagnosis divided by the total 
number of patients screened who had been prescribed a TKI. Demographic (e.g., age, sex, and 
race) and clinical factors (e.g., cancer type and hematopoietic stem cell transplantation status) 
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were collected to determine incidence rates within groups.      
Results  
Incidence of SJS and TEN 
A total of 108,825 unique cancer patients were screened for SJS/TEN ICD-9 codes in the 
electronic health records. ICD-9 codes corresponding to potential SJS and/or TEN were 
identified in 121 patients. Due to electronic billing system implementation in 2003, the number 
of patients screened in 2002 (the denominator for incidence) is uncertain, so 2002 cases are 
excluded from the incidence calculations. Manual chart review confirmed SJS/TEN diagnosis at 
Moffitt Cancer Center (condition 1) in 20 patients, possible SJS/TEN (condition 2) in 30 
patients, and historical SJS/TEN diagnoses (condition 3) in 12 patients (Table 2.1). SJS and/or 
TEN was ruled out or unconfirmed (condition 4) in 59 patients. The average annual incidence of 
confirmed cases of SJS/TEN (condition 1) at Moffitt Cancer Center was 5.9 (range 0-15.6) cases 
per 100,000 individuals; the average annual incidence of confirmed and possible cases SJS/TEN 
(conditions 1 + 2) was 15.3 (range 0-28.3) cases per 100,000 individuals (Table 2.2). Confirmed 
cases of SJS/TEN were more common in hematologic diagnoses (i.e., leukemias, lymphomas, 
multiple myeloma, and MDS) compared to solid malignancies [0.09% (14/15,813) vs. 0.007% 
(6/90,567), respectively]. Interestingly, 5 of the 20 (25%) confirmed cases occurred in patients 
with acute myeloid leukemia. Of the confirmed cases of SJS/TEN, 35% (7/20) had undergone 
hematopoietic stem cell transplantation prior to SJS/TEN diagnosis, 57% (4/7) of which were 
allogeneic.  
Triggers of SJS and TEN 
Classifying agents according to drug class, there were 69 physician-reported culprits for 
the 62 confirmed, possible, and historical cases of SJS/TEN; the trigger for 6 patients was 
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unknown. Physician-reported triggers for SJS/TEN diagnoses included antibiotics, 
anticonvulsants, anticancer agents, anti-gout, antifungals, and immunomodulators, amongst 
others (Figure 2.1). The most common trigger in all identified cases of SJS/TEN was antibiotics 
(33/62 cases, 53.2%), with trimethoprim/sulfamethoxazole being the most frequently stated 
culprit (14/62 cases, 22.6%). Anticonvulsants and antineoplastic agents were the second most 
commonly stated trigger (6/62 cases, 9.7% each). Antineoplastics attributed to SJS/TEN 
reactions included temozolomide, hyper-CVAD combination therapy, and irinotecan, amongst 
others, which were each attributed to one case. Immunomodulatory antineoplastics included 
interferon (n = 1), methotrexate (n = 2), and lenalidomide (n = 1). The miscellaneous agents, 
each attributed to one historical case of SJS/TEN, were bisphosphonates, estrogen or ibuprofen, 
epoetin alfa, saline, and clobetasol. (See Appendix 2.1 for a detailed list of all attributed 
triggers.) 
Of the 121 SJS/TEN diagnoses codes, 10 (8.3%) individuals received treatment with a 
TKI; however, 70% of the cases definitively could not be linked to the SJS/TEN reaction (4/10 
initiated the TKI after SJS/TEN diagnosis and in another 3/10, SJS/TEN diagnosis was ruled 
out). Of the three remaining cases that could potentially be linked to TKI use, only one possible 
case (condition 2) was attributed to a TKI by the physician; the patient was blinded to treatment 
on a clinical trial of sorafenib vs. sunitinib, both of which are multi-targeted TKIs, was 
diagnosed with erythema multiforme of unspecified degree, and treatment was discontinued. For 
the remaining two cases, one was treated with erlotinib one month prior to SJS/TEN, which was 
attributed to penicillin, and the other was treated with dastinib three months prior to SJS/TEN, 
which was attributed to trimethoprim/sulfamethoxazole. This corresponds to possible SJS/TEN 
prevalence of 20-60 cases per 100,000 individuals (1-3 cases/4,977 patients prescribed a TKI) in 
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individuals treated with TKIs.      
Discussion 
 We utilized our institutional electronic health system biorepository of over 100,000 
patients to determine the incidence and identify potential triggers of SJS/TEN in cancer patients. 
In our study cohort, the average annual incidence of SJS/TEN was 6-15 cases per 100,000 per 
year. Most conservatively, this corresponds to a 25-60-fold higher incidence in cancer patients 
than reported in the general population; leniently, the incidence observed is 77-150-fold higher in 
cancer patients. Other diseases, such as HIV, also have a heightened incidence of SJS/TEN 
compared to the general population.
181
 An elevated incidence of SJS/TEN has also been 
observed in specific geographic regions, in particular East Asia, likely due to the presence of 
high susceptibility HLA loci.
182
 Overall, reported triggers of SJS/TEN in our cancer patient 
cohort were similar to those known to be associated with the reaction in the general population, 
and included antibiotics, anticonvulsants, and anti-gout agents; however, some cases of SJS/TEN 
were attributed to cancer-specific therapies, including antineoplastics, monoclonal antibodies, 
and immunomodulators. We observed a relatively low prevalence of SJS/TEN in patients 
receiving TKIs, with only one possible case of SJS/TEN being linked to TKI use. Due to the 
relatively small number of patients prescribed a TKI in our cohort, we have insufficient evidence 
to draw a definitive conclusion regarding the possible association between TKI use and 
SJS/TEN. While we cannot confirm a heightened risk of SJS/TEN, challenges to culprit drug 
attribution exist. Physicians are likely to preferentially attribute SJS/TEN reactions to drugs with 
reported associations, and, due to the severity of the reaction, patients will never be re-
challenged with potential triggers, so culprits cannot be confirmed and causality is not definitive. 
If all three cases of individuals on TKIs were, in fact, associated with TKI usage, this would 
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correspond to an approximately 600-fold increased risk compared to the general population. 
 Cancer patients have been shown to have increased mortality rates from SJS/TEN when 
compared to individuals without cancer,
183
 therefore, a thorough understanding of the factors that 
increase risk of SJS/TEN in cancer patients is especially critical to facilitate early culprit 
withdrawal and maximize patient outcomes. The immunocompromised state of many cancer 
patients, the observation of immunomodulators as a trigger, and the higher incidence of SJS/TEN 
in HIV patients suggest a possible role of the immune system in the increased risk of 
SJS/TEN.
167
 Other possible explanations include increased exposure to culprit medications, and 
the cancer disease process, or synergy between risk factors. 
 A notable strength of our study was the utilization of electronic medical records to 
confirm ICD-9 code diagnoses. It has been demonstrated that use of claims databases to 
investigate incidences of SJS results in significant overestimates; in fact, Strom and colleagues 
found that only 14.8% of individuals with SJS claims had a final diagnosis of SJS.
184
 Likewise, 
in our study we found that only 16.5% (20/121) of individuals with SJS/TEN ICD-9 codes had 
confirmed diagnoses. The use of claims data alone would have resulted in a 600 to 1200-fold 
higher incidence in cancer patients being reported. 
 Limitations of our study are inherent to the challenges of treating SJS. First, there are no 
definitive diagnostic criteria for SJS/TEN, so it is possible that cases of SJS/TEN were missed 
during our screening phase that relied on querying ICD codes. Additionally, as stated above, 
culprits cannot be confirmed and causality cannot be definitively determined. Variable follow-up 
times may have contributed to a decreased observation of cases, further contributing to the 
conservative nature of the estimate reported. Future studies are warranted to determine the role 
of the cancer disease process, immune system, and culprit drugs on SJS/TEN pathogenesis in 
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cancer patients. Ultimately, a comprehensive SJS/TEN prediction algorithm, incorporating 
drugs, immune system status, and relevant genetics (e.g., HLA type), may assist in identifying 
high-risk patients and facilitating early detection and withdrawal of causative agents to maximize 
patient outcomes.    
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Tables and Figures 
Table 2.1: Patient demographics for individuals screened for Stevens-Johnson syndrome. 
Summary information is provided for entire cohort screened and all possible cases of Stevens-
Johnson syndrome (SJS) and/or toxic epidermal necrolysis (TEN), sorted by classification based 
on manual chart review. Incidence is presented for confirmed cases (condition 1) and possible 
cases (condition 2).  
Characteristic 
Patients 
screened*  
Confirmed 
cases 
Possible 
cases 
Historical 
cases 
All cases 
(n = 108,825) (n = 20) (n = 30) (n = 12) (n = 62) 
Age# - 53 (29-78) 58 (23-76) 60 (32-80) 59 (23-80) 
Sex 
     
     Female 53,789 (49%) 7 (35%) 18 (60%) 6 (50%) 31 (50%) 
     Male 55,033 (51%) 13 (65%) 12 (40%) 6 (50%) 31 (50%) 
   Unknown 3 (<0.01%) 0 0 0 0 
Race 
     
     White 97,846 (90%) 18 (90%) 27 (90%) 12 (100%) 57 (92%) 
     Black 5,547 (5%) 1 (5%) 2 (7%) 0 3 (5%) 
     Asian 1,279 (1%) 1 (5%) 0 0 1 (2%) 
     Other 4,153 (4%) 0 1 (3%) 0 1 (2%) 
Ethnicity 
     
     Non-Hispanic 97,423 (89.5%) 17 (85%) 25 (83%) 12 (100%) 54 (87%) 
     Hispanic 7,088 (6.5%) 2 (10%) 4 (13%) 0 6 (10%) 
     Unknown 4,314 (4%) 1 (5%) 1 (3%) 0 2 (3%) 
Cancer Type 
     
     Solid 90,567 (83%) 6 (30%) 18 (60%) 9 (75%) 33 (53%) 
     Hematologic 15,813 (14.5%) 14 (70%) 10 (33%) 3 (25%) 27 (44%) 
     Unknown 2,445 (2%) 0 2 (7%) 0 2 (3%) 
Prevalence of 
SJS/TEN 
NA 18/100,000 28/100,000 11/100,000 57/100,000 
*Patients were initially screened under a de-identified protocol, so age at diagnosis is 
unavailable. Cancer type represents primary site as reported in Florida Cancer Registry. 
#
Age listed represents the median and range at time of SJS/TEN ICD-9 code 
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Table 2.2: Incidence of Stevens-Johnson syndrome and toxic epidermal necrolysis by year. 
 
Minimum 
 
Maximum 
Time period 
Confirmed 
only 
# Screened 
Incidence/ 
100,000 
  
Confirmed 
+ Possible 
# 
Screened 
Incidence
/ 100,000 
6/15 - 12/31/02 2 * * 
 
4 * * 
2003 0 14,125 0 
 
4 14,125 28.32 
2004 3 19,193 15.63 
 
3 19,193 15.63 
2005 3 21,365 14.04 
 
4 21,365 18.72 
2006 1 25,411 3.94 
 
5 25,411 19.68 
2007 0 26,499 0 
 
3 26,499 11.32 
2008 0 23,683 0 
 
0 23,683 0 
2009 2 25,244 7.92 
 
4 25,244 15.85 
2010 1 18,763 5.33 
 
3 18,763 15.99 
2011 1 28,313 3.53 
 
5 28,313 17.66 
2012 1 31,124 3.21 
 
3 31,124 9.64 
2013 2 32,116 6.23 
 
4 32,116 12.45 
2014 3 33,001 9.09 
 
6 33,001 18.18 
1/1 - 6/15/15 1 25,092 3.99   2 25,092 7.97 
01/01/03-6/15/15 18 323,929#  5.56 
 
46 323,929#  14.2 
Average annual 
incidence 
  5.91 
 
  15.3 
 
*Electronic billing system implementation in 2003 complicates denominator determination for 
2002. 
#Due to patients being treated over multiple years, this sum does not represent unique patients 
screened, rather it is the total number of patients screened during all periods.    
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Figure 2.1: Triggers of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis 
(TEN). Triggers were identified from patient medical records and are reported according to 
SJS/TEN occurrence: confirmed cases (n = 20 patients), possible cases (n = 30) and historical 
cases (n = 12). For some patients, there was not a single definitive trigger, resulting in attribution 
to and discontinuation of multiple medications, which results in a higher number of attributed 
cases on the y-axis than number of cases in some groups (confirmed: 28, possible: 35, and 
historical: 12). Three patients (yellow) were on TKIs closely preceding or at time of SJS/TEN 
diagnosis.  
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CHAPTER 3: IDENTIFYING POTENTIAL DEMOGRAPHIC AND CLINICAL 
FACTORS PREDICTIVE OF RESISTANCE TO MULTI-TARGETED TYROSINE 
KINASE INHIBITORS  
Summary 
Multi-targeted tyrosine kinase inhibitors (TKIs) are widely prescribed antineoplastic 
agents that provide significant benefit in overall and progression-free survival across a wide 
range of cancer types. Despite their overall efficacy, approximately 20% to 30% of individuals 
with clinical indication for a multi-targeted TKI will not respond, demonstrating intrinsic 
resistance. We conducted a retrospective cohort study to identify potential demographic and 
clinical features associated with intrinsic resistance to multi-targeted TKIs. Chart reviews of 266 
cancer patients treated with multi-targeted TKIs were completed and clinical imaging studies, 
radiologists’, and oncologists’ impressions of disease before and after TKI initiation were 
evaluated to classify patients as resistant or non-resistant. Demographics, including age, sex, 
race, and ethnicity, and clinical factors, including tumor type, TKI received, and duration of 
treatment, were compared between resistant and non-resistant patients. We observed an overall 
resistance rate of 21% in our cohort of patients receiving multi-targeted TKIs in the context of 
routine clinical practice. There were no significant differences in the demographics or clinical 
features of resistant versus non-resistant patients, other than duration of multi-targeted TKI 
treatment, which was significantly longer in non-resistant compared to resistant patients (11 mo 
vs. 3.6 mo, FDR p-value = 1.1 x 10
-6
). In conclusion, the phenomenon of intrinsic resistance to 
multi-targeted TKIs observed in both clinical trials and routine practice was not explained by 
differences in demographics, tumor type, or TKI received in our cohort. Similar rates of 
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resistance in the subgroups analyzed suggest that there may be other unidentified shared markers 
of resistance to these agents.  
 
Introduction 
Tyrosine kinase inhibitors (TKIs) are widely prescribed antineoplastic agents that provide 
significant benefit in progression-free and overall survival in a wide range of solid tumors and 
hematologic malignancies. A subset of TKIs, the multi-targeted TKIs function by inhibiting 
multiple tyrosine kinases known to be important in regulation of oncogenic cell proliferation, 
differentiation, and survival (Table 3.1). The promiscuity of these agents results in broad efficacy 
across cancer types, as well as potential for adverse effects driven by inhibition of off-target, 
non-cancer driving tyrosine kinases. Therefore, a benefit-to-risk assessment is crucial to inform 
personalized decision-making when prescribing these medications.  
 The clinical trials that led to approval of the multi-targeted TKIs demonstrated overall 
improvements in progression free and overall survival, however, a significant percentage of 
individuals in each clinical trial did not derive even transient benefit from these agents – 
demonstrating intrinsic resistance. For example, in the phase III clinical trial that led to approval 
of sorafenib for the treatment of advanced hepatocellular carcinoma, 21% of individuals in the 
sorafenib treatment arm experienced progressive disease from the outset.
136
 Similarly, in the 
phase III GRID trial for regorafenib in advanced gastrointestinal stromal tumors (GIST), 20% of 
individuals discontinued treatment at first follow-up due to disease progression.
104
 The phase III 
clinical trial for cabozantinib in medullary thyroid cancer demonstrated similar resistance rates 
with 26% of individuals in the active treatment arm discontinuing therapy due to progressive 
disease.
185
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Pre-emptive identification of individuals who may respond to multi-targeted TKIs versus 
those not likely to benefit, but only be subjected to adverse effects, is critical to optimize the 
benefit-to-risk assessment when prescribing these medications. The aforementioned clinical trials 
performed analyses to identify potential demographic and clinical factors (e.g., sex, race, 
ethnicity, tumor type, etc.) associated with response to active drug versus placebo, however, 
analyses have not been performed within the active drug arms to identify potential prognostic 
factors characteristic of individuals who did not respond to active treatment. The primary 
objective of this study was to identify potential demographic and clinical factors that may be 
predictive of intrinsic resistance to multi-targeted TKIs. We conducted a retrospective cohort 
study of individuals treated with multi-targeted TKIs within routine clinical practice and 
explored differences in demographic and clinical features of individuals who demonstrated 
intrinsic resistance compared to those who achieved any degree of response (i.e., stable disease, 
partial response, or complete response).   
Methods 
Patient population 
Patients were identified from the Total Cancer Care (TCC) cohort at Moffitt Cancer 
Center, an institutional review board (IRB)-approved biobanking protocol in which individuals 
agree to provide tissue and blood samples for research and to be followed throughout their 
lifetime.
186
 Additional IRB approval was granted to conduct this particular study in the TCC 
cohort (MCC #18603). Individuals eligible for study inclusion were patients consented between 
January 1, 1994 and December 31, 2015 over the age of 18 years at diagnosis, who had a solid 
tumor diagnosis and were treated at Moffitt Cancer Center with a multi-targeted TKI (axitinib, 
cabozantinib, pazopanib, regorafenib, sorafenib, sunitinib, or vandetanib). Exclusion criteria 
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included individuals treated with a single-targeted TKI (e.g., gefitinib, which selectively targets 
the epridermal growth factor receptor or crizotinib, which selectively targets the anaplastic 
lymphoma kinase, etc.) and individuals treated with a multi-targeted TKI for a hematologic 
malignancy, due to challenges in determining response in the adjuvant setting.   
Data collection 
Data was initially abstracted in a standardized manner from the TCC biorepository 
system (TransMed, Cupertino, CA). Data abstracted from TransMed included demographic 
variables (date of birth, sex, race, and ethnicity) as well as clinical information, including date of 
diagnosis, primary site at diagnosis, histology, first course of treatment, multi-targeted TKI(s) 
received, and start and stop date of TKI(s). Sources for these data were Florida Cancer Registry 
and electronic medical records (Appendix 3.1). Information abstracted from TransMed was used 
to guide manual chart reviews.  
Chart reviews were conducted by two independent clinicians and researchers to verify 
abstracted data and generate treatment phenotypes for eligible individuals. Patients were 
classified as either “resistant” or “non-resistant” based on clinical response to first multi-targeted 
TKI received. Specifically, the date of initiation of the first multi-targeted TKI received was 
collected from clinical notes and recorded; the tumor type being treated with the first multi-
targeted TKI was also noted. Imaging scans (including PET, CT, MRI, and ultrasounds) 
conducted most recently prior and soonest after TKI initiation were reviewed. Radiologists’ and 
oncologists’ assessments of patient response were utilized to determine whether each patient 
derived some clinical benefit from the TKI (non-resistant) or progressed despite TKI treatment 
(intrinsically resistant). If a patient had imaging at any point after TKI initiation that 
demonstrated clinical response, they were classified as non-resistant; a trial period of at least one 
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month was required to determine resistance to TKI treatment. Independently derived phenotypes 
(i.e., resistant vs. non-resistant) were compared between reviewers. In the case of discrepancies, 
adjudication was conducted by a third clinician and researcher (Jeffrey Russell, MD, PhD).       
Data analysis 
This was an exploratory study which included 266 patient cases identified in the TCC 
biorepository. Non-parametric statistics were employed as to not assume normality of our data. 
Patient demographics between intrinsically resistant and non-resistant individuals were 
compared using contingency tables and Fisher’s exact test for categorical variables, and Mann 
Whitney U test for continuous variables. Odds ratios and 95% confidence interval (CI) were 
calculated using logistic regression. A false-discovery rate (FDR) correction was used to correct 
for multiple comparisons, and an FDR-corrected p-value less than 0.05 was considered 
significant. A post-hoc power calculation was conducted using an FDR-corrected threshold of α 
= 0.00714, β = 0.8, and incorporating variable proportions of individuals with exposures to 
account for differences in variables (Table 3.2). Statistical analyses were conducted using R 
(version 3.2). A box and whisker plot and histogram were created in GraphPad Prism 6, and a 
forest plot was generated using SAS (version 9.3).  
Results 
Patient population  
The approval timeline of multi-targeted TKIs (Table 3.1) resulted in a recruitment period 
of 2005 – 2016. A total of 266 patient charts were reviewed for this study. Of those charts 
reviewed, four patients first received a multi-targeted TKI to treat a hematologic malignancy and 
were excluded from further analyses. The demographics and clinical characteristics of the study 
cohort were as expected based on the patient demographics at Moffitt Cancer Center and the 
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FDA-approved indications and off-label uses of multi-targeted TKIs (Table 3.3). The median age 
of the study cohort was 56 years old (interquartile range 47-66). There were slightly more males 
(170/262, 65%) than females (92/262, 35%), and the vast majority of the population self-
indicated as white (247/262, 94%) non-Hispanic (242/262, 92%). The primary tumor types being 
treated with the multi-targeted TKIs were renal cell carcinoma (RCC, 137/262 or 52%) and 
sarcoma, not otherwise specified (including GIST, 53/262 or 20%). Thirty-two patients (12%) 
were prescribed, but never started, a multi-targeted TKI, so were excluded from resistant versus 
non-resistant classification.  
Clinical factors and associations with resistance 
Of the 230 evaluable patients, 45 (20%) could not be classified as resistant or non-
resistant because drug discontinuation was attributed to side effects only and no imaging studies 
were available to assess response (n = 21), patient was lost to follow-up (n=15), patient was not 
on therapy long enough to assess response (n = 6), or, specifically, patient died before response 
was assessed (n = 3). Of the remaining 185 evaluable patients, 39 (21%) were classified as 
resistant and 146 (79%) were classified as non-resistant.  
There were no statistically significant differences in the age, sex, race, or ethnicity of 
resistant and non-resistant patients (Table 3.4). Neither tumor type being treated nor multi-
targeted TKI received were associated with resistance (FDR-corrected p-value = 0.59 and 0.49, 
respectively). As an exploratory observation, tumor types that demonstrated higher rates of 
resistance than would be expected based on published literature included hepatocellular 
carcinoma (2/6 or 33% resistance), melanoma (3/7 or 43% resistance), and pancreatic 
neuroendocrine (4/11 or 36% resistance); patients treated with pazopanib also demonstrated 
higher resistance rates than would be expected (6/17 or 35%) (Figure 3.1). Odds ratios 
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demonstrated essentially no difference in resistance by age (OR = 0.98, 95% CI 0.96 – 1.01) or 
race (OR = 0.93, 95% CI 0.093 – 4.96) (Figure 3.2). Females were slightly more likely to be 
non-resistant than males (OR = 0.54) and non-Hispanics were slightly more likely to be resistant 
than Hispanics (OR = 1.37), however, these findings did not reach statistical significance (95% 
CI = 0.21 – 1.29 and 0.36 – 7.79, respectively). Duration of multi-targeted TKI administration 
was significantly longer in non-resistant patients compared to resistant patients (11 mo vs. 3.6 
mo, FDR p-value = 1.1 x 10
-6
, Figure 3.3).      
Discussion 
We conducted an exploratory retrospective study to identify demographic and clinical 
features associated with intrinsic resistance to multi-targeted TKIs. Our overall observations of 
this routine clinical practice cohort closely mimicked that observed in large phase III clinical 
trials. We observed an intrinsic resistance rate of 21% in our study cohort, and approximately 
20% of individuals discontinued treatment early due to intolerable side effects.
104,136,185
 
Demographic factors explored for association with resistance included age, sex, race, and 
ethnicity; clinical factors of interest were tumor type/indication and multi-targeted TKI received. 
We did not identify any statistically significant associations between the demographics or 
clinical factors with intrinsic resistance. However, there was a highly significant association 
between duration of multi-targeted TKI administration and resistance, with resistant patients 
discontinuing therapy 35% sooner than non-resistant patients. Significance of this finding 
supports our phenotyping methodology and reiterates the dichotomy of responses to multi-
targeted TKIs. Furthermore, the time on therapy for resistant patients (median = 3.6 mo) 
represents valuable time that patients were put at risk for adverse effects while not receiving 
therapeutic benefit.  
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 This exploratory study suggests that intrinsic resistance to multi-targeted TKIs cannot be 
predicted based on demographics, cancer type/indication, or multi-targeted TKI administered. 
This finding is echoed by the results of the phase III clinical studies, which, when stratifying by 
demographic and clinical features, found that the multi-targeted TKIs provided significantly 
better outcomes than placebo or standard of care across all subgroups.
104,134,138,139,185
 For 
example, Cox proportional hazards analysis of progression-free survival in pancreatic 
neuroendocrine patients receiving sunitinib versus placebo resulted in hazard ratios (HR) of 0.37 
(95% CI 0.2 – 0.7) for males and 0.48 (95% CI 0.2 – 0.9) for females, 0.49 (95% CI 0.3 – 0.9) 
for whites and 0.35 (95% CI 0.2 – 0.7) for non-whites.138 The similarity in the effect sizes and 
variability of the parameters provides support for the lack of association of these variables with 
response or resistance. Some of these clinical studies also performed molecular analysis in 
attempts to identify molecular predictors of response. The study of cabozantinib in thyroid 
carcinoma explored RET mutational status as a predictor of response and found that response 
rates were similar in RET mutated and RET wildtype individuals (objective response rates = 32% 
and 25%, respectively).
185
 Similarly, the GRID study found no differences in response in 
individuals harboring common KIT mutations (HR 0.21 and 0.24).
104
  
Despite clinical relevance, there is a paucity of data exploring resistance to multi-targeted 
TKIs. To date, there have been no successful studies identifying predictive markers of response 
or resistance to these widely prescribed medications. In this study we conducted an exploratory 
analysis in attempts to identify demographic and clinical factors that may be predictive of 
resistance. While failure to detect a significant association with any of the factors explored and 
resistance may be due to insufficient statistical power, based on similar observations in clinical 
studies, we believe that these characteristics are not informative in predicting response to these 
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agents. Additionally, the finding that there were no significant differences in resistance rates 
based on demographic characteristics, tumor type, or TKI received, suggests that there may be 
other shared factors that contribute to resistance to these agents. Additional studies are warranted 
to identify robust predictive markers of resistance to multi-targeted TKIs that can be used to 
optimize personalized treatment recommendations and maximize patient outcomes.   
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Tables and Figures 
Table 3.1: FDA-approved multi-targeted tyrosine kinase inhibitors. Information provided 
includes FDA-approved and off-label indication(s), approval date(s), and select drug target(s). 
Abbreviations – CRC: colorectal carcinoma, GIST: gastrointestinal stromal tumor, HCC: 
hepatocellular carcinoma, pNET: pancreatic neuroendocrine tumor, RCC: renal cell carcinoma 
Drug 
FDA-approved indications 
(approval date, mo/yr) 
Off-label uses Select drug targets 
axitinib RCC (1/2012) thyroid cancer 
KIT, PDGFR, 
VEGFR1-2 
cabozantinib 
RCC (4/2016) 
thyroid cancer (1/2012)  
KIT, FLT3, MET, 
RET, VEGFR1-3 
pazopanib 
RCC (10/2009) 
soft tissue sarcoma (4/2012) 
thyroid cancer 
KIT, PDGFR, 
VEGFR1-3 
regorafenib 
GIST (2/2013) 
CRC (2/2013) 
HCC 
BRAF, KIT, PDGFR, 
RET, TEK, TIE2, 
VEGFR1-3 
sorafenib 
HCC (11/2007) 
RCC (12/2005) 
thyroid cancer (3/2013) 
angiosarcoma 
GIST 
BRAF, CRAF, FLT3, 
KIT, PDGFR, 
VEGFR1-2 
sunitinib 
GIST (1/2006) 
pNET (5/2011) 
RCC (1/2006) 
thyroid cancer 
soft tissue sarcoma 
CSF1, FLT3, KIT, 
PDGFR, RET, 
VEGFR1-3 
vandetanib thyroid cancer (4/2011) 
 
EGFR, FGFR, RET, 
VEGFR1-2 
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Table 3.2: Post-hoc power calculation. Alpha represents an FDR-corrected alpha level. The p0 
represents the proportion of individuals with the exposure.  For example, with a 10% proportion 
of females, an odds ratio (OR) of approximately 5 could be detected with these defined statistical 
thresholds.  
Cases (n) Controls (n) alpha beta p0 OR 
39 146 0.00714 0.8 0.1 5.053 
39 146 0.00714 0.8 0.2 4.047 
39 146 0.00714 0.8 0.3 3.853 
39 146 0.00714 0.8 0.4 4.001 
39 146 0.00714 0.8 0.5 4.525 
39 146 0.00714 0.8 0.6 5.906 
39 146 0.00714 0.8 0.7 11.808 
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Table 3.3: Patient demographics.  
Characteristic Number (%),  
n = 262 
Age at diagnosis 56 (47-66) 
Sex 
   Male 
   Female 
 
170 (65) 
92 (35) 
Race 
   White 
   Black 
   Asian 
   Unknown 
 
247 (94) 
10 (4) 
4 (2) 
1 (0) 
Ethnicity 
   Hispanic 
   Non-Hispanic 
 
20 (8) 
242 (92) 
Diagnosis (tumor type) 
   Brain 
   Breast 
   Colorectal 
   Gynecologic 
   Hepatocellular 
   Melanoma 
   Pancreatic neuroendocrine 
   Renal cell 
   Sarcoma 
   Thyroid 
   Other 
 
6 (2) 
8 (3) 
4 (2) 
5 (2) 
9 (3) 
11 (4) 
14 (5) 
137 (52) 
53 (20) 
6 (2) 
9 (3) 
TKI received 
   axitinib 
   cabozantinib 
   pazopanib 
   sorafenib 
   sunitinib 
   N/A 
 
4 (2) 
1 (0) 
20 (8) 
74 (28) 
131 (50) 
32 (12) 
Continuous data is presented as median (interquartile range). 
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Table 3.4: Comparison of patient demographics and clinical characteristics by phenotype.   
Characteristic 
Resistant,  
N (%) (n=39) 
Non-resistant, 
N (%) (n=146) 
P-value 
FDR-
corrected 
P-value 
Age at diagnosis 59 (47-68) 55 (46-64) 0.22* 0.49 
Sex 
   Male 
   Female 
 
30 (77) 
9 (23) 
 
94 (64) 
52 (36) 
0.18 
 
0.49 
 
Race 
   White 
   Other 
      Black 
      Asian 
     Unknown 
 
37 (95) 
  2 (5) 
  1 (50) 
  1 (50) 
  0 
 
138 (95) 
    8 (5) 
   7 (88) 
   0 
   1 (13) 
1.0 
 
1.0 
 
Ethnicity 
   Hispanic 
   Non-Hispanic 
 
3 (8) 
36 (92) 
 
15 (10) 
131 (90) 
0.77 
 
0.90 
 
Diagnosis (tumor type) 
   Brain 
   Breast 
   Colorectal 
   Gynecologic 
   Hepatocellular 
   Melanoma 
   Pancreatic neuroendocrine 
   Renal cell 
   Sarcoma 
   Thyroid 
   Other 
 
1 (3) 
0  
0 
1 (3) 
2 (5) 
3 (8) 
4 (10) 
16 (41) 
11 (28) 
0 
1 (3) 
 
3 (2) 
4 (3) 
3 (2) 
4 (3) 
4 (3) 
4 (3) 
7 (5) 
80 (55) 
29 (20) 
5 (3) 
3 (2) 
0.42 0.59 
TKI received 
   axitinib 
   pazopanib 
   sorafenib 
   sunitinib 
 
0 
6 (15) 
10 (26) 
23 (59) 
 
4 (3) 
11 (8) 
51 (35) 
80 (55) 
0.28 0.49 
Duration of TKI treatment 
(mo) 
3.6 (2-5.3) 11 (6.8-18.1) <0.0001* 1.1x10
-6 
Continuous data is presented as median (interquartile range).  
*P-value calculated using Mann Whitney U test.  
 
  
 62 
 
Figure 3.1: Observed resistance rates by clinical characteristics. Gray dashed lines represent 
the commonly reported range of non-responders in clinical trials. No bar corresponds to zero 
resistant individuals in our cohort. Sample sizes for each classification are presented in Table 5. 
Abbreviation – pNET: pancreatic neuroendocrine tumor. 
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Figure 3.2: Forest plot of the relationship between demographic features and resistance. 
Blue diamonds represent odds ratios (OR) and bars represent the upper and lower 95% 
confidence intervals (95% CI). An OR greater than one favors the resistance phenotype, while an 
OR less than one favors the non-resistance phenotype.  Reference groups for sex, race, and 
ethnicity were female, non-white, and non-Hispanic, respectively. Duration corresponds to the 
amount of time, in months, that individuals remained on the first multi-targeted tyrosine kinase 
inhibitor prescribed.  
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Figure 3.3: Duration of multi-targeted TKI treatment by phenotype. Boxes represent the 
fiftieth percentiles, with the lines in the middle representing the median values; whiskers 
represent the 2.5 to 97.5 percentiles.  
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CHAPTER 4: IDENTIFYING VARIABLES INFLUENCING THE FEASIBILITY OF 
USING FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE SAMPLES TO 
GENERATE WHOLE EXOME SEQUENCING 
Summary 
Formalin-fixed paraffin-embedded (FFPE) tissue samples represent one of the most 
potentially valuable resources for clinical research. However, molecular alterations caused by the 
formalin fixation process, such as DNA crosslinking and degradation, present challenges to 
optimizing the value of these samples. Despite these challenges, multiple studies have 
demonstrated that next-generation sequencing of matched FFPE and fresh frozen tissue samples 
generate highly concordant sequencing data; however, a couple of studies have provided 
preliminary evidence to suggest that older FFPE samples may not yield quality sequencing 
results.  
We conducted an exploratory study to determine if age of FFPE tumor samples affects 
ability to generate high quality whole exome sequencing (WES) data. Patient samples were 
identified from the Total Cancer Care cohort at Moffitt Cancer Center. Patients were included 
based on cancer diagnosis (sarcoma or renal cell), receipt of a multi-targeted tyrosine kinase 
inhibitor, and age of FFPE sample available (grouped into 1 to 3, 3 to 5, 5 to 7, 7 to 10, and 
greater than 10 years old). To maximize data quality, DNA was extracted from FFPE blocks 
using an FFPE-specific DNA extraction kit and WES was conducted using protocols modified 
for FFPE samples. Quality of WES was assessed using standard criteria for tumor sequencing, 
and included fold-coverage, percent of duplicate reads, percent of properly paired paired-end 
reads, percent of reads that mapped to the reference genome, and transition-to-transversion ratio. 
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Factors explored as potential predictors of WES success included the age, tissue source, amount 
of DNA yield, and DNA integrity (DIN) of the FFPE samples.  
DNA extraction and sequencing of the 28 selected samples found that 2 (7.1%) failed to 
generate a sufficient quantity of DNA and 1 (3.6%) had some low-quality WES metrics. Both of 
the samples that failed to yield sufficient DNA were the only tumors derived from bone tissue. 
There was no association between the age of FFPE samples and failure to generate quality WES 
(p = 0.99). However, there was an association between DNA yield from FFPE samples and DIN 
and ability to generate quality WES (p <0.001 and 0.04, respectively). Our results suggest that 
FFPE tumor samples provide a reasonable, valuable source for retrospective genetic studies 
regardless of storage time. Rather, factors that may limit usability of samples include amount of 
DNA yield and potentially DNA integrity or derivation from bone tissue.  
 
Introduction 
Formalin fixation with paraffin embedding was first described over 100 years ago, and 
represents the standard tissue sample preparation method used by pathologists for decades. A 
major benefit of formalin-fixed paraffin-embedded (FFPE) samples is that they are stable at 
room temperature, making them easily storable and suitable for large collections of clinical 
samples associated with historical clinical records. In fact, it has been reported that there are 
more than a billion FFPE tissue samples archived in hospitals and tissue banks around the world, 
making FFPE samples one of the most potentially valuable resources for retrospective clinical 
research.
187
  
 The potential advantage of FFPE samples in clinical research is challenged by the 
molecular alterations that result from the formalin fixation and paraffin embedding process. It is 
 67 
 
well established that FFPE samples undergo extensive degradation and nucleic acid alterations 
during preparation. Specifically, the formalin fixation process causes hydrolysis of 
phosphodiester bonds leading to DNA fragmentation.
188
 When performing paired-end 
sequencing (i.e., DNA sequencing in the forward and reverse direction), DNA fragmentation has 
potential to result in an excess of overlapping, or duplicate reads. Additionally, the cross-linking 
of cytosine nucleotides with formalin inhibits DNA polymerase from recognizing the cytosine 
residues and incorporates adenine in place of guanine, resulting in erroneous C>T or G>A 
mutations.
189
 These artificial mutations as known as sequencing artifacts, and are more common 
in FFPE samples when compared to fresh frozen (FF) samples.
190
   
 The advent of next-generation sequencing (NGS) has the potential to overcome the 
molecular challenges inherent to FFPE samples. NGS is high-throughput, massively parallel, 
deep sequencing. The power of NGS to analyze small segments of DNA in depth with repetitive 
coverage minimizes the challenges of fragmentation and mutations introduced by formalin 
fixation. First, the presence of introduced overlapping reads in FFPE-derived samples will 
become apparent at high coverage, allowing for duplicate reads to be discarded. Similarly, the 
sequencing artifacts will be distributed randomly throughout the genome and excessive 
mismatches within a region will not align properly to the reference genome and will be discarded 
as erroneous mutation calls. In fact, there have been numerous studies demonstrating high 
concordance between NGS of matched FF and FFPE tissues. Oh and colleagues conducted 
whole-exome sequencing (WES) of matched FF and FFPE samples from four cancer patients 
and found evidence of DNA damage in the FFPE samples, including higher rates of artificial 
base alterations (mostly C>T or G>A) and higher number of overlapping paired reads (29% vs. 
12%); however, after filtering these artifacts and regions of low coverage, high concordance of 
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mutation calls were reported.
190
 In a similar study, Munchel and colleagues conducted targeted 
and whole genome sequencing of 13 pairs of matched FF and FFPE tissue samples, and found 
high (>98.9%) concordance of WES base calls and single nucleotide variant calls (>96%) in all 
matched pairs.
191
 Bonfiglio and colleagues reported slightly higher duplicate rates in FFPE 
samples than FF samples (3.6% vs. 1.8%, respectively), as would be expected, but also observed 
high (>90%) concordance between single nucleotide variant calls in FF and FFPE-derived tumor 
samples.
192
 Astolfi and colleagues classified FFPE samples as generating low quality or high 
quality DNA, and found that the sequencing calls from high-quality FFPE samples generated 
results highly concordant (94-96%) to FF-derived sequencing.
193
 These findings emphasize the 
importance of high-quality DNA and high sequencing coverage to overcome challenges with 
generating quality sequencing data from FFPE samples.  
 Limited studies have suggested that age of FFPE samples (i.e., amount of time stored) 
may be an important factor to consider when using FFPE-derived samples for NGS. A study 
exploring the effects of formalin fixation on nucleic acids hypothesized that extensive storage of 
FFPE samples at room temperature may lead to nucleic acid degradation.
188
 A comparative study 
of matched FF/FFPE samples (some from tumor and some from normal tissue) from a range of 
storage times reported that there was a tendency for DNA degradation and percent of duplicates 
to increase with storage time.
194
 The limiting step for DNA sequencing generation from older 
FFPE samples was preparation of the library, and library preparation yields were inversely 
correlated with storage time. Another study demonstrated that older FFPE samples had lower 
coverage (6% lower per 10 years) and lower average read depth (40x lower per 10 years), but 
usable NGS data was generated from 90% of samples, regardless of storage time.
195
 Therefore, 
while FFPE samples provide a vast resource for retrospective clinical studies, the usability of all 
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of the samples, particularly older samples, remains uncertain. We conducted a pilot study to 
explore the effect of age of FFPE samples on WES quality using the Agilent SureSelect
XT
 
Clinical Research Exome kit in conjunction with the newly released FFPE QC kit (Agilent, Santa 
Clara, CA). Additional factors explored for association with WES quality were FFPE-derived 
DNA quality and quantity. We hypothesized that older FFPE blocks would result in low-quality 
WES.   
Methods 
Patient samples 
Patients were identified from the Total Cancer Care (TCC) cohort at Moffitt Cancer 
Center, an institutional review board (IRB)-approved biobanking protocol in which individuals 
agree to provide tissue and blood samples for research and to be followed throughout their 
lifetime.
186
 Additional IRB-approval was granted to request tissue samples and conduct this 
particular study under a de-identified pilot protocol (MCC #50113) using the TCC cohort. 
Therefore, patient protected health information (PHI) was not accessible for detailed analysis. 
Individuals eligible for study inclusion were patients consented between January 1, 1994 and 
October 31, 2015 over the age of 18 years diagnosed with any type of renal carcinoma or 
sarcoma and treated with a multi-targeted tyrosine kinase inhibitor (axitinib, cabozantinib, 
pazopanib, regorafenib, sorafenib, sunitinib, or vandetanib). A tumor FFPE sample that could be 
used for DNA extraction and WES was also required. Eligible patients were identified through 
collaboration with Moffitt Cancer Center Tissue Core.   
 For this pilot study, we aimed to include a total of 25 individuals with samples spanning a 
range of ages and divided by tumor type: age 1-3 years, 3-5 years, 5-7 years, 7-10 years, >10 
years, with each category consisting of three renal carcinoma patients and two sarcoma patients 
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(the most common indications for the multi-targeted TKIs). FFPE samples were diagnostic 
specimens collected during routine clinical practice at Moffitt Cancer Center. Therefore, the 
detailed information on sample handling from the time of surgery and sample preparation and 
specific fixation methods are unavailable; however, this represents the typical situation for 
research using FFPE-derived samples.  
DNA extraction and quantification 
DNA was extracted from macrodissected FFPE tissue, quantified using Qubit™ 
quantification (ThermoFisher Scientific, Waltham, MA), and quality was assessed using a 2200 
TapeStation Instrument (Agilent, Santa Clara, CA). One 4 µm section and multiple thick (20 
µm) sections were cut from each FFPE block and mounted on glass slides. The number of thick 
sections cut depended on the target tissue area present on each FFPE block. The thin section was 
processed for haematoxylin and eosin (H&E) staining and target tissue of the thick sections was 
used for DNA extraction. A pathologist reviewed the H&E slides and circled the tissue areas 
containing target tissue to be harvested. The marked H&E slide was used as a template and target 
tissue was scraped with a razor from glass slides and transferred to an Eppendorf tube. DNA was 
extracted using a QIAamp DNA FFPE Tissue Kit (QIAGEN, Hilden, Germany) and dissolved in 
water. DNA was quantified using a NanoDrop (Wilmington, DE) 1000 spectrophotometer, and 
double-stranded DNA quantity was assessed with Qubit™. The TapeStation was used with 
Genomic DNA Analysis ScreenTape (Agilent) to assess DNA quality. Quantitative PCR (qPCR) 
was conducted using an NGS FFPE QC kit (Agilent), which is specifically designed to evaluate 
the quantity and quality (i.e., DNA integrity) of FFPE-derived DNA. The manufacturer’s 
protocol according to the provided modifications for the SureSelect
XT
 workflow was followed.   
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Whole exome sequencing 
Whole exome sequencing (WES) was performed in order to identify somatic mutations in 
the coding regions of the human genome. Briefly, 200 ng of DNA, as quantified by qPCR, was 
used as input for library preparation with the SureSelect
XT
 Reagent Kit (Agilent, Santa Clara, 
CA). For each tumor DNA sample, a genomic DNA library was constructed according to the 
SureSelect
XT
 Target Enrichment for Illumina Multiplexed Sequencing  (#G7530-90000)  
protocol (Agilent), including the suggested modifications for FFPE-derived DNA samples (i.e., 
DNA shearing for 4 min, no dilution of the oligo mix for ligation, and 30 L of captured DNA 
used for PCR). The pre-captured library was amplified using 12 PCR cycles, and the size and 
quality of the library was evaluated using a 2100 BioAnalzyer (Agilent) and Qubit™ 
quantification. About 500 to 750 ng of pre-captured library was used for hybridization at 65°C 
for 24 hr. Hybridization and target enrichment were conducted using the SureSelect
XT
 Clinical 
Research Exome kit (Agilent), which includes all targets of the SureSelect Human All Exon V5 
kit with increased coverage at 5000 disease-associated regions (including, but not limited to 
cancer). The post-captured library was amplified with 10 PCR cycles and evaluated with a 2100 
Bioanalyzer (Agilent). The enriched library was quantified using a Library Quantification Kit for 
NGS (KAPA Biosystems, Wilmington, MA), and samples were diluted to a 4 nM concentration. 
Denaturation was conducted using NaOH, followed by neutralization with Tris buffer pH 8.5, 
and samples were diluted in HT1 (hybridization buffer) to a concentration of 20 pM in HT1 
buffer. Next, samples were diluted to concentrations between 1.7 pM to 2.2 pM for sequencing 
with a v2 sequencing reagent kit and a NextSeq 500 desktop sequencer (Illumina, San Diego, 
CA). Approximately 85 million 75 base paired-end reads were generated for each DNA sample.      
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Whole exome sequencing quality control  
Sequence reads were aligned to the reference human genome (hs37d5) with the Burrows-
Wheeler Aligner (BWA),
196
 and duplicate identification, insertion/deletion realignment, quality 
score recalibration, and variant identification were performed with Picard (Broad Institute, 
http://broadinstitute.github.io/picard/) and the Genome Analysis ToolKit (GATK) v2.2-Lite.
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Genotypes were determined across all samples at variant positions. Sequence variants were 
annotated to determine genic context (i.e., non-synonymous, missense, splicing) using 
ANNOVAR,
198
 and summarized using spreadsheets and a genomic data visualization tool, 
VarSifter.
199
 Additional contextual information from other studies was added, including allele 
frequency from 1000 Genomes
200
 and the NHLBI Exome Sequence Project,
201
 in silico function 
impact predictions, and observed impacts from databases including ClinVar (NCBI, 
http://www.ncbi.nlm.nih.gov/clinvar/), the Catalogue of Somatic Mutations in Cancer 
(COSMIC),
202
 and The Cancer Genome Atlas (TCGA, https://cancergenome.nih.gov/). Somatic 
mutations were prioritized by excluding variants observed in 1000 Genomes
200
 and variants 
observed at >5% in an internal dataset of adjacent normal (i.e., non-tumor) tissue. Variants with 
GATK variant quality score recalibration (VQSR) tranche >99.90 or genotype quality (GQ) <15 
were excluded. 
Data analysis 
For this exploratory study, the primary outcome was generation of WES data that passed 
the quality control filters discussed above (yes/no) and the primary predictor was age group (i.e., 
1-3 years, 3-5 years, 5-7 years, 7-10 years, and >10 years) of FFPE blocks. Additional factors 
considered included DNA integrity number (DIN), a DNA quality metric generated using 
Agilent TapeStation,
203
  DNA yield (amount in µg) from FFPE sample, and source of the DNA 
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sample. The relationship between age of FFPE sample with DNA yield and DIN was also 
explored. For this exploratory study, noticeable trends in failed WES were identified and noted.  
Nonparametric statistics were used for analysis as to not assume normality of our data. 
Potential association between DNA yield and DIN with age group of FFPE samples was 
explored using a Kruskal-Wallis test. The relationship between DNA yield and DIN was tested 
using linear regression. Values plus or minus more than three standard deviations of the mean 
were excluded as outliers. Differences in variables between samples that passed WES quality 
control and those that failed were compared using Mann Whitney U tests for continuous 
variables. For this exploratory study, a p-value < 0.05 was considered significant. Statistics and 
figures were generated using GraphPad Prism 6.  
Results 
Patient population and DNA extraction from FFPE 
A total of 28 tumor FFPE samples from the Moffitt Cancer Center Tissue Core were used 
for DNA extraction (Table 4.1, Appendix 4.1). The final sample population consisted of 6 
(21.4%) renal cell carcinoma patients and 22 (78.6%) sarcoma patients; ages of the FFPE blocks 
received were 1-3 years (8/28, 28.6%), 3-5 years (6/28, 21.4%), 5-7 years (6/28, 21.4%), 7-10 
years (4/28, 14.3%), and >10 years (4/28, 14.3%). Two (7%) FFPE samples did not yield 
sufficient DNA (<80 ng) for library preparation and were excluded from WES. These samples 
were both sarcomas derived from bone tissue, and one was 1-3 years old while the other was 7-
10 years old (Table 4.1).    
Whole exome sequencing quality metrics 
A total of 26 human tumors underwent WES. The average total number of reads per 
sample was 1.83 x 10
8
 (95% CI 1.75 x 10
8
 – 1.92 x 108), with an average of 20% duplicate reads 
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(Figure 4.1). One sample (#15) had a much higher number of total reads (2.51 x 10
8
) and percent 
duplicates (60%) than all other samples, raising concern for sequencing quality. After removing 
duplicates, paired-end reads were properly paired overall (average per sample 94%), and 
resulting WES aligned well to the human genome, with an average of 98% of reads mapped 
(Figure 4.1). An average coverage of 151x (95% CI 139.8 – 163.2) per base was achieved; 
sample #15 had the lowest coverage (82x, Figure 4.2). An average of 74,349 variants were 
detected per sample, of which 22,993 (31%) were within coding regions of the genome, and 
11,590 (16%) were non-synonymous variants. The transition to transversion ratio (Ts/Tv) overall 
was close to 2 (1.9 ± 0.09), and for the coding region only was closer to 3 (2.7 ± 0.08), as would 
be expected.
197
  
Factors affecting whole exome sequencing quality 
 We explored multiple factors that could impact the ability to generate good quality WES 
from FFPE samples, including age of the sample, DNA yield, DNA quality as measured by DNA 
integrity number (DIN), and tissue source of the sample (Table 4.1). There was no significant 
association between age group of FFPE samples and DNA yield (H = 4.54, 4 df, p = 0.34) or 
DIN (H = 4.67, 4 df, p = 0.32) (Figure 4.3). Notable trends included the observation that only 
samples under the age of 7 yr yielded greater than 10 µg of DNA and only the FFPE samples less 
than 7 yr old had DIN readings below the limit of detection (Figure 4.3). After removing one 
outlier from analysis (DNA yield = 40.55 µg, > 3 SD of the mean) there was no relationship 
between the DNA yield and DIN (r
2
 = 0.12, p = 0.08).  
 There were a total of 3/28 (10.7%) samples that failed WES: two failed during library 
preparation and one (#15) resulted in potentially concerning WES data (high percent duplicates 
and low coverage, Figure 4.1 and Figure 4.2). There was no difference in age between the 
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samples that failed WES quality control and those that passed (U = 26.5, p = 0.99). However, the 
failed and low quality samples had significantly lower DNA extraction yields than the samples 
that passed quality control (median of failed samples: 0.09 µg, median of passed samples: 4.24 
µg; U = 0, p = 0.0006) (Figure 4.4). There was also a significant association between DIN and 
WES failure (median of failed samples: 0 µg, median of passed samples: 2.7 µg; U = 7.5, p = 
0.04), although 1/3 of the failed samples had a reasonable DIN (2.1) and 6/25 (24%) of the 
passed samples had a DIN ≤ 2.1(4 were below the limit of detection) (Figure 4.4).   
Discussion 
We conducted a pilot study to explore the effect of age of FFPE samples on the ability to 
generate good, usable, quality WES. We also explored other potential factors of variability in 
success of WES, including DNA quantity and quality, as well as the tissue source of DNA. 
Unexpectedly, we observed a low WES failure rate in our cohort, which did not appear to be 
associated with age of the FFPE samples. There was also no clear association between the age of 
the FFPE samples and the quantity or quality of DNA yield. Interestingly, the two failed samples 
were from a range of age groups and had varying DINs, but both were derived from bone tissue. 
It is established that DNA extraction from bone tissue is challenging,
204
 but to our knowledge, 
the ability or challenges of extracting DNA from bone FFPE samples has yet to be reported.  
 We successfully generated high quality WES data from the 26 samples that generated 
sufficient DNA yields. Samples generated, on average, over 180 million paired-end reads, with a 
low frequency of duplicate reads, which resulted in high coverage of the genome that mapped 
well to the human reference genome. One sample (#15) generated possibly concerning WES 
data, with a much higher percentage of duplicate reads than the other samples and the lowest 
average coverage; however, after discarding the duplicate reads the percentage of properly paired 
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paired-end reads and percentage of reads that properly mapped to the human reference genome 
remained high. Of note, this FFPE sample also had a low DNA extraction yield, an undetectable 
DIN, and was derived from a soft tissue tumor (3-5 yr old). All other samples resulted in high 
quality WES data that met our predefined quality control thresholds. A notable limitation of this 
study is the age cutoff of samples. Due to the drug approval timeline of multi-targeted tyrosine 
kinase inhibitors, the oldest sample included in our study was 16 yr old. Therefore, we are unable 
to determine if there is an older age, perhaps over 20 yr, that would indefinitely result in low 
DNA yield and poor sequencing output.   
 In conclusion, we found no association between age of FFPE sample and ability to 
generate quality WES data. Factors that may be important to consider before conducting WES 
using FFPE samples include amount of DNA yield (our two failed samples and one borderline 
sample all yielded less than 0.2 g of DNA) and tissue source of FFPE sample, since both 
samples that yielded insufficient DNA were derived from bone FFPE blocks. This study 
confirms our methods for generating high quality, usable, WES data from tumor FFPE blocks 
stored for a range of timeframes.    
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Tables and Figures 
Table 4.1: FFPE sample information including extracted DNA quantity and quality criteria. Sample number “NA” corresponds 
to FFPE samples that did not yield sufficient DNA for library preparation. WES: Whole exome sequencing; DIN: DNA integrity 
number. 
WES 
sample 
number 
Diagnosis Tissue Type 
Age of 
FFPE (yrs) 
Qubit 
dsDNA (µg) 
DIN Pass/Fail WES 
1 Sarcoma Kidney 5-7 2.60 3.10 Pass 
2 Sarcoma Rectum-Anus >10 9.85 2.60 Pass 
3 Sarcoma Small Intestine >10 2.96 2.60 Pass 
4 Sarcoma Stomach >10 4.50 2.70 Pass 
5 Sarcoma Skin >10 2.19 2.20 Pass 
6 Sarcoma Soft Tissue 7-10 1.96 2.80 Pass 
7 Sarcoma Breast 7-10 0.24 1.80 Pass 
8 Sarcoma Soft Tissue 7-10 3.87 2.40 Pass 
NA Sarcoma Bone 7-10 0.16 2.10 Fail (insufficient DNA) 
9 Sarcoma Abdomen 5-7 1.55 2.10 Pass 
10 Sarcoma Soft Tissue 5-7 40.55 3.90 Pass 
11 Renal cell carcinoma Kidney 5-7 5.85 3.20 Pass 
12 Sarcoma Soft Tissue 5-7 0.21 - Pass 
13 Sarcoma Soft Tissue 5-7 0.82 2.90 Pass 
14 Renal cell carcinoma Kidney 3-5 10.15 3.10 Pass 
15 Sarcoma Soft Tissue 3-5 0.09 - Potential fail (WES QC) 
16 Sarcoma Retroperitoneum 3-5 10.95 2.70 Pass 
17 Sarcoma Kidney 3-5 19.35 3.60 Pass 
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18 Sarcoma Bone 3-5 11.35 2.90 Pass 
19 Sarcoma Thoracic 3-5 1.70 3.70 Pass 
20 Sarcoma Soft Tissue 1-3 7.90 - Pass 
21 Sarcoma Soft Tissue 1-3 2.87 2.30 Pass 
22 Renal cell carcinoma Kidney 1-3 11.30 2.50 Pass 
23 Sarcoma Bone 1-3 13.90 3.00 Pass 
NA Sarcoma Bone 1-3 0.04 - Fail (insufficient DNA) 
24 Renal cell carcinoma Kidney 1-3 4.24 - Pass 
25 Renal cell carcinoma Kidney 1-3 3.90 4.60 Pass 
26 Renal cell carcinoma Kidney 1-3 4.57 - Pass 
     - corresponds to samples with a DIN below the limit of detection
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Figure 4.1: Summary of whole exome sequencing sample reads. Information is presented for 
each sample for which whole exome sequencing was generated, and includes the total number of 
reads (blue circle), the percentage of duplicate reads (red square), the percent of reads mapped to 
the reference human genome (hs37d5) (green triangle), and the percent properly paired-end reads 
(purple upside-down triangle). The left y-axis represents the total reads, and the right y-axis 
represents all other values, presented as percents.  
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Figure 4.2: Average sequencing coverage depth per base by sample. Dashed line at 100x 
represents threshold for high quality yield from sequencing of a tumor sample.  
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Figure 4.3: Effect of age on FFPE DNA yield and DNA integrity. Graphs display median and 
interquartile ranges for age groups, with individual measurements also shown. Exes () 
represent samples that failed library preparation (n=2) or some whole exome sequencing quality 
metrics (n=1). DIN: DNA integrity number.  
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Figure 4.4: DNA extraction yield and DNA integrity (DIN) grouped by success of whole 
exome sequencing (WES). Graphs display median and interquartile ranges for age groups, with 
individual measurements also shown. 
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CHAPTER 5: IDENTIFYING GENETIC PREDICTORS OF INTRINSIC RESISTANCE 
TO MULTI-TARGETED  
Summary 
Multi-targeted tyrosine kinase inhibitor (TKIs) are widely prescribed anticancer agents 
that are effective in a range of solid and hematologic malignancies, including renal cell 
carcinoma, sarcomas, and pancreatic neuroendocrine tumors, amongst others. The broad FDA-
approved indications and efficacy of multi-targeted TKIs suggest shared molecular drug targets 
across cancer types. However, irrespective of tumor type, approximately 20% to 30% of patients 
treated with multi-targeted TKIs derive no benefit, with progressive disease as a best response, 
demonstrating intrinsic resistance. We hypothesized that there are genetic alterations, shared 
across tumor types, which are associated with intrinsic resistance to the multi-targeted TKIs. We 
conducted a retrospective cohort study to identify tumor (somatic) point mutations and copy 
number alterations that are associated with resistance to multi-targeted TKIs. We conducted 
combined analysis to develop an algorithm that to differentiate intrinsically resistant from non-
resistant patients based on molecular testing results. Patients were identified from the Total 
Cancer Care cohort at Moffitt Cancer Center based on previous treatment with a multi-targeted 
TKI for any solid tumor indication. Patients were classified as intrinsically resistant or non-
resistant based on detailed medical chart reviews. Intrinsic resistance was defined as progressive 
disease at first imaging follow-up and non-resistance was defined as no evidence of progressive 
disease (i.e., partial response, stable disease, or mixed response) at first imaging follow-up. Next-
generation sequencing (targeted exome capture) and whole genome copy number variation 
(CNV) analysis of tumor samples was performed to identify somatic alterations in resistant and 
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non-resistant individuals. We observed a 30% intrinsic resistance rate in our cohort. A total of 
243 candidate genes related to cancer pathogenesis or anticancer drug response were included in 
analyses. Resistant individuals more commonly harbored somatic point mutations in NTRK1, 
KDR, TGFBR2, and PTPN11 (uncorrected p-value < 0.1), and CNV in CDK4, CDKN2B, and 
ERBB2 was associated with resistance at an exploratory cut-off (FDR-corrected p-value < 0.3). 
Combined analysis using random forest resulted in a decision tree that included many of the 
same hits from individual analyses. CNV in CDK4 and CDKN2B were identified as the most 
important features and, alone, could be used to differentiate 55% of individuals as resistant or 
non-resistant, thus implicating the cyclin D pathway as an important factor in resistance to multi-
targeted TKIs. Despite insufficient statistical power, we identified candidate genes with strong 
biologic plausibility of conferring resistance to multi-targeted TKIs. Independent validation is 
warranted before implementing these results in clinical practice.  
 
Introduction 
Increasing evidence supports the classification of tumors based on genetic and molecular 
characteristics rather than site of origin, which has translated into the ability to predict drug 
response utilizing tumor genetics rather than tumor type (i.e., histology or site of origin) in some 
instances. For example, using multiple genetic platforms, The Cancer Genome Atlas Research 
Network defined four molecular subtypes of breast cancer (Luminal A, Luminal B, HER2-
enriched, and Basal-like) and found that one subtype (Basal-like) is more similar to serous 
ovarian cancer than to other breast cancers.
205
 Further analysis showed that, due to their 
molecular similarities, Basal-like breast cancers and serous ovarian cancers are likely susceptible 
to similar targeted treatments. In another multiplatform analysis of twelve tissue-defined cancer 
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types, eleven major subtypes were identified, with only five subtypes corresponding to their 
tissue of origin, and the remaining six subtypes being shared by distinct cancer types (e.g., lung 
squamous, head and neck, and some bladder cancers fell into a single subtype).
206
 Studies such 
as these have influenced clinical cancer drug development. The classification and treatment of 
tumors based on molecular alterations is currently being studied through the use of basket trials, 
such as NCI-MATCH and NCI-MPACT, which randomize patients to an individualized targeted 
therapy arm or a non-pathway-specific arm independent of tumor histology.
207
 We hypothesize 
that genetic alterations within tumors, regardless of site of origin or histology, can be used as a 
biomarker of response to targeted anticancer therapies.  
The broad efficacy of multi-targeted tyrosine kinase inhibitors (TKIs) across tumor types 
suggests similarities in the genetics of the tumors they are used to treat. The multi-targeted TKIs 
(i.e., axitinib, cabozantinib, pazopanib, regorafenib, sorafenib, sunitinib, and vandetanib) 
currently have FDA-approved indications in seven histological tumor types and are also used 
off-label in additional solid and hematologic malignancies. While the clinical trials of these 
agents demonstrated overall efficacy, a substantial minority of individuals never responded to 
therapy. In the pivotal phase III clinical trials that led to approval of each of these agents, 
approximately 20 to 30% of patients showed a best response of progressive disease, 
demonstrating intrinsic resistance.
104,134-140
 Similarly, in a systematic review analyzing clinical 
data from twelve medical centers, Heng and colleagues observed that 26% of 1,056 renal cell 
carcinoma patients treated with multi-targeted TKIs demonstrated primary, or intrinsic, 
resistance.
141
 These patients received no benefit from the multi-targeted TKIs, but were put at 
risk for serious, potentially fatal, adverse events while delaying use of other potentially effective 
treatments. Furthermore, it has been demonstrated that patients with intrinsic resistance to multi-
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targeted TKIs have poorer clinical outcomes with subsequent lines of therapies.
208
 In an 
exploratory study examining demographic and clinical factors that may contribute to intrinsic 
resistance to multi-targeted TKIs across tumor types (See Chapter 3), we observed an intrinsic 
resistance rate of 21%, which also correlated well with that observed in clinical trials. Most 
interestingly, we did not identify any demographic or clinical factors (e.g., tumor type or drug 
received) that were robustly associated with intrinsic resistance. Results of this study further 
support the hypothesis that genetic factors may be important in predicting intrinsic resistance to 
the multi-targeted TKIs.     
Targeted cancer therapies, such as the TKIs, function by inhibiting molecular targets 
involved in cancer cell proliferation, growth, and survival, making the genetics of the tumor (i.e., 
somatic genetics) critical in therapeutic response. Elegant studies utilizing tissue from patients 
treated with TKIs have demonstrated that tumors can acquire mutations or gene amplifications 
that confer secondary resistance.
209-211
 However, potential mechanisms of intrinsic resistance to 
multi-targeted TKIs are unexplored.
212-214
 Possible causes of intrinsic resistance include 
mutations or alterations in expression of drug targets or important oncogenic pathway genes 
within a tumor. The single-targeted epidermal growth factor receptor (EGFR)-TKI, erlotinib, and 
the monoclonal antibody EGFR inhibitors, cetuximab and panitumumab, provide an example of 
the importance genetic variation can play in intrinsic resistance. Post-FDA approval, it was 
discovered that mutations in the RAS gene, which is downstream of the EGFR receptor, confer 
intrinsic resistance to EGFR-targeted inhibitors.
47,215,216
 EGFR and KRAS mutation status are 
now routinely tested in clinical practice before prescribing EGFR inhibitors. Recently, Carter and 
colleagues utilized circulating tumor cells to identify copy number alterations in small cell lung 
cancer patients and demonstrated that the copy number alterations in individuals with intrinsic 
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resistance were unique from those with acquired resistance, providing evidence that intrinsic 
resistance is a distinct molecular phenomenon.
217
  
Preemptive identification of patients intrinsically resistant to multi-targeted TKIs is 
critical to avoid unnecessary toxicity risk and guide treatment selection toward other potentially 
effective therapies. We hypothesize that there are somatic alterations in the molecular targets or 
pathways inhibited by multi-targeted TKIs that can be used to predict intrinsic resistance. We 
utilized an extensively annotated tissue biobank to conduct a retrospective candidate gene study 
aimed at identifying somatic point mutations and copy number alterations associated with 
intrinsic resistance to multi-targeted TKIs.  
Methods 
Patient Population 
Patients were identified from the Total Cancer Care (TCC) cohort at Moffitt Cancer 
Center, an institutional review board (IRB)-approved biobanking protocol in which individuals 
agree to provide tissue and blood samples for research and to be followed throughout their 
lifetime.
186
 Additional Moffitt Cancer Center Scientific Review Committee and IRB-approvals 
(MCC #18318 and #18790) were granted to request tissue samples and conduct this particular 
study using the TCC cohort. Individuals eligible for study inclusion were patients consented 
between January 1, 1994 and December 31, 2015 over the age of 18 years diagnosed with any 
type of solid tumor and treated with a multi-targeted tyrosine kinase inhibitor (axitinib, 
cabozantinib, pazopanib, regorafenib, sorafenib, sunitinib, or vandetanib). Individuals were 
included if they had targeted exome sequencing or whole exome sequencing (WES) data 
available through the TCC protocol or if a tumor FFPE sample was available that could be used 
for DNA extraction and WES. Exclusion criteria included individuals treated with a multi-
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targeted TKI for a hematologic malignancy and individuals whose tumor FFPE sample(s) were 
collected after more than three drug regimens post-multi-targeted TKI administration, since the 
genetics of those tumors may not be representative of the tumor treated with multi-targeted TKI.  
Phenotyping 
 Data was initially abstracted in a standardized manner from the TCC biorepository 
system (TransMed, Cupertino, CA). Data abstracted included demographic variables (date of 
birth, gender, race, and ethnicity) as well as clinical information [medical record numbers 
(MRNs), date of diagnosis, primary site at diagnosis, histology, first course of treatment, multi-
targeted TKI received, start and stop date of TKI, and date of death or last follow-up]. Sources 
for these data were the Florida Cancer Registry and electronic medical records. Information 
abstracted from TransMed was used to guide manual chart reviews.  
 Independent manual chart reviews were performed by two clinicians and researchers 
using the patients’ MRNs. Chart reviews included the validation of information generated using 
TransMed abstraction and manual review of patients’ clinical notes and imagining 
(PET/CT/MRI) results before and after TKI administration. Additional information collected 
included radiologists’ and clinicians’ impressions of disease before and after TKI initiation (e.g., 
stable vs. progressive vs. responding) and time to drug change or discontinuation. Based on these 
data, reviewers documented their individual impressions of patients as either “resistant” or “non-
resistant”. Phenotype classifications were then compared and a third reviewer, a physician 
experienced with TKI prescribing and follow-up, was available for adjudication if necessary.  
 Physicians’ recommendations at first imaging follow-up (generally 2-3 months post-
initiation) were used to identify patients intrinsically resistant to multi-targeted TKIs. The 
decision to stop TKI therapy due to cancer progression was classified as “intrinsic resistance”. 
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Patients who continued TKI therapy after first follow-up due to response, stable disease, or 
mixed response, and patients who met these criteria but stopped therapy due to side effects were 
classified as “non-resistant”. 
Next-generation sequencing and copy number variation  
 Whole exome sequencing (WES) was performed in order to identify somatic mutations in 
the coding regions of the human genome. Briefly, 200 ng of DNA, as quantified by qPCR, was 
used as input for library preparation with the SureSelect
XT
 Reagent Kit (Agilent, Santa Clara, 
CA). For each tumor DNA sample, a genomic DNA library was constructed according to the 
SureSelect
XT
 Target Enrichment for Illumina Multiplexed Sequencing (#G7530-90000) protocol 
(Agilent), including the suggested modifications for FFPE-derived DNA samples. The pre-
captured library was amplified, and the size and quality of the library was evaluated using a 2100 
BioAnalzyer (Agilent) and Qubit™ quantification (Thermo Fisher Scientific, Waltham, MA). 
Approximately 500 to 750 ng of pre-captured library was used for hybridization at 65°C for 24 
hr. Hybridization and target enrichment were conducted using the SureSelect
XT
 Clinical 
Research Exome kit (Agilent). The post-captured library was amplified and evaluated with a 
2100 Bioanalyzer (Agilent). The enriched library was then quantified using a Library 
Quantification Kit for NGS (KAPA Biosystems, Wilmington, MA), and samples were diluted to 
a 4 nM concentration. Denaturation was conducted using NaOH, followed by neutralization with 
Tris buffer pH 8.5, and samples were diluted to a concentration of 20 pM in HT1. Next, samples 
were diluted to concentrations between 1.7 pM to 2.2 pM for sequencing with a v2 sequencing 
reagent kit and a NextSeq 500 desktop sequencer (Illumina, San Diego, CA). Approximately 85 
million 75 base paired-end reads were generated for each DNA sample.      
 Individuals with targeted gene sequencing data available had sequencing performed 
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previously through collaboration with the Beijing Genomics Institute (Shenzhen, China). Briefly, 
tumor samples underwent targeted gene sequencing using a custom SureSelect platform (Agilent, 
Santa Clara, CA) targeting 1,321 cancer-related genes and 2 x 90bp massively parallel 
sequencing using a Genome Analyzer IIx (Illumina, San Diego, CA). In order to identify whole 
genome copy number variation (CNV) and loss-of-heterozygosity, the OncoScan
®
 FFPE Assay 
Kit (Affymetrix, Santa Clara, CA) was used according to the manufacturer’s protocol, with an 
input of 80 ng of FFPE-extracted DNA.   
Candidate gene selection  
To decrease multiple comparison correction and increase the likelihood of identifying 
biologically plausible associations, we utilized a candidate gene approach for analysis. Candidate 
genes included genes known to be important in solid tumor biology and anticancer drug response 
and were selected utilizing the overlapping genes reported on a validated clinical cancer genetic 
testing platform (FoundationOne
®
, Foundation Medicine, Cambridge, MA) and those captured 
with the targeted sequencing platform designed specifically for the TCC study cohort. A list of 
the candidate genes is provided in Appendix 5.1.   
Data quality control and variant detection 
 Whole exome sequencing reads were aligned to the reference human genome (hs37d5) 
with the Burrows-Wheeler Aligner (BWA),
196
 and duplicate identification, insertion/deletion 
realignment, quality score recalibration, and variant identification were performed with Picard 
(Broad Institute, http://broadinstitute.github.io/picard/) and the Genome Analysis ToolKit 
(GATK) v2.2-Lite.
197
 Genotypes were determined across all samples at variant positions. 
Sequence variants were annotated to determine genic context (i.e., non-synonymous, missense, 
splicing) using ANNOVAR,
198
 and summarized using spreadsheets and a genomic data 
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visualization tool, VarSifter.
199
 Additional contextual information from other studies was added, 
including allele frequency from 1000 Genomes
200
 and the NHLBI Exome Sequence Project,
201
 in 
silico function impact predictions (PolyPhen and SIFT), and observed impacts from databases 
including ClinVar (NCBI, http://www.ncbi.nlm.nih.gov/clinvar/), the Catalogue of Somatic 
Mutations in Cancer (COSMIC),
202
 and The Cancer Genome Atlas (TCGA, 
https://cancergenome.nih.gov/). Somatic mutations were prioritized by excluding variants 
observed in 1000 Genomes
200
 and variants observed at >5% in an internal dataset of adjacent 
normal (i.e., non-tumor) tissue. Variants with GATK variant quality score recalibration (VQSR) 
tranche > 99.9 or genotype quality (GQ) < 15 were excluded. 
 The CNV data generated was analyzed using Nexus Copy Number™ 6.0 software 
(BioDiscovery, El Segundo, CA) utilizing the TuScan™ algorithm, specifically designed for 
OncoScan
®
 FFPE Assay data.
218
 The estimated CNV regions were annotated with the reference 
human genome (hg19) and the evaluation of array performance was measured using default 
criteria (MAPD ≤ 0.3 and ndSNPQC ≥ 26). Plots of whole genome CNVs and minor allele 
frequencies (BAFs) were generated for each individual. Briefly, the BAF was calculated as the 
count of minor (B) alleles (A/T) divided by the total count of major (A) (G/C) and minor (B) 
alleles.
219
 Using the TuScan™ algorithm the average CNV of all cells within each sample was 
generated. Genes with 70% or greater overlap in copy number abberated regions were classified 
as being altered. Copy number gains greater than seven and homozygous losses were considered 
potentially clinically significant, as is standard in clinical tumor testing, and included in analyses.    
Data analysis 
 Patients were classified into one of two cohorts: (1) resistant or (2) non-resistant using the 
phenotyping methods described above. Descriptive statistics were used to summarize 
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demographic and clinical characteristics of patients included. Means, standard deviations and 
ranges were calculated for continuous variables, and frequencies and percentages were generated 
for categorical variables. As a conservative approach and where applicable, non-parametric 
statistical tests were implemented to avoid assuming the data was normally distributed. 
Demographic and clinical characteristic comparisons between resistant and non-resistant patients 
were performed using two-tailed Fisher’s exact tests for categorical variables and the Mann-
Whitney U test for continuous variables. Batch effects between the two sequencing methods 
were detected using a two-tailed Fisher’s exact test and, when comparing between sequencing 
platforms, mutated genes with an FDR-corrected p-value < 0.05 were excluded from further 
analyses. The two-tailed Fisher’s exact test was used to test the statistical significance of mutated 
candidate genes identified in resistant and non-resistant patients. An FDR-corrected p-value < 
0.1 was considered statistically significant, and an uncorrected p-value < 0.10 was significant for 
exploratory associations. Cytoscape (v.3.4.0) Enrichment Map
220
 was utilized to conduct gene 
set enrichment of top gene hits and the Genomics in Drug Sensitivity in Cancer database
221
 was 
utilized to explore in vivo-derived predictions of sensitivity to multi-targeted TKIs based on 
mutation status of the top hits.  
 For CNV analysis, copy number gains and losses were grouped and presence of copy 
number aberrations between resistant and non-resistant individuals were arranged in contingency 
tables and analyzed using a two-sided Fisher's exact test. FDR-corrected p-values < 0.1 were 
considered statistically significant, and a threshold of FDR-corrected p < 0.3 was used for 
exploratory analysis.
222,223
 Cytoscape (v.3.4.0) Enrichment Map
220
 was utilized to conduct gene 
set enrichment of top gene hits. 
 Statistical analysis was conducted using the open-source, statistical programming 
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language, R (version 3.3.2).
224
 CNV and WES data were combined to build a model leveraging 
both technologies. CNVs were annotated as 1, 0, -1 for gain, no change, or loss, respectively, 
based on the criteria described above. Subjects with > 20% missing data and genes with > 5% 
missing data were excluded from further analysis. Remaining missing genes were imputed using 
the mean of the study cohort. Subsequently, feature selection, via a random forest model was 
constructed using 2000 trees and 12 features at each split.
225
 CNV and WES features with a 
mean decrease in Gini score > 0.2 were selected for inclusion in the decision tree classification 
model using recursive partitioning trees.
226
 Figures were generated using R (version 3.3.2) and 
GraphPad Prism 6.   
Results 
Patient population and phenotypes 
A total of 50 unique patients were included in this study (Table 5.1). The average age was 
59 years old and the majority of individuals were white (86%) non-Hispanic (86%) males (72%). 
The most common tumor types being treated were sarcoma (52%) and renal cell carcinoma 
(36%), and the majority of patients received pazopanib (42%), followed by sorafenib (30%) and 
sunitinib (26%). One patient was treated with regorafenib. Of the 50 patients included, 11 (22%) 
were classified as resistant, 26 (52%) as non-resistant, and 13 had unclassifiable responses. This 
corresponded to an overall resistance rate of 30.5% (11/36) observed in our cohort. There were 
no statistically significant differences in the demographic and clinical characteristics of resistant 
and non-resistant patients; however, non-resistance trended toward being more common in renal 
cell carcinoma patients (Table 5.1). Resistant patients discontinued multi-targeted TKIs 
significantly sooner than non-resistant patients (U = 14.5, p <0.0001, Figure 5.1).        
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Next-generation sequencing results 
A total of 24 samples underwent targeted exome sequencing under the TCC protocol. The 
target region was 1,321 genes covering 3.8 Mb. The median number of reads aligning per 
samples was 15,283,830. Median read depth of coverage was 141x. A median of 93.7% of 
coding bases were covered ≥ 10x across samples. For the 25 tumor samples that underwent 
whole exome sequencing (WES), an average coverage of 151x (95% CI 140 - 163) per base was 
achieved. The average total number of reads per sample was 1.83 x 10
8
 (95% CI 1.75 x 10
8
 - 
1.92 x 10
8
), with an average of 20% duplicate reads. After removing duplicates, paired-end reads 
were properly paired overall (average per sample 94%), and resulting WES aligned well to the 
human genome, with an average of 98% of reads mapped. An average of 74,349 variants were 
detected per sample, of which 22,993 (31%) were within coding regions of the genome, and 
11,590 (16%) were non-synonymous variants. There were five genes (CDK12, FGFR4, MLL2, 
LRP1B, and ARAF) with significant variation by sequencing batch (FDR-corrected p-values all < 
0.005), warranting exclusion from further analyses.  
 We identified four genes (NTRK1, KDR, TGFBR2, and PTPN11) more commonly 
mutated in resistant patients than non-resistant patients (Figure 5.2). The finding with the lowest 
p-value was NTRK1, in which 3 (30%) resistant patients carried somatic coding mutations (2 
point mutations and 1 splice site variant) versus zero non-resistant patients (p = 0.02). 
Nonsynonymous coding mutations in KDR, PTPN11, and TGFBR2 were present in 2 (20%) 
resistant patients and zero non-resistant patients (p = 0.08).  Altogether, 55% of resistant patients 
harbored mutations in one or more of these genes, while zero non-resistant patients carried 
mutations in these genes (Fisher’s exact p-value = 0.0002, Figure 5.3). Gene set enrichment 
identified trends of receptor binding, activity, protein kinase, tyrosine, and transmembrane within 
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the top gene hits. Of the four top hits, KDR and PTPN11 were included in screening 1,001 cancer 
cell lines in the Genomics in Drug Sensitivity in Cancer database.
227,228
 Presence of KDR 
mutations was consistently predicted to confer resistance to multi-targeted TKIs, while presence 
of PTPN11 mutations tended to predict sensitivity to multi-targeted TKIs (Appendix 5.2).    
Copy number variation results 
Copy number variation (CNV) data was generated for 29 individuals, of which 8 (27.6%) 
were classified as resistant. All samples resulted in data that met pre-specified quality control 
criteria. Individuals exhibited a diverse range of copy number aberrations, with some individuals 
demonstrating much more genomic instability than others (Appendix 5.3). A total of 55 (22.6%) 
genes harbored copy number alterations that met specified filtering criteria (Figure 5.4). No 
genes met the FDR-corrected significance level, however, three genes (CDK4, CDKN2B, and 
ERBB2) met the exploratory cut-off (FDR-corrected p = 0.28 for each). CNVs in CDKN2B were 
only observed in resistant patients, while CNVs in CDK4 and ERBB2 were less common in 
resistant patients (only non-resistant patients harbored CNVs in ERBB2). All of the CNVs in 
CDKN2B and ERBB2 were homozygous losses, and the majority (14/16, 87.5%) of aberrations 
in CDK4 were also losses. Gene set enrichment identified cancer pathways, cyclin, and kinase as 
network trends between the three gene hits for CNV.   
Decision tree for combined data 
The most informative CNV and next-generation sequencing features from the random 
forest classification model were used to generate a decision tree for identifying resistant 
individuals. After quality-control, data for the 29 individuals with sequencing and CNV results 
were used in the construction of the final tree. Five genes (CDKN2B, CDK4, TGFBR2, EPHA3, 
and TNFAIP3) were identified as important for differentiating resistant from non-resistant 
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individuals and were incorporated into the final decision tree (Figure 5.5). CNV in CDKN2B and 
CDK4 were most informative and explained responses for 55% (16/29) of the population. 
Interestingly, in measuring the importance of variables using the mean decrease in Gini score, all 
gene hits from individual sequencing (NTRK1, KDR, TGFBR2, and PTPN11) and CNV (CDK4, 
CDKN2B, and ERBB2) analysis were identified as being amongst the most informative variables 
(Figure 5.5, Appendix 5.4). The decision tree model resulted in a high sensitivity and specificity 
for differentiating resistant individuals (0.75 and 1, respectively; balance accuracy 0.88); 
however, leave-one-out cross validation resulted in a lower sensitivity and specificity (0.25 and 
0.95, respectively; balance accuracy 0.6). It further suggested that having the identified 
combination of mutations increases one’s odds of being resistant (OR 6.67, insufficient power).  
Discussion 
We conducted a retrospective candidate gene study to identify somatic point mutations 
and copy number alterations associated with intrinsic resistance to multi-targeted TKIs. Using 
next-generation sequencing we identified four genes commonly mutated in resistant patients, but 
not mutated in non-resistant patients: NTRK1, KDR, TGFBR2, and PTPN11. Interestingly, three 
of the four top hits (TGFR, KDR, and NTRK1) encode transmembrane protein kinases that are 
known targets of multi-targeted TKIs. The final gene, PTPN11, encodes SHP2, a tyrosine 
phosphatase that mediates signaling of oncogenic tyrosine kinases, such as Ras-ERK-AKT 
signaling pathways.  
All four of the top gene hits from sequencing analysis are known to be mutated in cancer 
patients and have some literature suggesting possible associations with resistance and/or 
prognosis. KDR encodes the vascular endothelial growth receptor 2 (VEGFR2), a tyrosine kinase 
that mediates VEGF-induced endothelial proliferation, survival, and migration. KDR is 
 97 
 
commonly mutated across cancer types, and is one of the primary targets of the multi-targeted 
TKIs, with up to eighty percent of activity being inhibited by TKIs.
133
 Therefore, mutations in 
the gene encoding VEGFR2 represent a plausible mechanism of resistance to these agents. In 
fact, escape from VEGFR2 signaling dependency has been proposed as a mechanism of acquired 
resistance to the multi-targeted TKIs.
229
 In a recent retrospective analysis of archived renal cell 
carcinoma patients treated with sunitinib, Stubbs and colleagues found no association between 
KDR expression and overall or progression-free survival.
230
 However, a retrospective study of 
275 sarcoma patients identified a significant correlation between high VEGFR2 protein 
expression (measured using immunohistochemistry) and decreased patient survival (p <0.001).
231
 
The most common NTRK1 alterations observed in cancer are gene fusions, however, point 
mutations have also been reported in numerous solid tumors.
232,233
 Multiple studies have linked 
NTRK1 overexpression to tumor progression and poor outcomes in solid cancers,
234-236
 and 
NTRK1 mutations are known to confer acquired resistance to NTRK inhibitors.
237
 Somatic 
mutations of TGFBR2 are commonly observed across solid tumor types.
232,233
 The majority of 
studies exploring the clinical significance of TGFBR2 mutations are in the context of breast 
cancer, where it has been demonstrated that high expression of TGFBR2 is associated with tumor 
metastasis and response to chemotherapy.
208,238,239
 Associations between somatic TGFBR2 
alterations and cancer progression have also been reported in a range of solid tumor types, 
including gastric, bladder, and squamous cell carcinoma.
240-242
 PTPN11 mutations are most 
commonly associated with Noonan syndrome and juvenile myelomonocytic leukemia (JMML), 
however, activating somatic mutations have also been observed in solid tumors, including 
colorectal, breast, and renal cell carcinomas.
232,233
 These mutations have been shown to enhance 
cancer progression, invasion, and metastasis,
243-245
 and have been associated with decreased 
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response rates in hepatocellular carcinoma, glioma, and gastric cancers.
243,246,247
 In an elegant in 
vitro study utilizing colon and melanoma cancer cells, Prahallad and colleagues demonstrated 
that PTPN11 activating mutations were present in the setting of both intrinsic and acquired 
resistance and that inhibition of PTPN11 is lethal in cancer cells driven by activated tyrosine 
kinases.
248
  
 We identified three genes (CDK4, CDKN2B, and ERBB2) with differential patterns of 
copy number alterations between resistant and non-resistant patients. Interestingly, CDK4 and 
CDKN2B both encode for proteins involved in the cyclin-dependent (cyclin D) pathway, which 
regulates progression through the cell cycle. The cyclin D pathway is commonly deregulated in 
solid malignancies through somatic copy number alterations.
249
 In our cohort, we observed a 
higher frequency of CDKN2B losses in resistant patients, while non-resistant patients more 
commonly harbored losses in CDK4. Biologically, CDK4 functions as a positive regulator of the 
cell cycle, while CDKN2B is a negative regulator. Therefore, loss of CDK4 results in cell cycle 
arrest and tumor cell senescence, while loss of CDKN2B maintains cell cycle progression and 
tumor cell growth.  The CNVs observed in our cohort suggest that cyclin D regulation may serve 
as an important secondary or bypass track for cancer progression in individuals treated with 
multi-targeted TKIs. ERBB2 encodes HER2, a transmembrane tyrosine kinase which regulates 
the PI3K/AKT pathway upstream of mTOR. Interestingly, after therapeutic failure with multi-
targeted TKIs, mTOR inhibitors are recommended as treatment options. We observed that 
patients non-resistant to multi-targeted TKIs more commonly harbored ERBB2 losses, which 
may suggest that mTOR is not overregulated in these individuals, but perhaps is an important 
mechanism of tumorogenesis in the resistant patients.  
 Random forest analysis using the combined next-generation sequencing and CNV results 
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generated a relatively easily translatable decision tree. The genetic alterations that fell out as 
most informative were copy number variations in CDKN2B and CDK4, further supporting a 
potential roll of the cyclin D pathway in resistance to multi-targeted TKIs. Additional genes that 
fell out as important in decision tree analysis that were not identified in separate next-generation 
sequencing or CNV analyses were EPHA3 and TNFAIP3, both of which have been previously 
associated with prognosis and resistance. EPHA3 encodes a protein tyrosine kinase receptor and 
its expression has been associated with high invasive capacity and poor overall survival in 
hepatocellular carcinoma, gastric cancer, and glioblastoma.
250-252
 Additionally, EPHA3 has been 
associated with the regulation of multi-drug resistance in small cell lung cancer via the 
PI3K/BMX/STAT3 signaling pathway.
253
 TNFAIP3 encodes a zinc finger protein that serves as a 
tumor suppressor through its potent inhibition of the NF-κB signaling pathway.254 TNFAIP3 has 
also been associated with regulating drug resistance in multiple solid tumor types.
255,256
 
Therefore, dysregulation of these genes presents biologically plausible mechanisms of intrinsic 
resistance to multi-targeted TKIs. While the decision tree generated explained our data well, its 
ability to describe additional datasets may not be as strong, as demonstrated by leave-one-out 
cross validation. A larger cohort would improve our ability to more robustly predict intrinsic 
resistance in independent datasets.     
 The most notable limitation of this study is the sample size. Due to challenges in 
procuring patient samples, we were underpowered to detect significant associations after 
multiple comparisons corrections. With a study of two-to-one non-resistant-to-resistant cases, 
our data indicate that there is a 5% probability of observing a mutation in the candidate genes. If 
the true odds ratio for resistance in subjects with mutations relative to non-resistant subjects is 7, 
we would have needed to study 81 resistant patients and 162 non-resistant patients to be able to 
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reject the null hypothesis of no difference in odds with a probability (power) equal 80% and a 
type I error rate equal to 0.0002 (Bonferroni-corrected p < 0.05 for 243 genes tested). This 
highlights the challenge of detecting significant mutations and CNV given the available number 
of samples. Although we generated whole exome sequencing and whole genome copy number 
alteration data, we elected to use a candidate gene approach to decrease the multiple testing 
burden. While this was a good method for statistical purposes, limitations to the candidate gene 
approach exist, with the main disadvantage being the inability to identify completely novel or 
unexpected findings. However, the complete paucity of data on resistance to multi-targeted TKIs 
and, even more-so, intrinsic resistance to multi-targeted TKIs makes any information novel and 
valuable to this field.  
 We conducted an exploratory study to identify somatic point mutations and copy number 
alterations characteristic in individuals with intrinsic resistance to multi-targeted TKIs. We 
identified potential predictors of resistance that each have some degree of biological plausibility; 
however, we acknowledge that multiple other factors may be important in determining who will 
respond to these agents. For example, pharmacokinetics and pharmacodynamics may affect drug 
penetration and exposure. Using MALDI-MSI (matrix-assisted laser desorption ionization mass 
spectrometry imaging) to visualize the distribution patterns of multi-targeted TKIs in mouse 
models, Torok and colleagues determined that poor drug penetration in some tumors resulted in 
primary resistance.
257
 Clinical variability in drug concentrations, despite receiving the same dose, 
has also been observed and associated with variability in side effects and survival 
outcomes.
258,259
 Lysosomal sequestration has also been demonstrated to confer resistance to the 
multi-targeted TKIs
148,149
 and has also been associated with conferring cross-resistance to the 
multi-targeted TKIs.
142
 Finally, germline genetics in drug transporters, such as ABCB1 and 
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ABCG2, or pharmacodynamic proteins, such as BIM, may also influence response to these 
agents.
10,29,260
 While we identified somatic markers of resistance to multi-targeted TKIs, there are 
many factors that must be considered when developing an optimized predictive algorithm for 
predicting resistance in clinical practice.      
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Tables and Figures 
Table 5.1: Patient demographics (n = 49). Demographics are also broken down by phenotype for individuals who underwent next-
generation sequencing (n=37) and copy number variation analysis (n=29).  
  Next-generation sequencing Copy number variation 
Characteristic 
All patients 
(n = 50) 
Resistant 
(n = 11) 
Non-resistant 
(n = 26) 
P-value 
(FDR)
# 
Resistant 
(n = 8) 
Non-
resistant 
(n = 21) 
P-value 
(FDR)
#
 
Age* 
    Mean ± SD 
    Median 
    Range 
 
59.3 ± 12 
61 
36 – 81 
 
57.4 ± 12.7 
56 
37 – 79 
 
60.6 ± 12.1 
61.5 
36 – 81 
0.49 (0.55)  
58.8 ± 13.9 
60 
37 – 79  
 
64.1 ± 10.0 
67 
39 – 81  
0.25 (0.31) 
Sex 
    Male 
    Female 
 
36 (72) 
14 (28) 
 
7 (63.6) 
4 (36.3) 
 
24 (92.3) 
2 (7.7) 
0.05 (0.15)  
4 (50) 
4 (50) 
 
19 (90.5) 
2 (9.5) 
0.03 (0.07) 
Race 
    White 
    Black 
    Asian 
    Unknown 
 
43 (86) 
4 (8) 
2 (4) 
1 (2) 
 
9 (81.8) 
2 (18.2) 
0 
0 
 
24 (92.3) 
0 
1 (3.8) 
1 (3.8) 
0.16 (0.24)  
6 (75) 
2 (25) 
0 
0 
 
21 (100) 
0 
0 
0 
0.07 (0.10) 
Ethnicity 
    Hispanic 
    Non-Hispanic 
 
7 (14) 
43 (86) 
 
1 (9.1) 
10 (90.9) 
 
5 (19.2) 
21 (80.8) 
0.65 (0.65)  
1 (12.5) 
7 (87.5) 
 
3 (14.3) 
18 (85.7) 
1.0 (1.0) 
Cancer type 
    Sarcoma     
    Renal cell carcinoma 
    Hepatic 
    Colorectal 
    Melanoma 
 
26 (52) 
18 (36) 
4 (8) 
1 (2) 
1 (2) 
 
6 (54.5) 
2 (18.2) 
2 (18.2) 
1 (9.1) 
0 
 
12 (46.1) 
13 (50) 
1 (3.8) 
0 
0 
0.08 (0.16)  
4 (50) 
1 (12.5) 
2 (25) 
1 (12.5) 
0 
 
7 (33.3) 
13 (61.9) 
1 (4.8) 
0 
0 
0.02 (0.07) 
Multi-targeted TKI  
    Pazopanib 
    Sorafenib 
    Sunitinib 
    Regorafenib 
 
21 (42) 
15 (30) 
13 (26) 
1 (2) 
 
7 (63.6) 
2 (18.2) 
1 (9.1) 
1 (9.1) 
 
6 (23.1) 
11 (42.3) 
9 (34.6) 
0 
0.03 (0.15)  
5 (62.5) 
2 (25) 
0 
1 (12.5) 
 
3 (14.3) 
10 (47.6) 
8 (38.1) 
0 
0.007 (0.04) 
  
 
1
0
3
 
*Age represents the age at multi-targeted TKI initiation. 
#
P-value for continuous variables represents the Mann-Whitney U p-value and categorical data was compared between resistant and 
non-resistant individuals using Fisher’s exact test. FDR represents the FDR-corrected p-value.  
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Figure 5.1: Time to multi-targeted tyrosine kinase inhibitor by phenotype. Data represents 
mean and standard deviation. **Mann-Whitney U p-value < 0.0001 
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Figure 5.2: OncoPrint of somatic gene mutations observed differentially by phenotype.  
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Figure 5.3: Percent of patients with somatic nonsynonymous point mutations or splice site 
variants in the four top gene hits.   
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Figure 5.4: Copy number variations (CNVs) observed by phenotype. *Genes that met pre-
specified cut-off for exploratory hits (i.e., differential CNVs between resistant and non-resistant 
individuals). 
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Figure 5.5: Decision tree for differentiating resistant from non-resistant patients. Branches 
were generated from genes that were identified as influential in differentiating phenotypes using 
a random forest classification model. A loss represents a homozygous copy number loss; a gain 
represents a copy number gain greater than seven; a mutation represents any non-synonymous or 
missense mutation in a coding region of the gene.  
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CHAPTER 6: SIGNIFICANCE AND FUTURE DIRECTIONS  
Current challenges in the personalization of multi-targeted TKI prescribing 
This dissertation presents the first attempt at understanding the clinical and genetic 
factors mediating intrinsic resistance and detail the severe cutaneous toxicity risk to the widely 
prescribed multi-targeted TKIs. As discussed in Chapter 1, extensive data exists demonstrating 
that tumors acquire genetic alterations that confer secondary, or acquired, resistance to protein 
kinase inhibitors after an initial response period;
17,80
 however, there is a paucity of data 
describing mechanisms of intrinsic resistance. Specifically, there are no data available describing 
mechanisms of intrinsic resistance to the multi-targeted TKIs, despite up to thirty percent non-
response rates across tumor types. Through the aims of this dissertation, we provide the first data 
demonstrating potential clinical and genetic factors that may be important for optimizing the 
prescribing of the multi-targeted TKIs.  
 One of the most common reasons for inefficacy of anticancer agents is drug 
discontinuation or dose reductions due to side effects. In Chapter 2, we conducted the first large-
scale study of the incidence and triggers of the extremely rare life-threatening adverse events, 
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), which have been linked 
to tyrosine kinase inhibitors in multiple case reports.
176,178,180
 We screened 108,825 cancer 
patients and identified 121 with diagnosis codes for SJS/TEN. Using this large cohort, we were 
able to, for the first time, confirm a higher incidence rate of SJS/TEN in cancer patients than in 
the general population. Almost 5,000 individuals screened had received treatment with a TKI 
and we observed a possible prevalence of up to 60 cases per 100,000 individuals in this 
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subgroup, suggestive of an elevated risk; however, the incidence was too low to definitively 
confirm a link between TKI administration and SJS/TEN. The primary limitations of this study 
are inherent to the diagnosis and treatment of SJS/TEN, and include the lack of definitive 
diagnostic criteria and the severity of the reaction prohibiting definitive confirmation of 
presumed triggers. Our results, coupled with the increased mortality rate from SJS/TEN observed 
in cancer patients,
183
 emphasize the importance of early detection of SJS/TEN in cancer patients 
and warrant additional studies to confirm anticancer agents that may trigger this life-threatening 
event.  
 The retrospective study conducted in Chapter 3 provides insight into the demographic 
and clinical factors that may be important to incorporate into a predictive algorithm of intrinsic 
resistance to the multi-targeted TKIs. Concordance in classifying patients as intrinsically 
resistant or non-resistant by independent reviewers and the observed intrinsic rate falling in line 
with that reported in clinical trials and the literature
136,141,185
 provided support for the 
phenotyping methodology utilized for this and other aims. Failure to observe associations 
between resistance and demographics, tumor types, or multi-targeted TKIs received provides 
important evidence to support our original hypothesis that prescribing multi-targeted TKIs solely 
based on tumor type and FDA-approved indications neglects other factors important in 
optimizing individualized patient outcomes. The finding of similar rates of intrinsic resistance in 
various demographic groups, tumor types, and with multiple multi-targeted TKIs provides 
evidence there may be other unidentified shared markers, perhaps genetic, of resistance to these 
agents across tumor types.  
 To our knowledge, Chapter 4 is the first methodology study exploring the utility of 
FFPE-derived DNA from a range of ages and tissue types as a source for next-generation 
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sequencing of tumor samples. To our surprise, we found that age of the FFPE block does not 
determine the quality of next-generation sequencing results, but rather tissue source may 
influence DNA yield and affect the ability to generate usable next-generation sequencing data. 
Specifically, we found that FFPE samples derived from bone tissue tended to have low or 
insufficient DNA yield. This study provides invaluable insight into the utility of the over one 
billion FFPE blocks stored in hospitals around the world,
187
 confirming their potential as 
resources for retrospective studies. Furthermore, this chapter provided the methodology for 
executing our genetic analysis aim and cautioned against the utility of bone-derived FFPE 
samples with these methods.   
 Chapter 5 discusses the first study exploring somatic genetics as a predictor of intrinsic 
resistance to multi-targeted TKIs and presents data supporting an association between somatic 
mutations and copy number alterations and resistance. The hypothesis of genetics affecting 
response to multi-targeted TKIs was supported by the results of Chapter 3 and our methods for 
this aim were validated in Chapter 4. Also included in Chapter 5 is an easily translatable decision 
tree model that incorporates point mutations and copy number variations to discriminate between 
resistant and non-resistant patients. We observed a thirty percent resistance rate in our study 
cohort, consistent with that previously reported.
141
 The genes that fell out in each component of 
the genetic analysis represented biologically plausible predictors of resistance that have been 
previously associated with resistance to other anticancer agents.
229,243,256
 Some of our gene hits 
were also predicted to confer resistance to multi-targeted TKIs using in vivo models.
227,228
 The 
most interesting and most informative gene hits identified in these analyses, CDK4 and 
CDKN2B, harbored opposite frequencies of copy number losses between resistant and non-
resistant patients, which is intriguing because the genes encode for opposing regulators of the 
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same pathogenic pathway (i.e., one negatively regulates and one positively regulates the cyclin D 
pathway). The results presented in Chapter 5 provide a strong foundation for future studies 
aimed at confirming mechanisms of intrinsic resistance to multi-targeted TKIs.   
 The primary limitation of the aim addressed in Chapter 5 was the sample size. While we 
were able to identify genetic associations at pre-defined exploratory cut-offs in the largest study 
conducted to date, none of the gene hits met statistical significance after applying an FDR 
correction for multiple comparisons; however, this is commonly the case for genetic studies in 
cancer, where most studies of resistance include data from less than one hundred patients. For 
example, the study that identified TSC1 as predictive of everolimus response consisted of 13 
tumor samples and many other high-impact publications are single-patient case reports.
127,210,261
 
In Chapter 5 we provided estimates for the number of samples that would be needed to meet 
statistical significance given our results. The sample size also limited our ability to conduct 
stratified analyses of our cohort, although our Chapter 3 results suggest that stratification may 
not be necessary. Unlike most studies, the major challenge in including sufficient individuals for 
this study was not in the identification of eligible individuals, the recruitment process, or sample 
availability, but was in tissue procurement. Nonetheless, we identified a series of strong 
candidate genes that warrant further investigation in the setting of intrinsic resistance to multi-
targeted TKIs.        
Implications for current research and clinical practice  
 While the results generated in this dissertation are not sufficient to warrant immediate 
clinical implementation, they provide great insight into the previously underexplored 
phenomenon of intrinsic resistance to targeted anticancer agents. Our results contribute to the 
existing literature
205,206
 supporting shared molecular mechanisms of oncogenicity across various 
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histological tumor types, as discussed in Chapters 1 and 5, and provide novel evidence that there 
are likely shared mechanisms of resistance within the class of multi-targeted TKIs. Taken 
together, our data suggest that histological tumor type is unlikely the only crucial factor to 
determine a patient’s indication for multi-targeted TKIs and that genetics may also be important 
to consider before prescribing these agents. Coupled with the significant rates of intrinsic 
resistance to multi-targeted TKIs observed in clinical studies and in practice, our results further 
emphasize the limitation of histological-based prescribing that is the current standard practice for 
the vast majority of solid tumor types.  
 The data presented in this dissertation also provide insight into future research avenues. 
First, our results suggest that copy number alterations may be a more important determinate of 
resistance to multi-targeted TKIs than point mutations, a novel insight that may help prioritize 
future validation studies of this work. The methodological validation of next-generation 
sequencing using diverse FFPE samples provides evidence to support the broad use of FFPE 
samples for research. Since FFPE blocks are the standard method for clinical tissue storage and 
are generally linked with detailed medical records, the availability of these samples for genetic 
analyses provides an invaluable resource for retrospective studies. Specifically, in Chapter 4 we 
demonstrate that FFPE samples from a range of ages are potentially useful, therefore broadening 
the utility and potential impact of this resource.  
The confirmation of a heightened incidence of SJS and TEN in cancer patients, described 
in Chapter 2, directly impacts clinical practice. These results along with the life-threatening 
nature of SJS/TEN, highlight the importance of educating oncologists on early identification and 
management of SJS/TEN. The link we observed between some cases and anticancer agents 
emphasizes the necessity of additional studies exploring the triggers of SJS/TEN and the 
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pathological mechanism of the reaction. Novel methods are needed to definitively identify 
triggers in a high-throughput manner. Additionally, the mechanism of increased risk in certain 
diseases, such as cancer or HIV,
167,181
 and elucidation of genetic factors (e.g., HLA status)
182
 
warrant additional investigation. Ultimately, a thorough understanding of the risk factors for 
SJS/TEN will allow development of a comprehensive algorithm to determine highest risk 
patients and guide clinical decisions.       
Opportunities for personalized multi-targeted TKI prescribing 
This dissertation provides the foundation for multiple opportunities to optimize 
personalized prescribing of multi-targeted TKIs. First, if we could pre-emptively identify 
patients at risk for SJS/TEN, we could increase monitoring or withhold TKI treatment altogether. 
A comprehensive assessment of additional clinical factors, including diseases, drug exposures, 
genetics, and potentially immune system status would greatly improve our current understanding 
of why some individuals experience SJS/TEN when exposed to commonly prescribed 
medications. Due to the extremely rare incidence of this reaction, collaborative studies are 
needed to generate sufficient evidence for the development of a translatable decision algorithm 
to help inform personalized prescribing and monitoring of potential triggers, including multi-
targeted TKIs.  
The finding that long-time archived FFPE blocks are sufficient for next-generation 
sequencing can be implemented in clinical practice and research. For example, in the absence of 
fresh frozen samples, archived samples may be informative in understanding mechanisms of 
resistance in an individual’s tumor. If a patient was once responding to a targeted agent, but later 
stopped responding, their archived tumor sample may be helpful in understanding molecular 
changes in the tumor over time that mediated resistance. Likewise, if a patient fails to respond to 
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a treatment from time of initiation, analysis of their archived tumor block may be informative in 
understanding the mechanism of intrinsic resistance (if mediated by somatic genetics). This type 
of information would be beneficial to both the patient and the field of oncology, further 
elucidating potential mechanisms of resistance to targeted therapies.    
Future studies are warranted to confirm the genetic associations with intrinsic resistance 
reported in this dissertation before being implemented clinically. Additional studies exploring 
other potentially relevant mechanisms of intrinsic resistance, such as drug exposure, drug 
penetration, and germline pharmacogenetics may help develop a more refined prediction 
algorithm of intrinsic resistance to multi-targeted TKIs. Once validated in additional studies, 
implementation of these results has the potential to impact the many thousands of cancer patients 
treated with multi-targeted TKIs. Incorporation of genetic and clinical factors into an easily 
translatable decision algorithm will save physicians and patients valuable time, decrease the risk 
of unnecessary exposure to dangerous side effects, and save money.  
Conclusion  
This dissertation describes a series of innovative studies conducted to better understand 
the clinically significant problem of intrinsic resistance to multi-targeted TKIs. We conducted a 
series of retrospective studies to explore demographic, clinical, and genetic factors that may 
predict resistance to these agents. This work provides the first steps toward creating a 
personalized decision algorithm for multi-targeted TKI prescribing, which has the potential to 
greatly improve outcomes for up to thirty percent of patients with histologically-based 
indications for these agents.  
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APPENDIX 2.1: STEVENS-JOHNSON SYNDROME OR TOXIC EPIDERMAL 
NECROLYSIS CULPRIT AGENTS AS NOTED BY PHYSICIANS  
Classification Trigger Trigger (Figure 2.1) 
Confirmed 
sulfamethoxazole/trimethoprim, foscarnet, 
bumetanide, furosemide, levofloxacin, 
cefepime, "amongst other things" 
ANTIBIOTIC, 
ANTIVIRAL 
Confirmed sulfamethoxazole/trimethoprim ANTIBIOTIC 
Confirmed cefepime ANTIBIOTIC 
Confirmed 
sulfamethoxazole/trimethoprim and/or 
probenecid 
ANTIBIOTIC, ANTI-
GOUT 
Confirmed sulfamethoxazole/trimethoprim ANTIBIOTIC 
Confirmed sulfamethoxazole/trimethoprim ANTIBIOTIC 
Confirmed phenytoin vs. sulfonamides 
ANTIBIOTIC, 
ANTICONVULSANT 
Confirmed cefepime vs. vancomycin ANTIBIOTIC 
Confirmed phenytoin ANTICONVULSANT 
Confirmed aztreonam and penicillin ANTIBIOTIC 
Confirmed vancomycin or cefepime ANTIBIOTIC 
Confirmed piperacillin/tazobactam ANTIBIOTIC 
Confirmed 
sulfamethoxazole/trimethoprim vs. 
methotrexate 
ANTIBIOTIC, 
IMMUNOMODULATOR 
Confirmed piperacillin/tazobactam ANTIBIOTIC 
Confirmed irinotecan vs. phenytoin ANTINEOPLASTIC, 
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ANTICONVULSANT 
Confirmed 
chemo (etoposide, methotrexate, 
dactinomycin, cisplatin, filgrastim, 
leucovorin) vs. piperacillin/tazobactam 
ANTIBIOTIC, 
ANTINEOPLASTIC, 
IMMUNOMODULATOR 
Confirmed allopurinol ANTI-GOUT 
Confirmed 
cefepime, piperacillin/tazobactam, 
aztreonam, meropenem, vancomycin, 
tobramycin, voriconazole 
ANTIBIOTIC, 
ANTIFUNGAL 
Confirmed sulfamethoxazole/trimethoprim ANTIBIOTIC 
Confirmed lenalidomide IMMUNOMODULATOR 
Possible phenytoin ANTICONVULSANT 
Possible sulfamethoxazole/trimethoprim ANTIBIOTIC 
Possible interferon IMMUNOMODULATOR 
Possible sulfamethoxazole/trimethoprim ANTIBIOTIC 
Possible 
MLN0264 (antibody-drug conjugate 
targeting guanylyl cyclase C), ceftriaxone, 
amoxicillin/clavulanate, 
piperacillin/tazobactam 
ANTIBIOTIC, 
MONOCLONAL 
ANTIBODY 
Possible sulfa- ANTIBIOTIC 
Possible capecitabine ANTINEOPLASTIC 
Possible sulfamethoxazole/trimethoprim ANTIBIOTIC 
Possible 
Herpes simplex virus vs. 
cyclophosphamide vs. doxorubicin 
ANTINEOPLASTIC, 
VIRUS 
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Possible sunitinb or sorafenib ANTINEOPLASTIC 
Possible apitolisib vs. paclitaxel ANTINEOPLASTIC 
Possible Merck PD1 antibody (pembrolizumab?) 
MONOCLONAL 
ANTIBODY 
Possible 
Herpes simplex virus vs. allopurinol, 
levofloxacin, or famciclovir 
ANTIBIOTIC, ANTI-
GOUT, ANTIVIRAL 
Possible Herpes simplex virus VIRUS 
Possible bisphosphonate MISC. 
Possible levofloxacin ANTIBIOTIC 
Possible sulfamethoxazole/trimethoprim ANTIBIOTIC 
Possible caspofungin vs. vancomycin 
ANTIBIOTIC, 
ANTIFUNGAL 
Possible temozolomide ANTINEOPLASTIC 
Possible phenytoin ANTICONVULSANT 
Possible epoetin alfa MISC. 
Possible colchicine ANTI-GOUT 
Possible unknown UNKNOWN 
Possible unknown UNKNOWN 
Possible phenytoin ANTICONVULSANT 
Possible minocycline ANTIBIOTIC 
Possible likely sulfa ANTIBIOTIC 
Possible saline MISC. 
Possible fluconazole ANTIFUNGAL 
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Possible unknown UNKNOWN 
Historical sulfamethoxazole/trimethoprim ANTIBIOTIC 
Historical unknown UNKNOWN 
Historical estrogen or ibuprofen MISC. 
Historical sulfamethoxazole/trimethoprim ANTIBIOTIC 
Historical penicillin ANTIBIOTIC 
Historical erythromycin ANTIBIOTIC 
Historical voriconazole ANTIFUNGAL 
Historical sulfamethoxazole/trimethoprim ANTIBIOTIC 
Historical unknown UNKNOWN 
Historical clindamycin ANTIBIOTIC 
Historical unknown UNKNOWN 
Historical clobetasol MISC. 
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APPENDIX 3.1: SOURCE DATA FOR DISCRETE VARIABLES ABSTRACTED FROM 
THE TOTAL CANCER CARE BIOREPOSITORY  
Abbreviations – EMR: electronic medical record, TKI: tyrosine kinase inhibitor 
Data Variable Data Source 
Age at diagnosis 
Derived from date of diagnosis (Cancer 
Registry) minus date of birth (EMR) 
Sex Cancer Registry 
Race Cancer Registry 
Ethnicity Cancer Registry and EMR 
Primary Site Cancer Registry 
Histology Cancer Registry 
First course of treatment Cancer Registry 
First course of treatment facility Cancer Registry 
Multi-targeted TKI received Cancer Registry and EMR 
Start and stop date of TKI EMR 
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APPENDIX 4.1: BREAKDOWN OF FFPE SAMPLES FOR DNA EXTRACTION AND 
WHOLE EXOME SEQUENCING  
 
Sample 
age (yr) 
GOAL IDENTIFIED RECEIVED 
RCC  
(n) 
Sarcoma 
(n) 
RCC  
(n) 
Sarcoma 
(n) 
RCC 
(n) 
Sarcoma 
(n) 
1-3 3 2 6 4 4 4 
3-5 3 2 3 7 1 5 
5-7 3 2 3 6 1 5 
7-10 3 2 3 4 0 4 
>10 3 2 3 4 0 4 
TOTAL 
15 10 18 25 6 22 
25 43 28 
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APPENDIX 5.1: CANDIDATE GENES INCLUDED IN NEXT-GENERATION 
SEQUENCING AND COPY NUMBER VARIATION ANALYSES  
ABL1 ABL2 ACVR1B AKT1 AKT2 AKT3 ALK APC 
AR ARAF ARFRP1 ARID1A ASXL1 ATM ATR ATRX 
AURKA AURKB AXIN1 AXL BAP1 BARD1 BCL2 BCL2L1 
BCL2L2 BCL6 BCORL1 BLM BRAF BRCA1 BRCA2 BRIP1 
BTK CARD11 CBL CCND1 CCND2 CCND3 CCNE1 CD79A 
CD79B CDC73 CDH1 CDK12 CDK4 CDK6 CDK8 CDKN1A 
CDKN1B CDKN2A CDKN2B CDKN2C CEBPA CHEK1 CHEK2 CIC 
CREBBP CRKL CRLF2 CSF1R CTNNA1 CTNNB1 CYLD DAXX 
DDR2 DNMT3A DOT1L EGFR EP300 EPHA3 EPHA5 EPHA7 
EPHB1 ERBB2 ERBB3 ERBB4 ERG ERRFI1 ESR1 EZH2 
FANCA FANCC FANCD2 FANCE FANCF FANCG FANCL FAS 
FBXW7 FGF10 FGF19 FGF3 FGF4 FGFR1 FGFR2 FGFR3 
FGFR4 FH FLT1 FLT3 FLT4 FOXL2 GATA1 GLI1 
GNA11 GNAQ GNAS GRIN2A GRM3 GSK3B HGF HNF1A 
HRAS HSP90 IDH1 IDH2 IGF1R IGF2 IKBKE IKZF1 
INHBA INPP4B IRF4 IRS2 JAK1 JAK2 JAK3 JUN 
KDM5A KDM5C KDM6A KDR KEAP1 KIT KRAS LRP1B 
LYN MAGI2 MAP2K1 MAP2K2 MAP2K4 MAP3K1 MCL1 MDM2 
MDM4 MEN1 MET MITF MLH1 MLL MLL2 MLL3 
MPL MRE11A MSH2 MSH6 MTOR MUTYH MYC MYCN 
MYD88 NF1 NF2 NKX2-1 NOTCH1 NOTCH2 NOTCH3 NPM1 
NRAS NTRK1 NTRK2 NTRK3 PAK3 PALB2 PARK2 PAX5 
PDGFRA PDGFRB PDK1 PIK3C2B PIK3CA PIK3CB PIK3CG PIK3R1 
PIK3R2 PLCG2 PMS2 POLE PPP2R1A PREX2 PRKAR1A PRKCI 
PRKDC PTCH1 PTEN PTPN11 RAC1 RAD50 RAD51 RAF1 
RARA RB1 RET RICTOR ROS1 RPTOR RUNX1 RUNX1T1 
SDHB SDHC SDHD SETD2 SMAD2 SMAD3 SMAD4 SMARCA4 
SMARCB1 SMO SOCS1 SOX10 SOX2 SPEN SPOP SRC 
STAT3 STAT4 STK11 SUFU SYK TERT TET2 TGFBR2 
TNFAIP3 TOP1 TOP2A TP53 TSC1 TSC2 TSHR VEGFA 
VHL WT1 ZNF217      
  
 123 
 
APPENDIX 5.2: EXAMPLE GRAPH GENERATED USING THE GENOMICS OF 
DRUG SENSITIVITY IN CANCER DATABASE
221,227
  
(A) Represents the effect of KDR mutations on the IC50 value for axitinib in cancer cell lines 
screened (represented by different color dots). In this example, KDR mutations increase the IC50, 
suggesting resistance to axitinib. (B) Represents the effect of PTPN11 mutations on the IC50 for 
sorafenib in cancer cell lines. In this example, PTPN11 mutations decrease the IC50, suggesting 
potential increased sensitivity to sorafenib. 
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APPENDIX 5.3: WHOLE-GENOME COPY NUMBER VARIATION PLOTS  
Plots represent data from an individual with relatively stable genomic copy number (top two 
graphs) and an individual with instable whole genome copy number aberrations (bottom two 
graphs). The top graphs for each individual display whole genome copy number alterations, 
where > 0 represents a gain and < 0 represents a loss. The bottom graphs for each individual 
present B allele frequency information, which enables detection of mosaic gains and losses and 
loss of heterozygosity.
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APPENDIX 5.4: MEAN DECREASE GINI SCORES FOR DECISION TREE ANALYSIS  
Values for non-resistant and resistant represent the mean raw importance score for the alteration 
for classification of that genotype. The mean decrease accuracy represents the proportion of 
observations that are incorrectly classified by removing the alteration. The mean decrease Gini 
score represents the number of splits (across all trees) that include that alteration, proportionally 
to the number of samples it splits. Therefore, the larger the decrease Gini score, the more 
important that alteration is in differentiating resistant from non-resistant individuals. Alterations 
with a mean decrease Gini > 0.2 were included in the decision tree (highlighted yellow). Bolded 
alterations are those that fell out as important factors in the final decision tree model.  Remaining 
factors with a mean decrease Gini > 0.2 that are not in the decision tree are still important, but do 
not add any additional information to those selected for inclusion in the model.  
 
Non-resistant Resistant 
Mean Decrease 
Accuracy 
Mean Decrease 
Gini Score 
cnv_CDKN2B 0.0106 0.0255 0.0145 0.6324 
wes_TGFBR2 0.0040 0.0073 0.0045 0.3909 
cnv_EPHA3 0.0039 0.0070 0.0047 0.3764 
cnv_CDK4 0.0004 0.0293 0.0070 0.3686 
cnv_ERBB2 0.0038 0.0264 0.0084 0.3444 
wes_KDR 0.0025 0.0054 0.0032 0.3405 
wes_PTPN11 0.0039 0.0067 0.0045 0.3310 
cnv_CDKN2A 0.0014 0.0065 0.0026 0.3009 
wes_TNFAIP3 0 0 0 0.2865 
wes_NTRK1 0.0024 0.0045 0.0029 0.2431 
wes_RICTOR -0.0077 -0.0094 -0.0074 0.2257 
wes_TERT 0.0010 0.0016 0.0011 0.2182 
wes_SDHD 0 0 0 0.1691 
wes_PRKDC -0.0006 -0.0022 -0.0009 0.1689 
wes_IKZF1 0.0021 -0.0028 0.0006 0.1681 
cnv_SRC -0.0007 0.0094 0.0017 0.1604 
wes_APC -0.0014 -0.0022 -0.0016 0.1521 
wes_AR -0.0013 -0.0062 -0.0022 0.1493 
cnv_JUN -0.0041 0.0060 -0.0016 0.1411 
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cnv_AKT2 -8.91E-06 0.0071 0.0016 0.1369 
wes_IKBKE -0.0011 -0.0023 -0.0014 0.1345 
wes_VHL 0.0004 0.0070 0.0018 0.1324 
cnv_MYC -0.0034 0.0029 -0.0019 0.1234 
cnv_TOP1 0 0 0 0.1233 
wes_NOTCH2 -0.0007 -0.0032 -0.0015 0.1229 
wes_JAK2 0.0024 0.0049 0.0030 0.1156 
wes_AXIN1 -0.0011 -0.0026 -0.0014 0.1120 
cnv_FLT1 0 0 0 0.1120 
wes_NRAS 0 0 0 0.1119 
cnv_FLT3 0 0 0 0.1100 
cnv_GSK3B 0 0 0 0.1091 
cnv_NF1 0 0 0 0.1089 
cnv_ASXL1 0 0 0 0.1053 
cnv_MAP2K4 0 0 0 0.1048 
wes_CBL 0 0 0 0.1047 
wes_JAK3 -0.0005 -0.0038 -0.0013 0.1035 
wes_NOTCH1 0 0 0 0.1032 
wes_FOXL2 -0.0002 0.0005 -0.0001 0.0969 
wes_ATR -0.0004 0.0039 0.0006 0.0949 
cnv_CCND1 -0.0013 0.0056 0.0001 0.0941 
wes_PMS2 -0.0014 -0.0019 -0.0014 0.0941 
wes_MLL -0.0007 -0.0011 -0.0008 0.0937 
wes_DAXX 0 0 0 0.0918 
wes_STAT4 0 0 0 0.0882 
wes_PIK3C2B 0 0 0 0.0878 
wes_FLT4 -0.0005 -0.0031 -0.0010 0.0850 
wes_BRCA2 -7.72E-05 -0.0024 -0.0006 0.0843 
wes_MLL3 -0.0022 0.0015 -0.0013 0.0829 
wes_BARD1 0.0002 -0.0009 -4.66E-05 0.0820 
wes_ATRX 0 0 0 0.0813 
wes_TP53 -2.52E-05 -0.0023 -0.0006 0.0744 
cnv_RARA -0.0019 0.0010 -0.0010 0.0713 
cnv_RET -0.0010 0.0041 9.75E-06 0.0667 
wes_FLT1 -0.0006 -0.0014 -0.0008 0.0665 
wes_MDM2 -0.0006 -0.0007 -0.0007 0.0566 
wes_BAP1 0.0005 0.0008 0.0006 0.0561 
cnv_FLT4 -0.0004 -0.0007 -0.0005 0.0545 
wes_POLE 0.0005 0.0013 0.0006 0.0544 
wes_EPHA5 -0.0002 0.0008 1.13E-05 0.0540 
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wes_CDH1 -0.0003 -0.0007 -0.0003 0.0508 
cnv_MDM2 -0.0004 -0.0005 -0.0004 0.0483 
wes_CIC -0.0008 -0.0021 -0.0010 0.0472 
wes_SETD2 -0.0012 -8.33E-
05 
-0.0009 0.0464 
wes_PTCH1 0 0 0 0.0461 
wes_KIT 0 0 0 0.0411 
wes_PDGFRB 0 0 0 0.0410 
wes_MLH1 0 0 0 0.0384 
wes_PREX2 -0.0002 0.0001 -0.0001 0.0355 
wes_TSC1 -0.0002 0.0004 -5.32E-05 0.0345 
wes_KDM5C -0.0001 0.0010 0.0001 0.0344 
wes_SDHC 0 0 0 0.0300 
wes_JUN 0 0 0 0.0296 
wes_KDM5A -0.0006 -0.0005 -0.0005 0.0296 
cnv_GLI1 -0.0006 -0.0016 -0.0007 0.0286 
wes_CDKN1B 0 0 0 0.0268 
wes_RAF1 0 0 0 0.0257 
wes_SMO 0 0 0 0.0253 
wes_HNF1A 0 0 0 0.0232 
wes_TOP2A 0 0 0 0.0218 
wes_NTRK2 0 0 0 0.0218 
wes_FANCL 0 0 0 0.0215 
cnv_PARK2 0 0 0 0.0207 
cnv_PDGFRB -0.0004 0.0011 -8.47E-05 0.0202 
wes_ROS1 0 0 0 0.0198 
wes_FGFR3 0 0 0 0.0198 
cnv_EPHA7 0 0 0 0.0198 
wes_ALK 0 0 0 0.0195 
cnv_FGF4 -6.81E-05 0.0005 8.26E-05 0.0190 
wes_EGFR 0 0 0 0.0182 
cnv_TNFAIP3 0 0 0 0.0176 
wes_AKT1 0 0 0 0.0174 
wes_BCL6 0 0 0 0.0161 
wes_BCORL1 -0.0002 0.0009 -1.41E-05 0.0158 
cnv_IDH2 -8.51E-05 0.0003 2.59E-05 0.0158 
wes_FH -0.0005 0.0001 -0.0003 0.0142 
wes_FANCG 0 0 0 0.0141 
wes_FANCA 0 0 0 0.0137 
cnv_FGF19 0 0 0 0.0136 
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wes_PDGFRA 0 0 0 0.0136 
cnv_IGF2 0 0 0 0.0133 
cnv_IRF4 -8.33E-05 0.0005 -2.40E-05 0.0130 
cnv_WT1 0 0 0 0.0122 
wes_BRIP1 0 0 0 0.0120 
wes_ERBB3 0 0 0 0.0117 
cnv_VEGFA -6.25E-05 0 -5.00E-05 0.0099 
cnv_ATM 0 0 0 0.0098 
cnv_MRE11A 0 0 0 0.0093 
wes_RB1 -0.0001 0 -0.0001 0.0092 
cnv_CHEK1 0 0 0 0.0091 
cnv_CBL 0 0 0 0.0089 
wes_BRCA1 0 0 0 0.0089 
cnv_FGF3 0 0 0 0.0088 
wes_CHEK2 0 0 0 0.0085 
wes_AXL 0 0 0 0.0082 
wes_ERBB4 0 0 0 0.0082 
cnv_SDHD 0 0 0 0.0078 
cnv_MEN1 0 0 0 0.0077 
cnv_FANCF 0 0 0 0.0066 
wes_FLT3 0 0 0 0.0063 
wes_SPEN 0 0 0 0.0062 
cnv_HRAS 0 0 0 0.0062 
cnv_FANCA 0 0 0 0.0057 
wes_RPTOR 0 0 0 0.0053 
cnv_MLL 0 0 0 0.0053 
wes_GNAS 0 0 0 0.0052 
wes_ATM 0 0 0 0.0046 
wes_MTOR 0 0 0 0.0042 
wes_ERBB2 0 0 0 0.0040 
wes_RAD50 0 0 0 0.0039 
wes_CDKN1A 0 0 0 0.0038 
cnv_SMAD2 0 0 0 0.0038 
wes_STK11 0 0 0 0.0038 
cnv_CIC 0 0 0 0.0038 
cnv_NKX2.1 0 0 0 0.0036 
wes_EP300 0 0 0 0.0036 
wes_PLCG2 0 0 0 0.0033 
wes_SMAD4 0 0 0 0.0033 
wes_TSC2 0 0 0 0.0033 
 129 
 
wes_NOTCH3 0 0 0 0.0030 
wes_PIK3CG 0 0 0 0.0030 
cnv_BCL2L2 0 0 0 0.0029 
wes_CDKN2A 0 0 0 0.0029 
cnv_NOTCH1 0 0 0 0.0028 
wes_GRIN2A 0 0 0 0.0024 
cnv_SMO 0 0 0 0.0023 
cnv_FGFR1 0 0 0 0.0023 
cnv_FGFR4 0 0 0 0.0020 
cnv_CD79A 0 0 0 0.0020 
wes_CTNNA1 0 0 0 0.0013 
cnv_DOT1L 0 0 0 0.0006 
wes_SMARCA4 0 0 0 0.0006 
cnv_FANCG 0 0 0 0.0002 
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APPENDIX 6: RELEVANT PUBLISHED WORK AND ABSTRACTS  
 
ABSTRACT PRESENTED AT THE AMERICAN SOCIETY OF CLINICAL 
PHARMACOLOGY AND THERAPEUTICS 2017 ANNUAL MEETING, 
WASHINGTON, D.C. 
 
Identifying somatic mutations associated with intrinsic resistance to multi-targeted tyrosine 
kinase inhibitors. 
Nancy K. Gillis, Christine M. Walko, Daniel M. Rotroff, Tania E. Mesa, Sean J. Yoder, Zhihua 
Chen, Jamie K. Teer, Howard L. McLeod 
 
Background: Approximately 15% - 30% of individuals with therapeutic indications for multi-
targeted tyrosine kinase inhibitors (TKIs) fail to show even transitory benefit, demonstrating 
intrinsic resistance (IR). Early identification of inherently resistant tumors is essential to avoid 
exposure to non-effective therapies and unnecessary toxicities and to guide selection toward 
other therapies.  
Methods: We conducted a retrospective cohort study to identify somatic mutations associated 
with IR to multi-targeted TKIs. Adult patients treated with multi-targeted TKIs were classified as 
intrinsically resistant (progression at 1st imaging follow-up), non-resistant (no progression), or 
unknown (insufficient follow-up). Targeted exome or whole exome sequencing was performed 
using tumor FFPE samples (data collection completed 9/7/16, giving insufficient time for 
analysis by the 9/8 deadline). A candidate gene approach was employed to identify differences in 
mutations between resistant and non-resistant individuals.  
Results: A total of 51 individuals were included (median age 61 yo). The most prevalent tumor 
type was renal cell (48%). The majority received sorafenib (29%), sunitinib (27%), or pazopanib 
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(41%). Thirty percent demonstrated IR. Median time to drug discontinuation was statistically 
different between resistant and non-resistant individuals (2.2 vs 8.5 mo, p < 0.001). Five genes 
(NTRK1, KDR, TGFBR2, PTPN11, and NOTCH2) were more commonly mutated in resistant 
individuals (OR = 5.5, insufficient power). These genes have strong biologic plausibility 
supporting their potential roles in resistance to TKIs.  
Conclusion: Somatic mutations in multi-targeted TKI drug targets may serve as biomarkers of 
IR to these agents. Future studies will further explore these associations. 
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ABSTRACT PRESENTED AT THE AMERICAN ASSOCIATION FOR CANCER 
RESEARCH 2016 ANNUAL MEETING, NEW ORLEANS, LA 
 
Prevalence and triggers of drug-induced Stevens-Johnson syndrome (SJS) and toxic 
epidermal necrolysis (TEN) in a cancer patient cohort. 
Nancy K. Gillis, Gillian C. Bell, Amy J. Brandt, Howard L. McLeod 
 
SJS and TEN are extremely rare (approximately 2-7 cases per million per year) 
hypersensitivity reactions most commonly attributed to medications. The life-threatening nature 
of SJS/TEN necessitates early diagnosis and immediate identification and withdrawal of 
causative agents. Some of the most commonly associated culprits include sulfonamide 
antibiotics, aromatic anticonvulsants (phenytoin, carbamazepine, lamotrigine), -oxicam NSAIDs 
(e.g., meloxicam), allopurinol, and nevirapine. Individual case reports of SJS/TEN have been 
associated with anti-cancer agents, but a comprehensive assessment has not been performed. A 
large-scale retrospective analysis of the prevalence of SJS/TEN in cancer patients treated at 
Moffitt Cancer Center (MCC) between Jan 1, 2002 – Dec 31, 2014 was conducted. A total of 
104,917 cancer patients were screened for SJS/TEN-related ICD-9 codes in the MCC health 
research informatics database. SJS/TEN diagnoses were identified in 121 patients. Manual chart 
review of physician, dermatology, and pathology notes confirmed SJS/TEN in 47 patients (in-
patient + historical) and possible SJS/TEN in an additional 17 patients, corresponding to an 
overall prevalence of 0.06%. Confirmed in-patient cases of SJS/TEN were more common in 
hematologic malignancies compared to solid tumors (n = 12 vs. n=7, respectively). Notably, 5 of 
the 19 (26.3%) confirmed cases were observed in patients with acute myeloid leukemia. 
Physician-reported culprits for SJS/TEN diagnoses included antibiotics, immunomodulators, 
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anticonvulsants, and anti-cancer agents. The observed prevalence of SJS/TEN was higher in 
cancer patients than previous reports from the general USA population. There were 19 confirmed 
in-patient diagnoses of SJS/TEN and an additional 45 historical and possible cases of SJS/TEN 
in 104,917 cancer patients, corresponding to an overall prevalence of 0.018% to 0.06%, an 
approximately 90-fold increase when compared to the general population. Possible explanations 
for increased risk in cancer patients include increased exposure to culprit medications, cancer 
disease process, immunocompromised state, or synergy between risk factors. A thorough 
understanding of the factors that increase risk to SJS/TEN in cancer patients is critical to 
facilitate culprit withdrawal and maximize patient outcomes and survival.    
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ABSTRACT PRESENTED AT THE AMERICAN PHARMACISTS ASSOCIATION  
2016 MIDYEAR MEETING, LAS VEGAS, NV 
 
Exploring potential predictors of intrinsic resistance to multi-targeted tyrosine kinase 
inhibitors in patients with solid tumors 
Michael A. Carulli, Christine M. Walko, Howard L. McLeod, Nancy K. Gillis 
 
Purpose: Tyrosine kinase inhibitors (TKIs) are commonly prescribed antineoplastics used to 
treat a variety of cancer types. Unfortunately, approximately 15-25 percent of patients will not 
respond to treatment, which poses a significant burden considering the high potential for side 
effects and cost of these medications. This study explores the demographics and clinical factors 
of patients treated with multi-targeted TKIs in the context of whether they derived benefit or 
were resistant to treatment. We conducted a retrospective cohort study to investigate potential 
predictive factors of response in patients prescribed multi-targeted TKIs (i.e., axitinib, 
cabozantinib, pazopanib, regorafenib, sorafenib, sunitinib, or vandetanib).  
Methods: Patients were identified from Moffitt Cancer Center’s Total Cancer Care cohort with 
the inclusion criteria that they received a multi-targeted TKI and were diagnosed with a solid 
tumor. We performed chart reviews of electronic medical records to confirm diagnosis, TKI 
administration, and duration of treatment. Patient response to TKI was determined using imaging 
scans before TKI initiation and at first imaging follow-up, incorporating tumor size changes and 
radiologists’ and oncologists’ impressions to classify individuals as either a “responder” or “non-
responder (resistant)”. Patients with complete response, partial response, mixed response, or 
stable disease were classified as “responders”, while patients who had progressive disease at first 
imaging follow-up were classified as “non-responders”; patients who discontinued treatment 
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early due to side effects were excluded. Data was organized using Microsoft Excel, and 
demographic information, including age at diagnosis, sex, race, ethnicity, diagnosis, and multi-
targeted TKI received was summarized. Each demographic and clinical category was evaluated 
to determine the rate of resistance based on the number of patients who were non-responders 
divided by the total number of patients, in that category, who received the drug. We calculated 
the average, median, and range of treatment duration stratified by response, medication, and 
diagnosis. The primary objective of this study was to identify demographic or clinical variables 
that may be associated with resistance to multi-targeted TKIs. 
Results: A total of 262 solid tumor patients who were prescribed multi-targeted TKIs were 
included in this study. The majority of patients were white (94 percent), non-Hispanic (92 
percent), and the median age was 56 years old (range 21-88). The most common diagnosis in our 
cohort was renal cell carcinoma (RCC, 52 percent), followed by sarcoma (20 percent), and less 
than 10 percent for all other tumor types. Half of the patients received sunitinib, followed by 
sorafenib (28 percent). A total of 77 patients were excluded from further analyses due to 
unknown response. The overall resistance rate in our cohort was 21 percent, consistent with that 
observed in phase III clinical trials of these medications. Responders remained on treatment 
significantly longer than non-responders (median duration 11.0 mo vs. 3.6 mo, p less than 
0.001). Patients aged 60-69 had a higher rate of resistance than expected (30 percent), as did 
patients who received pazopanib (35 percent). Tumor types with higher resistance rates than 
expected included melanoma (43 percent), pancreatic neuroendocrine (36 percent) and sarcoma 
(28 percent), among others. Overall, patients who received axitinib remained on therapy the 
longest (median 11.7 mo, range 9.6-20.7 mo).  
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Conclusion: Multi-targeted TKIs are highly effective therapies for a wide range of tumor types; 
however, according to phase III clinical trials, approximately 15-25 percent of patients do not 
respond. We conducted a retrospective cohort study to identify demographic and clinical factors 
that may be predictive of response to these agents. Results from our study suggest that 
demographic and clinical factors, including but not limited to, sex, age, and diagnosis, may 
influence likelihood of response to multi-targeted TKIs. Future studies will explore the utility of 
genetics to better predict resistance to these widely-prescribed medications. 
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ABSTRACT PRESENTED AT THE H. LEE MOFFITT CANCER CENTER AND 
RESEARCH INSTITUTE 2015 SCIENTIFIC SYMPOSIUM, TAMPA, FL 
 
Identifying genetic predictors of intrinsic resistance to multi-targeted tyrosine kinase 
inhibitors 
Nancy K. Gillis, Anders E. Berglund, Howard L. McLeod 
 
Background: While results from multi-targeted tyrosine kinase inhibitor (TKI) clinical trials 
demonstrated overall efficacy, approximately 20% of individuals failed to show even transitory 
clinical benefit, demonstrating inherent resistance.  Early identification of inherently resistant 
tumors is essential to avoid exposure of patients to non-effective therapies and unnecessary 
toxicities, and to guide selection of other potentially effective therapies.   
Methods: This is a retrospective cohort study to identify genetic predictors of inherent resistance 
to TKIs across tumor types.  All Moffitt Total Cancer Care (TCC) patients who received a multi-
targeted TKI and have gene expression data available are included.  Candidate genes were 
selected based on the major drug targets of the selected TKIs.  This list was further expanded to 
include additional genes within the same pathway or genes shown to interact with the drug 
targets. 
Results: A total of 2,511 TCC patients received a multi-targeted TKI; 144 (5.7%) have gene 
expression data available.  There are a wide range of primary tumor sites included, with kidney 
(44%), colorectal (8%), and soft tissue (6%) tumors being most prevalent.  Candidate gene 
selection identified 28 genes that are known to interact with ≥ 4 of the 7 multi-targeted TKIs.  
There is wide variability (>2 log2-fold) in the expression level of 23 (82%) of candidate genes.  
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PCA and correlation analysis indicate that many of the candidate genes show unique expression 
patterns across individuals.  
Conclusion: We observed high variability in mRNA expression of candidate genes hypothesized 
to be important in the pharmacodynamics of multi-targeted TKIs.  Future work will be aimed at 
exploiting the observed differences in expression to identify patients who will be inherently 
resistant to TKIs.   
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APPENDIX 7: GRANTS AND AWARDS  
 
Spring 2017 University of North Carolina Off-Campus Dissertation Fellowship 
Scholarship awarded to doctoral students conducting impressive research and 
making notable progress toward degree completion while away from the UNC 
campus 
 
2016 – 2017 American Foundation for Pharmaceutical Education Pre-Doctoral 
Fellowship in Pharmaceutical Sciences 
National award given to doctoral students who possess the skill and aptitude to 
become outstanding scientists and leaders in the pharmaceutical industry, 
academia, and the government/nonprofit sectors 
 
Fall 2016 American Society of Hematology Abstract Achievement Award 
Merit-based scholarship awarded to top abstracts selected for presentation at 
the ASH annual conference 
 
Spring 2016 Khalid Ishaq Graduate Travel Award 
Awarded to graduate students presenting research at national conferences   
 
2012 – 2013 Eshelman Fellowship Award 
Merit-based award for selected incoming students into the graduate program at 
UNC 
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